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9Chapter 1 | General introduction
1.1 Prostate cancer
Prostate cancer is the second most common cancer and the fifth leading cause of cancer 
death among men worldwide. In 2012 an estimated 1.1 million men were diagnosed 
with prostate cancer and 307,000 men died of their disease [1]. The highest incidence 
rates are to be found in Australia/New Zealand, Northern America and Western and 
Northern Europe. In the Netherlands 10,897 men were diagnosed with prostate cancer 
in 2013 and 2,535 died of their disease [2].
The incidence of prostate cancer in the Netherlands has been rising since the early 
1990’s. This is most probably due to increased prostate cancer awareness, diagnostic 
improvements, early detection through prostate-specific antigen (PSA) testing and the 
ageing of the male population [3]. Prostate cancer mortality slightly decreased [2].
The difference seen between the incidence and mortality rate indicates that many more 
men die with prostate cancer than from prostate cancer which brings us to the natural 
history of the disease. Some prostate cancers grow and spread quickly; most prostate 
cancers, however, have a slow growing nature. Autopsy studies have shown that many 
older men who died of other causes also had prostate cancer [4].
1.2 PSA based prostate cancer screening
PSA is a protein produced by cells of the prostate gland. The PSA test was first described 
in the 1960’s after which it became an approved biomarker in 1986 and a potential 
screening tool for prostate cancer in the early 1990’s [5-7]. Before the introduction of 
the PSA-test, approximately half of the prostate cancers detected were lethal [3,8].
With increasing evidence that PSA could be used for the early detection of prostate can-
cer [7] three randomized controlled trials, aiming to evaluate whether population-based 
screening could reduce prostate cancer mortality, were initiated in the early 1990’s; the 
European Randomized study of Screening for Prostate Cancer (ERSPC) and the Göteborg 
Randomized Population-based Prostate Cancer Screening trial in Europe and the Pros-
tate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial in the United States [9]. 
Screening refers to the active search for diseases, precancerous or risk factors in order to 
discover them at the earliest possible stage so that early treatment is possible [10]. Ideally, 
screening should lead to an increased, but not excessive rate of early-stage detected 
cancers, a decrease in metastatic disease and a reduction in disease-specific mortality [10].
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1.2.1 The European Randomized study of Screening for Prostate Cancer
The ERSPC is a randomized controlled, multicenter trial, which was initiated in the early 
1990’s [11]. Men from eight European countries, i.e. Belgium, Finland, France, Italy, the 
Netherlands, Spain, Sweden and Switzerland, aged 50-74 years, were identified from 
population registries and, after signing informed consent, randomized into a screening 
(n=72,890) or control arm (n=89,353). Men in the screening arm received PSA testing, 
followed by a lateralized sextant biopsy in case the PSA value was ≥ 4.0 ng/ml, or later 
in case the PSA was ≥ 3.0 ng/ml. Men in the control arm received usual care. In 2009, 
with a median follow-up of nine years, the ERSPC group reported that prostate cancer 
was detected in 5,990 men (8.2%) in the screening arm and in 4,307 men (4.8%) in 
the control arm. 214 and 326 men died of prostate cancer, respectively, corresponding 
to a 20% reduction (p=0.04) in men dying from prostate cancer in the screening arm 
[11]. The corresponding number of men that needed to be screened (NNS) and needed 
to be treated (NNT) amounted to 1410 and 48 [11]. Since 2009, two analyses with 11- 
and 13-year follow-up outcome data have been published [12,13] both confirming the 
21% substantial relative reduction in prostate cancer mortality due to screening. In the 
13-year follow-up publication the absolute risk reduction of death from prostate cancer 
amounted to 0.11 per 1,000 person years or 1.28 per 1,000 men randomized. This 
translates into averting one prostate cancer death per 781 men invited for screening 
(NNI) or one per 27 additional prostate cancers detected (NND) [13].
Screening for prostate cancer did not only reduce disease-specific mortality, it also de-
creased the rate of metastatic disease [14]. Schröder et al. assessed the effect of screen-
ing for prostate cancer on the incidence of metastatic disease in four ERSPC centers 
(Finland, the Netherlands, Sweden and Switzerland). Among 76,813 men (n = 36,270 
for the screening arm, n = 40,543 for the control arm) aged 55-69 years, 666 men (256 
in the screening arm and 410 in the control arm) with metastatic prostate cancer were 
detected at a median follow-up of 12 years. In an intention-to-screen analysis a relative 
reduction of 30% (RR 0.70, 95%CI 0.60-0.82, p=0.001) was found. When adjusted for 
those men actually screened the relative reduction amounted to 42% (RR 0.58, 95%CI 
0.45-0.74, p<0.001) [14].
1.2.2 The Göteborg Randomized Population-based Prostate Cancer 
Screening trial
Shortly after the 2009 publication of the ERSPC, the results of the Göteborg Randomized 
Population-based Prostate Cancer Screening trial were published [15]. The Göteborg 
screening trial was initiated in 1994 as an independent study, but joined the ERSPC 
study shortly thereafter. With a follow-up of 14 years, the researchers found a prostate 
cancer mortality reduction in favor of the screening arm of 44% (rate ratio 0.56, 95% 
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CI 0.39-0.82, p=0.002). When adjusted for non-compliance, prostate cancer mortality 
was reduced by 56% (rate ratio 0.44, 95% CI 0.28-0.68, p=0.002). This translated into 
a NNS of 293 and a NNT of 12; for attendees after adjustment for non-compliance a 
NNS of 234 and a NNT of 15 was found [15]. In 2014, with a follow-up of 18 years, the 
study group reported a relative risk reduction of 42% (rate ratio 0.58, 95% CI 28-54%) 
and a NNI and NND of 139 and 13 [16]. Main differences between the Göteborg screen-
ing trial and the ERSPC trial as a whole are the type of randomization, the younger 
age of the participants, a shorter screening interval (2 years vs. 4 years in ERSPC as a 
whole), and the longer follow-up available due to the simultaneous randomization of all 
participants in 1994 in Sweden [17].
1.2.3 The Prostate, Lung, Colorectal, and Ovarian cancer screening trial
The prostate component of the PLCO trial included a total of 76,685 men, aged 55-74 
years. These men were enrolled in ten centers and randomly assigned to an interven-
tion or control arm. The intervention arm entailed organized screening, consisting of 
PSA testing for 6 years and annual digital rectal examination (DRE) for 4 years. Men 
included in the control arm received usual care, which included opportunistic screening. 
After nine years of follow-up, contrary to the findings of the ERSPC and the Göteborg 
screening trial, the PLCO trial found no evidence of a mortality benefit [18]. The lack of a 
mortality benefit was confirmed in later publications where longer follow-up data were 
presented [19,20]. The results of the PLCO trial were influenced by issues in the design 
and execution of the study, which affected the power of the study. Men included into 
the trial were allowed to have undergone one screening within the three years before 
enrollment and an unlimited number of PSA screens. The results were furthermore influ-
enced by the 52% contamination rate in the control arm and the low biopsy compliance 
rate (40%) in the screening arm. Al together this led to an identical stage distribution 
of the detected cancers in the screen and control arm, making the occurrence of a 
difference in prostate cancer mortality between the two arms difficult, also with longer 
follow-up [18,19,21].
1.2.4 Harms of screening for prostate cancer
The benefits of screening for prostate cancer are, as shown above, the reduced risk of 
advanced disease and the reduced risk of dying from the disease. Screening, however, is 
also associated with downsides. Adverse effects of screening are the overdiagnosis and 
subsequent overtreatment. Overdiagnosis is referred to as the detection of cancers that 
would not have been diagnosed during the patients’ lifetime had he not been screened 
[22]. In the ERSPC trial the rate of overdiagnosis was estimated to be no less than 
50% in the screening arm [22]. If such overdiagnosed cancers are treated, we speak of 
overtreatment. ‘Overdiagnosed’ men have to live longer with the knowledge of having 
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prostate cancer, or, for those who opt for curative treatment, with the side-effects of 
treatment [23] while these years might otherwise have been symptom-free.
1.3 Active surveillance
During the last decade active surveillance has emerged as an alternative strategy for 
immediate active therapy in the management of potentially overdiagnosed prostate 
cancers. The aim of active surveillance is to delay or completely avoid unnecessary treat-
ment of a potentially indolent tumor, i.e. a tumor that has little or no lethal potential, and 
therewith avert side-effects of treatment and preserving quality of life [24,25]. Patients 
who choose active surveillance are offered a monitoring program that includes PSA 
measurements, rectal examinations, repeat prostate biopsies and (only recently added) 
the option of undergoing an MRI. If risk classification towards a higher risk or disease 
progression is suspected, men can switch to active therapy with curative intent [24,25].
The difficulty when selecting patients for active surveillance is to identify only patients 
with indolent prostate cancer. Up to now, there is no marker available that distinguishes 
indolent perfectly from aggressive prostate cancer. The inclusion of patients on active 
surveillance is currently based on a combination of clinical and pathological markers 
like Digital Rectal Examination (DRE), Gleason score and PSA-density which are gained 
at diagnosis. Frequent follow-up of these patients should warrant early detection of 
potential misclassification of low-risk disease or true progression in order not to miss 
the window of curability.
Several studies assessing the value of active surveillance have been initiated worldwide 
during the last ten years. Examples are the active surveillance cohorts at Johns Hopkins 
in Baltimore, USA [26]; University of California, San Francisco (UCSF), USA [27]; Miami, 
Florida, USA [28]; Klotz, Canada [29]; Royal Marsden Hospital, London, UK [30]; and the 
Prostate cancer Research International: Active Surveillance (PRIAS) study which operates 
worldwide [25,31]. All active surveillance cohorts use different sets of inclusion criteria, 
one set being more stringent than the other.
Results of these cohorts so far seem promising with respect to disease-specific survival, 
active-therapy free survival, rate of metastases and prostate cancer death [32]. Klotz et 
al. recently published data with a follow-up of 15 years [29]. The authors reported that 
2.8% of men developed metastatic disease and that 1.5% died of prostate cancer. Be-
cause this mortality rate is consistent with expected mortality in favorable-risk patients 
with initial definitive intervention, Klotz et al. conclude that active surveillance seems 
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feasible and safe within a 15-year time frame [29]. More robust long-term follow-up 
outcomes are, however, warranted.
1.3.1 PRIAS
The Prostate cancer Research International: Active Surveillance (PRIAS) study, was set-up 
by investigators of the Rotterdam section of ERSPC and the department of Urology, 
Erasmus University Medical Center, Rotterdam, the Netherlands [25]. PRIAS is a pro-
tocol- and web-based, multicenter, worldwide observational study. It started including 
patients in 2006. PRIAS was designed to validate an active surveillance protocol based 
on the then available knowledge. If deemed necessary, the PRIAS protocol would be 
adapted to more current scientific evidence on the management of low-risk prostate 
cancer [25]. To date, PRIAS includes more than 5,000 patients from 17 countries.
In 2013 Bul et al. published results on 2,494 patients that were included in the PRIAS 
study and were followed for a median of 1.6 years. In 1,480 men one or more repeat 
biopsies were performed; 415 (28%) showed reclassification meaning Gleason upgrad-
ing, reclassification based on the number of positive cores or a combination of both. The 
2-year active therapy free survival amounted to 77.3% and the disease-specific survival 
rate was 100% [31].
1.3.2 Quality of Life
With the initiation of an active surveillance management strategy, also the question 
on how active surveillance might influence quality of life of men came up. Men who 
choose active surveillance have to deal with living with their ‘untreated’ prostate cancer. 
Although being closely monitored, active surveillance may cause distress and anxiety 
because of the continuous uncertainty that men might experience. Several studies have 
been carried out assessing the effect of active surveillance on quality of life of men. It 
has been shown that in the short run, anxiety and depression scores of men on active 
surveillance are favorably low [33-35]. The overall health related quality of life scores 
of men on active surveillance were good and therewith comparable or even slightly 
better than for those post radical treatment [35]. While these results yield optimism for 
those choosing active surveillance, longer follow-up is needed as well as studies that 
investigate the characteristics of patients that do not choose active surveillance to begin 
with or switch to curative therapy in a very early stage due to anxiety.
When localized prostate cancer is treated radically with surgery (radical prostatectomy) 
or radiotherapy (brachytherapy or external beam radiation therapy) side-effects of 
treatment, like impotence, erectile dysfunction, or urinary problems, could occur which 
can impact quality of life. Five years after radical prostatectomy for localized prostate 
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cancer 71-88% of patients reported erectile dysfunction and 14-31% reported urinary 
incontinence. After radiotherapy 64% of patients reported erectile dysfunction and 
11% experienced problems with their bowel functions [23,36]. With active surveillance 
treatment is delayed, or even completely avoided. The biopsies performed when on 
active surveillance are, however, not without risk. Glass et al. assessed whether repeated 
biopsies affect urinary function of men on active surveillance. They concluded that the 
repeated biopsies independently do not pose an additional risk of lower urinary tract 
symptoms in men on active surveillance [37]. Braun et al. assessed whether serial repeat 
biopsies affect erectile functioning of men on active surveillance. The authors found a 
small decrease in erectile functioning of men. They, however, could not separate the 
effect of aging and multiple biopsies. They therefore suggested that active surveillance-
related biopsies do not seem to have a large impact on erectile function [38]. In both 
studies, the follow-up was rather short. Studies with longer-term follow-up data would 
therefore be warranted.
1.4 This thesis
Part I – Screening for prostate cancer
The main endpoint of prostate cancer screening studies is to determine whether PSA-
based screening can reduce prostate cancer mortality. The ERSPC and the Göteborg 
Cancer Screening Trial have shown such an effect of screening on disease-specific mor-
tality. Screening programs furthermore, have secondary endpoints; one of them being 
the development of tumor characteristics and applied treatments in both the screening 
and control arm over time. Such an assessment can give insight into the rate of op-
portunistic testing within the screening and control arm of the study. This is needed 
to investigate whether a shift over time towards more favorable tumor characteristics 
at diagnosis due to opportunistic screening, possibly followed by a change in therapy 
choices, influences the main endpoint of the trial due to the potential diminished differ-
ences between the screening and control arm.
Research question 1: How do tumor characteristics and treatment patterns change in 
the course of a screening trial for prostate cancer?
It has been shown that screening has both advantages and disadvantages. Due to the 
conflicting situation that arose after the publications of the ERSPC, the Göteborg Can-
cer Screening Trial and the PLCO study, some professionals strongly recommend against 
PSA testing, while others strongly advise in favor of PSA testing.
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Research question 2: How to advice patients who consult their general practitioner or 
urologist with a screening request?
Part II – Active surveillance for low-risk prostate cancer
Overdiagnosis and overtreatment are two main concerns that have been acknowledged 
by all three prostate cancer screening trials. Currently, research is being done on how 
to reduce the overdiagnosis of prostate cancer. As no marker is available yet that 
distinguishes indolent disease perfectly from aggressive prostate cancer, an alternative 
management strategy has come up with which to reduce the rate of overtreatment. 
Active surveillance was introduced almost a decade ago alternatively to direct invasive 
therapy and aims to prevent, or delay, invasive therapy and its associated potential 
side-effects in selected patients with latent low-risk prostate cancer. Part two of this 
thesis will focus on the development of active surveillance as a management strategy, in 
particular by assessing quality of life and patient selection through risk stratification. To 
achieve these goals, several research questions will be addressed.
Research question 3: As active surveillance cohorts mature, how do the related clinical 
outcomes develop?
Research question 4: In the light of personalized medicine, what is the best way to select 
patients for active surveillance?
In the short run, men on active surveillance do not seem to experience much anxiety or 
depressive feelings. Longer follow-up data are, however, lacking.
Research question 5: How does quality of life develop in men who follow an active 
surveillance management strategy for a longer period of time? How does their quality 
of life compare to that of men who underwent direct curative therapy?
Research question 6: With the increasing clinical acceptance of active surveillance as a 
feasible alternative to immediate active therapy, how do urologists value active surveil-
lance and what should they be aware of in such a fast moving area of expertise?
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1.5 Outline of this thesis
In part one, chapter 2, of this thesis the results of an prospective, observational study 
on the change of tumor characteristics and treatment patterns in the screening and 
control arm of the ERSPC study are presented. Chapter 3 reviews options on how to 
advice patients that come to their general practitioner or urologist with a screening 
request.
In part two, chapter 4, the results of a review on oncologic outcomes for men on active 
surveillance are presented. In chapter 5, it is assessed whether probabilistic-based selec-
tion by applying a nomogram will improve patient selection for active surveillance as 
compared to the currently used rule-based criteria. Chapter 6 and 7 discuss patient re-
ported outcome measures (PROMS) for men on active surveillance. Chapter 6 describes 
quality of life of men who followed an active surveillance strategy for an 18-month 
period. Chapter 7 reports on quality of life of men who followed an active surveillance 
strategy for 5-years. These results are compared to quality of life results of men who 
were treated curatively ≥5 years ago and to a reference group of men who do not 
have prostate cancer. In chapters 8 and 9 active surveillance is looked upon from two 
different perspectives. Chapter 8 discusses how urologists value active surveillance as a 
management strategy and alternative to direct curative treatment. Chapter 9 is written 
from a legal perspective and reports on the elements that urologists should be aware 
of when offering active surveillance to patients. Finally, in chapter 10, the key findings 
of the studies will be discussed and placed into perspective after which directions for 
future research will be proposed.
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Abstract
Objective. To evaluate a change in tumor characteristics and applied treatments over 
time in the control arm of all centers of the European Randomized study of Screening 
for Prostate Cancer (ERSPC) and to compare this with similar data of the screening arm.
Methods. Between 1993 and 2003, 182,160 men, aged 50-74 years, were randomized 
to the screening arm (N=82,186) and the control arm (N=99,184). Men in the screening 
arm were offered Prostate Specific Antigen (PSA) testing every four years whilst men in 
the control arm received usual care. Tumor characteristics and treatment were evaluated 
in all men diagnosed with prostate cancer up to December 2006 or the third screening 
round. Data on the control arm were divided into three periods: 1994-1998, 1999-2002 
and 2003-2006.
Results. Tumor characteristics were more favorable over time in both the control and 
the screening arm, with especially increasing proportions of T1C tumors with 29% in 
1994-1998 vs. 50% in 2003-2006 and 48% at the initial screening round vs. 75% 
at the third screening round, respectively. Tumor characteristics observed in the last 
period of the control arm were comparable to tumor characteristics in the initial screen-
ing round. In the control arm, treatment changed over time with surgery as the most 
common treatment in the entire observed period, but almost doubling of expectant 
management and the combination of hormone therapy and radiotherapy over time. In 
the initial screening round, surgery was the most common treatment (42%), changing 
over time to expectant management as the most frequently applied treatment in the 
third screening round (33%).
Conclusion. Tumor characteristics in the control arm became more favorable over time 
and show similarity with prostate cancer cases detected at the initial screening round. 
The most prominent change in treatment over time was an increase of application 
of expectant management in both arms of the ERSPC. These observations reflect an 
increasing rate of opportunistic testing over time in men randomized to the control arm.
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Introduction
The European Randomized study of Screening for Prostate Cancer (ERSPC) was initi-
ated in 1994 to assess whether screening for prostate cancer is effective in decreasing 
prostate cancer mortality at an acceptable cost, both in terms of quality of life and 
finance [1].
After a mean follow-up of 9 years the third interim intention to screen analysis resulted 
in a significant 20% reduction in prostate cancer mortality in favor of screening [2]. This 
reduction was 30% when corrected for non-compliance and contamination [3]. The 
study is still ongoing, continued follow-up will provide further information needed for 
the decision on whether prostate cancer screening should become a population-based 
program.
Next to the main endpoint, disease specific mortality, studies on the so-called secondary 
endpoints (i.e. stage and grade shift of tumors detected in both intervention and control 
arm) are of great value. Earlier studies comparing the tumor characteristics between the 
screening and the control arm showed that prostate cancer patients in the control arm 
had significantly higher PSA levels at diagnosis and had more advanced clinical stage as 
compared to prostate cancer patients in the screening arm. The distribution of Gleason 
score of the sextant prostate biopsies showed a similar pattern, the prostate cancers 
detected in men in the control arm had a significantly higher proportion of cancers with 
Gleason >7. All data point towards a shift towards more favorable tumor characteristics 
at diagnosis in the screening arm [4-6]. This was also confirmed when comparing tumor 
characteristics between two subsequent screening rounds [5-8].
Therapy choices reflect stage and grade distribution at diagnosis and hence were dif-
ferent between the screening arm and the control arm. Men in the screening arm were 
offered curative therapy more often, whilst men in the control arm received endocrine 
therapy more often [4]. A similar pattern was seen between prostate cancers detected 
at initial and repeat screening. The proportion of men managed by active surveillance 
increased drastically and more than doubled, reflecting the more favorable tumor 
characteristics at diagnosis [8]. It must be noted however, that within ERSPC there was 
no imbalance in treatments applied between the two study arms after correcting for 
differences in tumor characteristics at diagnosis [9].
Meanwhile, PSA testing in asymptomatic men occurs in the control arm, and if the 
contamination is effective: i.e. opportunistic PSA testing followed by a prostate biopsy 
and early diagnosis it may have an effect on the characteristics of the prostate cancers 
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detected and thus therapy. This so-called opportunistic PSA testing or contamination 
testing occurs also in men randomized to the screening arm but to a lesser extent [10].
The aim of the study presented here was to inventory the tumor characteristics and 
applied treatments over time in the control arm of the different ERSPC centers and to 
compare this with similar data from the screening arm in order to (a) assess the effect 
of contamination (i.e. opportunistic screening ) in the control arm over time and (b) to 
further explore the earlier reported favorable grade and stage shift and subsequent 
treatment changes as a result of PSA based screening.
Materials and methods
Study population
Between 1993 and 2003, a total of 182,160 men, aged 50-74 years, were included 
in the screen and control arm of the ERSPC. Participating centers were located in Fin-
land, the Netherlands, Sweden, Belgium, Italy, Switzerland and Spain. Men who were 
randomized to the intervention arm (N=82,816) received systematic screening every 
2 or 4 years and men who were randomized to the control arm (N=99,184) received 
usual care [11]. Follow-up for mortality analyses began at randomization and ended 
at death, emigration or a uniform censoring date (December 31, 2006) with identical 
follow-up in the two study arms [2]. The mean follow-up for both arms is 9 years. In 
the current study, all men diagnosed with prostate cancer in the control arm between 
January 1994 and December 2006 and all men diagnosed with prostate cancer in the 
intervention arm from the initial screening round up to the third screening round are 
included (for Sweden, men are included up to the 6th screening round because of a 
2-year screening interval). Cancers diagnosed in men who did never attend screening, 
and cancers diagnosed between the two screening intervals clinical or due to opportu-
nistic screening, transurethral resection of the prostate (TURP) for benign disease, and 
cystoprostatectomy specimens, were considered as well and defined as interval cancers.
Men with prostate cancer in the control group were identified through a linkage with 
national cancer registries. These men received standard medical care consisting of 
symptom evaluation as well as prostate cancer diagnosing and treatment by a general 
practitioner and a local urologist. Screening methodology was reviewed for all centers by 
Schröder et al. In most centers a PSA cut-off value of 3.0 ng/ml was used as an indication 
for prostate biopsy. In Finland a PSA value of ≥4.0 ng/ml was defined as a biopsy indica-
tion. Men with a PSA value of 3.0-3.9 ng/ml underwent an ancillary test. Up to 1998 this 
meant that men underwent a digital rectal examination (DRE). In 1999 the Finnish center 
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started to calculate the ratio of the free PSA value to the total PSA value. If the ancillary 
test was positive, men were referred for biopsy. In Italy, men with a PSA value of 2.5-3.9 
ng/ml underwent ancillary tests (i.e. DRE and transrectal ultrasonography (TRUS)). A PSA 
of ≥4.0 ng/ml was defined positive to refer men for prostate biopsy. In both the Dutch 
and the Belgium centers, a combination of DRE, TRUS and PSA testing with a cut-off 
value of 4.0 ng/ml was used for screening up to February 1997. After February 1997 
this combination was replaced by PSA testing only with the cut-off value of 3.0 ng/ml. In 
Belgium, they initially used a PSA cut-off value of 10.0 ng/ml since the results of a pilot 
were included in the dataset.  Most centers used sextant biopsies guided by TRUS. From 
June 1996 on, lateralized sextant biopsies were recommended. In Italy they have used 
transperineal sextant biopsies, whilst in Finland a biopsy procedure with 10-12 biopsy 
cores was adopted as the general policy in 2002. Most centers adopted a screening 
interval of 4 years; whilst Sweden used a 2-year interval [2,11].
Screening rounds 1 and 2, 3 and 4, and 5 and 6 in Sweden were added to screening 
rounds 1,2 and 3 of the centers with a 4-year interval, respectively.
Cancers were classified according to the 1992 TNM classification. Grading of the cancers 
was done using the Gleason grading system. Organ confined disease was considered as 
T1 and T2 disease, advanced disease as T3 and T4 disease and metastatic disease as N1, 
N2, N3 and M1. Incidence data of the control arm were subdivided according to year of 
diagnosis. The periods were: 1994-1998, 1999-2002 and 2003-2006 and compared to 
the initial, repeat and third screening round. Prostate cancers diagnosed before random-
ization were excluded, both in the control and the screening arm. Missing data on stage 
and grade were filled in taking into account the stage and grade distribution in the 
available data, assuming that there is no bias in this respect in obtaining follow-up data.
Statistical analysis
The statistics are mainly descriptive. Cumulative incidence was calculated for tumour 
characteristics per 10,000 men at risk. We used the men at risk at the start of the 
predefined periods of the control arm for both arms. Tumour characteristics, i.e. 
stage and grade, and treatment were compared amongst the predefined successive 
periods. Furthermore, we compared the change in tumour characteristics over time in 
the control arm with the tumour characteristics in subsequent screening rounds of the 
screening arm. The Statistical Package for Social Sciences (SPSS) for Windows, version 
15.0, software was used. T-test for independent samples and the Mann-Whitney-U test 
were used to compare between groups.
ERSPC is registered under the Current Controlled Trials number ISRCTN49127736.
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Results
Patient characteristics and incidence data
A total of 4,782 prostate cancers (4.8%) were diagnosed between January 1994 and 
December 2006 in the control arm (N=99,184). In the screening arm (N=82,816) a total 
of 6,567 prostate cancers (7.9%) were detected in subsequent screening rounds.
Median PSA at diagnosis decreased in the successive periods in the control arm; 12.7 
ng/ml (1994-1998), 10.9 ng/ml (1999-2002) and 9.4 ng/ml in the period 2003-2006. 
Median PSA at diagnosis in subsequent screening rounds was quite stable; 5.3 ng/ml 
(initial screening), 4.7 ng/ml (repeat screening) and 5.4 ng/ml at the third screening 
round (4 year interval). Men diagnosed with prostate cancer in the control arm had sig-
nificantly (P<0.01) higher PSA levels at diagnosis as compared to men in the screening 
arm. Mean age at diagnosis was 67.7 years in the control arm and 66.2 in the screening 
arm and differed significantly (P<0.001).
Tumor characteristics
Clinical TNM classification
The clinical T stage distribution showed a favorable shift over time, in both the control 
arm and the screening arm (table 1). The proportion of T1c tumors in the control arm 
increased from 29% (95% CI 28.2-28.8) in 1994-1998 to 37% (36.7-37.3) in 1999-
2002 and to 50% (49.7-50.3) in 2003-2006. The percentage of screen detected T1c 
prostate cancers increased from 48% (47.4-48.2) in the initial screening round, 65% 
(64.8-65.4) in the repeat screening round to 75% (74.6-75.2) in the third screening 
round. The opposite was seen in T3 prostate cancers. In the control arm T3 tumors 
decreased from 23% in 1994-1998 to 13% in 2003-2006. At the initial screening round 
T3 tumors accounted for 14% of all tumors detected. This proportion decreased to 
4% in the third screening round. This positive effect was also reflected by cumulative 
incidence in the screening arm, particularly between the initial screening round and the 
second screening round where advanced disease decreased (61.6 to 14.8 per 10,000 
men at risk) and T1c cancers increased (204.9 to 214.1 per 10,000 men at risk).
Prostate cancers in the control arm showed in the last period (2003-2006) a similar clini-
cal T stage distribution as compared to prostate cancers detected at the initial screening 
round. In 2003-2006 in the control arm, T1c and T3 accounted for 50% and 13% of 
the tumors, respectively. At the initial screening round T1c and T3 tumors had similar 
proportions of 48% and 14%, respectively.
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A favorable shift over time was seen in metastasis status in the control arm (3.2 to 1.6% 
in lymph node metastasis and 10 to 4% in distant metastasis), whilst in the screening 
arm the proportion of lymph node metastasis was slightly decreasing (1.3 to 0.9%) and 
distant metastasis were quite stable over time (2%).
Gleason score
Gleason score distribution showed no explicit shift over time in both trial arms (table 1). 
Only low-grade tumors, i.e. Gleason scores 2-6, decreased over time (58 to 51%) and 
moderate Gleason grade tumors (Gleason score 7) increased over time (21 to 32%) in 
the control arm. A decreasing trend was however seen in high Gleason grade tumors 
(Gleason 8-10) in the control arm. In the first study period the proportion was 21% 
(21.0-21.6), decreasing to 17% (16.6-17.0) in the last study period. In the screening 
arm these proportions were 7.9% (7.7-8.1), 7.0% (6.8-7.2) and 9.2% (9.0-9.4) at 1st, 
2nd, and 3rd screening, respectively.
The comparison of Gleason score distributions between the control arm and the screen-
ing arm showed that in the control arm only Gleason scores 8-10 reached a comparable 
proportion with that of the initial screening round in 2003-2006 (17% versus 8%, 
respectively). A substantial difference remained in Gleason scores 2-6 (51% in 2003-
2006 versus >70% in the initial screening round).
Treatment
Table 2 shows the distribution of initial treatment over time in both the control and the 
screening arm. The category “Other treatments” consists of therapies rarely applied 
in at most 9 prostate cancer cases per arm and comprised surgery with gene therapy, 
surgery with radiotherapy and hormone therapy, expectant management followed by 
surgery, expectant management followed by radiotherapy and expectant management 
followed by hormone therapy.
In the control arm surgery was the most frequently applied treatment in 1994-1998, 
in 31% of the patients. This was followed by hormone therapy and radiotherapy, ac-
counting for 24% and 21% of treatments, respectively. At the initial screening round 
surgery was the most frequently applied treatment in 42% of the cases, followed by 
radiotherapy, applied in 29% of the cases.
In the last period of the control arm surgery was still the most common treatment, but 
had decreased to 25% of all treatments applied. Surgery was now closely followed 
by hormone therapy (22%) and the increased proportion of expectant management 
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(19%). In the screening arm, at the third screening round, expectant management was 
most commonly applied (33%) and followed by surgery (30%) and radiotherapy (16%).
The comparison of treatments applied between the control and the screening arm 
showed that the changes over time regarding expectant management (increasing) and 
the combination of hormone therapy and radiotherapy (increasing) and the decreas-
ing proportion of surgery and radiotherapy were similar. A difference was seen in the 
frequency of the combination of hormone and radiotherapy and hormone therapy. 
These therapies are being more frequently applied in the control arm during the study 
period. The proportion of men treated with hormone therapy was on average 22% in 
the control arm versus 8% in the screening arm. The combination of hormone therapy 
and radiotherapy was chosen in 17% of cases in the control arm versus 7% of cases in 
the screening arm on average.
Tables 2a and 2b show treatment broken down by stage for the screening arm and the 
control arm, respectively. Both trial arms showed an increase over time of expectant 
management and the combination of hormone therapy and radiotherapy in both organ 
confined and advanced disease.
First, surgery was the most applied treatment in organ confined disease for both trial 
arms. Surgery remained the most applied treatment for the control arm, but changed 
into expectant management for the screening arm in the third screening round.
In advanced disease radiotherapy was the most common treatment at initial screen-
ing and the combination of hormone therapy and radiotherapy in the third screening 
round. In the control arm hormone therapy was the most applied treatment during the 
whole observation period.
Hormone therapy was the most common applied treatment in metastatic disease during 
the whole observation period in both trial arms.
Discussion
In this report based on data of the ERSPC, tumor characteristics (stage and grade) at di-
agnosis and applied treatments of prostate cancers detected in men randomized to the 
screening or control arm were inventoried over a period covering the years 1994-2006.
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During the study period especially the clinical T stage of prostate cancers detected in the 
control arm showed a more favorable distribution over time. This is most likely a direct 
consequence of the increasing rate of opportunistic PSA screening in the control arm 
of ERSPC. Beemsterboer et al. found an opportunistic testing rate in the control arm 
of 7.6% per year in the first 1.5 years after randomization (ERSPC, Rotterdam section) 
[12]. Otto et al., also using ERSPC Rotterdam data, found that after 3 years of follow-up, 
20.2% of men in the control arm had had at least one PSA test as compared to 14.1% 
opportunistic PSA testing in the screening arm [10]. In other ERSPC centers the rate of 
opportunistic screening in men randomized to the control arm varied from 6.7% up to 
36% [13].
At the beginning of the study period surgery and endocrine therapy were most fre-
quently applied in prostate cancers detected in the control arm. At the end of the 
study period the combination of endocrine therapy and radiotherapy and expectant 
management were seen relatively more, but surgery and endocrine therapy remained 
the most common treatments. These changes in treatment are most likely due to (a) 
the observed change in tumor characteristics, (b) ageing of the cohort (more expectant 
management), mean age at diagnosis (table 2) and (c) positive results for adjuvant or 
neoadjuvant hormone therapy in addition to radiotherapy in locally advanced prostate 
cancer [14]. Cooperberg et al. found that in the U.S. the majority of patients younger 
than 60 years with low-risk cancers (i.e. PSA at diagnosis ≤10.0 ng/ml, biopsy Gleason 
<7 and clinical stage T1 or T2a) received radical prostatectomy. With increasing age, 
like in our study cohort, this proportion dropped rapidly, whilst endocrine therapy and 
expectant management increased with advancing age [15]. In older patients (>65 years) 
diagnosed with these low-risk tumors diagnosed in the years 1989-2001, expectant 
management was relatively uncommon. Most patients received radiotherapy or endo-
crine therapy [16]. Wolters et al. compared all treatments applied in both arms of the 
ERSPC during the median follow-up period of 9 years and found that PSA at diagnosis, 
age and clinical T stage are the most important factors in treatment choice [9]. But 
whereas that study focused on differences in treatment in screening and control arm, 
our aim was to describe change of treatment over time taking into account stage at 
time of diagnosis.
Men diagnosed with prostate cancer in the screening arm had more favorable prog-
nostic factors than those cases in the control arm when comparing time periods side 
by side. During the total observation period, mean age at diagnosis was 66.2 years for 
those men randomized to the screening arm versus 67.7 years for men in the control 
arm. In the screening arm organ confined disease was more frequent (92% versus 80% 
in the control arm) and also a larger proportion of low-grade tumors (72% versus 54% 
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in the control arm) were observed. Endocrine therapy was offered much more often 
in the control arm (22% versus 8% in the screening arm) and surgery and expectant 
management more often in the screening arm 37% versus 28% in the control arm for 
surgery and 21% versus 15% in the control arm for expectant management. These 
observations are in line with other studies comparing the tumor features and applied 
treatments of screen detected and clinically diagnosed prostate cancer [4,5,17-19].
However, when comparing tumor characteristics of the last period (2003-2006) in the 
control arm with tumor characteristics of cancers detected at the initial screening round 
we observed similarities. The proportion of T1c tumors in the control arm was 50% in 
the last period whilst 48% of the cancers detected at the initial screening round were 
staged as T1c, pointing to more screening activities in the control arm over time.
Despite the fact that the ERSPC cohort is a closed and thus ageing cohort, prostate 
cancer was detected more often in an early stage in the control arm. Our data showed 
that the proportions of organ confined disease in the control arm were 73.1% in 1994-
1998 and 83.7% in 2003-2006. Advanced disease reduced from 26.9% to 16.4%. 
This is in line with the study of Cremer et al. [20] describing the situation in the Dutch 
population, using incidence data. They also report an increase in detection of early stage 
disease, leading to a decrease of metastatic prostate cancer and a lower mortality rate 
and increased survival [20].
The decrease of Gleason >7 prostate cancers in the control arm (from 21.3% towards 
16.8%) should be interpreted with caution due to the so-called Will Rogers Phenom-
enon. However, the statistical artefact of Gleason score reclassification results in higher 
Gleason score readings between 1992 and 2002; strengthening our observation of 
decreasing high grade tumors in the control arm over time [21].
The comparison of prostate cancers detected at the initial screening round with those 
cases detected at repeat screening rounds showed a remarkable stage and grade shift 
in favor of the repeat screening rounds. These observations were reported earlier. In two 
subsequent screening rounds, advanced disease reduced from 19% to 4% and tumors 
with Gleason scores >7 decreased from 8% to 3% in the Dutch center [8]. Sweden also 
reported that PSA screening rapidly cause a stage shift, which leads to only detecting 
low-stage and also low-grade malignancies [19].
In conclusion, the earlier reported favorable stage and grade shift as a result of screen-
ing is confirmed with longer follow-up data. Also, the tumor characteristics of prostate 
cancers found in the control arm of the ERSPC showed a favorable shift over time. The 
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stage and grade shift coincided with a change of treatment reflected in an increasing 
occurrence of expectant management as initial treatment. The tumor characteristics 
of prostate cancers detected in men in the control arm become, with advancing time, 
more comparable to prostate cancers detected in the initial screening round. These 
observations point towards an increasing rate of opportunistic testing in men random-
ized to the control arm. We propose that future studies perform a survival analysis in 
different time periods after randomization in the control arm of the ERSPC.
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Abstract
Since the first publication describing the identification of prostate-specific antigen (PSA) 
in the 1960s, much progress has been made. The PSA test changed from being initially 
a monitoring tool to being also used as a diagnostic tool. Over time, the test has been 
heavily debated due to its lack of sensitivity and specificity. However, up to now the PSA 
test is still the only biomarker for the detection and monitoring of prostate cancer. PSA-
based screening for prostate cancer is associated with a high proportion of unnecessary 
testing and overdiagnosis with subsequent overtreatment. In the early years of screen-
ing for prostate cancer, high rates of uptake were very important. However, over time 
the opinion on PSA-based screening has shifted towards the notion of informed choice. 
Nowadays, it is thought to be unethical to screen men without them being aware of the 
pros and cons of PSA testing, as well as the fact that an informed choice is related to 
better patient outcomes. Now, as the results of three major screening studies have been 
presented and the downsides of screening are becoming better understood, informed 
choice is becoming more relevant.
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Introduction
The incidence of prostate cancer (PC) is rising in most Eastern and Western countries. In 
Europe the disease affects approximately 225.000 men each year [1]. The increase can 
be explained by the increasing overall life expectancy of men, the increasing number 
of biopsies and cores per biopsy, and most importantly, the increasing use of prostate-
specific antigen (PSA) measurements as a screening test [2].
The first publication describing PSA appeared in 1960 [3]. Difference of opinion exists 
as to who should be credited for its discovery, as different groups isolated the same 
protein simultaneously [4]. In 1986, the American Food and Drug Association approved 
the PSA as a test to aid in the management of patients diagnosed with PC. In 1994, the 
PSA test was approved by the American Food and Drug Association as a diagnostic tool 
which can be used, for instance, for the early detection of PC [4]. Throughout the years, 
it became clear that the use of the PSA test in a screening setting has both advantages 
and disadvantages. The published results of the European Randomized study of Screen-
ing for Prostate Cancer (ERSPC) [5], the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial [6], and the Göteborg randomized population-based PC screening trial 
[7], all initiated in the early 1990s, provide evidence on whether PSA testing is beneficial. 
The data from the three studies point towards a disease-specific mortality reduction due 
to screening , as well as the fact that screening by using a PSA test leads to overdiagnosis 
and therefore overtreatment [5-7]. The apparent controversial outcomes – with on the 
one hand a mortality reduction and on the other hand overdiagnosis and overtreatment 
– have motivated some professionals (i.e. primary care providers and/or urologists) to 
strongly recommend against PSA testing and some to strongly advise in favor of testing. 
Very few professionals truly inform men about the pros and cons of the PSA test [8]. 
Because more specific biomarkers are still lacking, the most commonly used screening 
test remains the serum PSA test. Disadvantages of the PSA test are the false-positive and 
false-negative results. A false-negative result can create uncertainty, while false-positive 
tests may lead to unnecessary additional testing [9,10]. At the same time, men feel 
pressured or even encouraged by family members, friends or media to consider PSA 
testing [8,11,12]. In the light of the confusing situation that has occurred, informed 
decision making about whether a man should or should not get tested seems more 
needed than ever.
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Incidence and mortality of PC
Different incidence and mortality rates for PC are found around the world (table 1). It 
appears that Asia has the lowest incidence and mortality rates, while the highest rates 
are nowadays found in the United States [13]. After the introduction of the PSA test, the 
incidence of PC increased drastically. Recent data from the US Surveillance, Epidemiol-
ogy and End Results program confirm this; new cases of PC have increased substantially 
in 1975-2005. The introduction of the PSA test led to a steep increase in PC incidence. 
Over time incidence declined; however, incidence rates did not retain to the level that 
was seen before the introduction of the PSA test. If this would reflect a true increase 
of the disease, it should be accompanied by an increase in disease-specific death rates, 
which is not the case. In fact, the mortality rates for PC declined during this period [14]. 
As the increase in incidence and mortality rates does not appear simultaneously, another 
explanation has to be found. According to Murphy et al. [15], the trend can be explained 
by the large stage shift from palpable and locally advanced disease to impalpable and 
localized disease. Due to PSA-based screening for PC, increasing numbers of patients 
with low-risk tumors (with low risk for both metastasis and mortality) are being detected 
[1]. These potentially clinically insignificant PCs (PSA < 10 ng/ml, stage ≤T2a disease and 
Gleason ≤6) [16,17] would not have been diagnosed without screening and may not 
lead to symptoms or death during the patient’s lifetime. Within the screening arm of 
the ERSPC (section Rotterdam, the Netherlands), 27-56% of all cancers detected in men 
aged 55-75 years can be classified as potentially overdiagnosed [18].
Table 1: Age-standardized incidence (world standard population) and mortality rates for prostate cancer 
in Asia, Europe and America, 2002 estimates.
World region Incidence per 100,000 Mortality per 100,000
Eastern Asia 3.8 1.9
South Central Asia 4.4 2.8
South-Eastern Asia 7 4.5
Western Asia 10.9 6
Eastern Europe 17.3 9.7
Southern Europe 35.5 13.2
Northern Europe 57.4 19.7
Western Europe 61.6 17.5
Central America 30.6 15.5
South America 47 18
Northern America 119.9 15.8
Data source: Globocan – Cancer incidence, mortality and prevalence worldwide, 2002 [13].
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Overtreatment
The ERSPC reported in March 2009 that PSA-based screening reduced the rate of death 
from PC by 20% in the intention to screen analysis. However, this mortality reduction 
was associated with a high risk of overdiagnosis and overtreatment [5]. Overtreatment 
means that men with overdiagnosed tumors, which would not have caused any symp-
toms during a man’s lifetime if they had remained undiagnosed, are subject to unneces-
sary costly and invasive treatment [2]. Despite their indolent character, these low-risk 
tumors are often actively treated, resulting in so-called overtreatment [19]. Within the 
first round of the ERSPC (section Rotterdam), e.g. 293 out of 1014 men with detected 
PC could be classified as potentially overdiagnosed or ‘indolent’ and were eligible for 
active surveillance (AS). It turned out that in only 64 out of the 293 men an initial 
AS strategy was chosen [20]. The question thus arises how to deal with overdiagnosis 
and overtreatment more effectively. A specific biomarker for potentially life-threatening 
disease would probably solve a large part of the problem; however, no such biomarker 
is currently available. It is claimed that AS provides a realistic strategy to avoid overtreat-
ment by surgery or radiation therapy. AS starts with a selection process in which men 
with favourable disease-specific prognoses are included. The age of a patient and his 
estimated life expectancy play an important role. Radical treatment is withheld and 
replaced by closely monitoring the disease [21]. If progression occurs, curative treatment 
is indicated. The criteria for switching from AS to delayed curative treatment are based 
on both medical and non-medical aspects. A benefit of AS can be the delay of active 
treatment, including avoidance of possible side effects and the delay  of complications 
for a few years [22]. However, the psychological aspects of AS should not be ignored 
during the period of close monitoring. These include the anxiety of being too late for 
curative treatment.
Active surveillance
AS is subject of ongoing studies since the 1990s. Klotz et al. [23], Carter et al. [24,25], 
and Kakehi et al. [26] have all initiated studies regarding the value of AS (table 2). Klotz 
et al. [23] reported on the long-term clinical results of a large, AS cohort with localized 
PC at the beginning of 2010. The cohort consisted of 450 patients with a median age 
of 70.3 years and a median follow-up of 6.8 years. Klotz et al. [23] reported that among 
the 450 patients, 97 patients died (21.6%) and 353 were alive (78.4%). The 10-year 
overall survival was 68% (95% CI, 62-74%). There was no difference in overall survival 
between the patients who remained on surveillance and those who were reclassified 
and treated radically. The reported 5- and 10-year cancer-specific survival rates were 
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99.7% and 97.2% for AS and active treatment respectively. In the study period, five PC-
related mortalities occurred; all in men who had been reclassified as higher risk and who 
were offered radical treatment. Radical intervention was undertaken in three of the five 
patients (radiation n=2, prostatectomy n=1). The two other patients refused treatment. 
Klotz et al. [23] conclude that after a mean follow-up of 6.8 years only a single patient 
died after a relatively prolonged period of observation (>2 years) and subsequently 
experienced progression. Main reasons for discontinuing AS involve: short PSA doubling 
time (65/135, 14% of men of the total cohort) and grade progression (36/135, 8% 
of men of the total cohort). Carter et al. [25] reported in 2007 that out of the 407 
men included in the program on expectant management (i.e. the careful selection and 
monitoring of older men considered to have low-risk disease with the intention to cure 
if the disease progresses [25]), 239 (59%) men remained on AS at a median follow-up 
of 3.4 years (0.43-12.5). A total of 103 (25%) men underwent curative intervention at 
a median of 2.2 years after diagnosis (0.96-7.39), 45 (11%) men withdraw from the 
program, 12 (2%) men were lost to follow-up and 8 (3%) men died of causes other 
than PC. Reasons for withdrawal of the 45 men are not mentioned. Regarding the men 
who underwent curative intervention, older age at diagnosis (p=0.011) as well as an 
earlier date of diagnosis (p=0.001) was significantly associated with curative interven-
tion. It should be noted that the Johns Hopkins approach for selecting and monitoring 
men differs from that reported by Klotz et al. [23] and can be considered to be more 
conservative, i.e. a smaller amount of T2 cancers are included in the Johns Hopkins 
program. Kakehi et al. [26] reported the first prospective study on AS in Japanese pa-
tients where PC was detected using only a PSA elevation. The study included 134 men; 
Table 2: Criteria for active surveillance
Klotz et al [23]
1. Gleason ≤ 6
2. PSA ≤ 10 ng/mL
3. Stage T1b to T2b N0M0
4. Patients older than 70 years with PSA ≤ 15 ng/mL or Gleason ≤ 3 + 4
Carter et al [24,25]
1. PSAD* ≤ 0.15 ng/ml/cm³
2. Stage T1c
3.  Favourable biopsy characteristics, i.e. Gleason ≤ 6 with no Gleason pattern grade 4 or 5, no more than 
2 cores positive for cancer, and no more than 50% of any 1 core involved with cancer
Kakehi et al [26]
1. Age ranging between 50-80
2. Initial serum PSA of ≤ 20 ng/ml
3. Number of positive core being one or two per 6-12 systematic biopsy cores
4. Gleason score ≤ 6
5. ≤ 50% cancer involvement in any of the positive cores
* PSAD – PSA before diagnosis divided by prostate volume determined by transrectal ultrasound mea-
surement
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of whom 118 chose the AS program and 16 chose immediate curative treatment at 
enrolment. Up to 31 October 2006, no manifestation of metastasis or cancer death was 
observed in any of the participants. Three men died due to other disease, while five men 
were lost to follow-up [26]. Of the 118 patients who chose AS as initial treatment, 54 
(46%) remained on AS for the maximal observation period of 54 months. Reasons for 
discontinuing AS were: a PSA doubling time ≤ 2 years (17/65), pathology progression 
(16/65), change in T-stage (1/65), patient’s preference (15/65) and comorbidities (8/65). 
For seven men who discontinued AS, reasons are unknown. Kakehi et al. [26] reported 
that during the observation period, no serious adverse events were observed: not in the 
AS program group and not in those men who chose immediate treatment.
Prostate cancer Research International: Active Surveillance 
(PRIAS) study
Within the ERSPC (section Rotterdam, the prospective, observational PRIAS study has 
been initiated as a decision aid for the urologists managing their patients with AS 
and at the same time with the aim of validating this management [2]. It is an entirely 
web-based study. Potential patients can retrieve study information from the website 
(www.prias-project.org). Inclusion and follow-up data of patients can be entered in on 
the website after an urologist has gained access to the secured parts of the web tool. 
When data of a follow-up visit are entered, the website presents a graph survey of the 
PSA measurements and the PSA doubling time. On the basis of the follow-up criteria, 
a recommendation will be presented to the urologist on whether the patient should 
continue on AS or whether to discontinue and opt for active treatment. So, besides be-
ing a helpful tool for urologists in daily clinical practice, the website supports in clinical 
practice by providing decision points during AS.
By defining inclusion and follow-up criteria (table 3), the PRIAS study is attempting to 
select men with insignificant, organ-confined tumors who have a favorable prognosis. 
Other arguments in choosing AS include age, quality of life issues, ethical aspects and 
costs associated with treatment [27]. Currently, the PRIAS study is applied in several 
medical centers across the Netherlands, as well as in other European countries, the 
United States, Canada, Japan and Australia. The initiators and participating centers of 
the PRIAS study hope to provide a highly needed evidence-based guideline for AS in PC 
to prevent overtreatment [2].
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PRIAS – results so far
Currently, worldwide over 1500 patients are included in the PRIAS study. The first study 
interim analysis is based on the initial 500 study inclusions. These patients were included 
between December 2006 and July 2008 with a median follow-up time of 1.02 year 
(IQR (interquartile range) 0.6-1.5 years) [19]. The 2-year active therapy-free survival rate 
accounted for 73%. Eighty-two men changed to active therapy during follow-up; 83% 
(68/82) did so on protocol basis. The other 17% of the men who switched to active 
therapy did so because of anxiety and/or upon request. Two hundred and sixty-one 
repeat biopsies were available for analysis of which 34% showed no cancer, while 22% 
showed a Gleason score >6 or >2 positive biopsy cores. In 53% (102/194) of men with 
favorable biopsy results, a relatively unfavorable PSA doubling time of 0-10 years was 
seen. For men with an unfavorable biopsy result this percentage amounted to 62% 
(33/53). Seventeen percent (4/24) showed T3 disease after radical prostatectomy and 
50% showed a Gleason score of >6. This compares favorably to the results of Klotz et al. 
[23]. Overall, the authors stated that AS is a feasible strategy in avoiding overtreatment 
on the short term. When applying the strict PRIAS inclusion and follow-up protocol the 
result is that one out of four men who start on AS switch to active therapy within 2 
years after diagnosis [19].
The PRIAS study is still young and further follow-up data need to be obtained and 
analyzed. However, the first results look promising.
Several studies show that a program of careful selection and monitoring of men who are 
likely to harbor clinically insignificant cancers is a rational alternative to active treatment. 
Table 3: Inclusion and follow-up criteria for the PRIAS study [19]
Inclusion
1. Men should:
 • have histologically proven adenocarcinoma of the prostate
 • be fit for curative treatment
 • be willing to attend the follow-up visits
 • not have received former therapy for prostate cancer
2. Clinical stage is T1C or T2
3. Gleason score is ≤6 and ≤2 biopsy cores are invaded with prostate cancer
4. PSA is ≤10 ng/ml and PSA density is ≤0.2 ng/ml/ml
Follow-up
1. The patient is content with active surveillance
2. Clinical stage remains <T3
3. Gleason score remains ≤6 and ≤2 of the repeat biopsy cores are invaded with prostate cancer
4. PSA doubling time is favorable and remains longer than 3 years
PRIAS: Prostate cancer Research International: Active Surveillance study
PSA: prostate-specific antigen
Lionne Venderbos BW CP4.indd   48 08-10-15   11:18
49
Chapter 3 | PSA-based prostate cancer screening
The value of AS alone is still under study; however, it is not clear how AS performs in a 
combined approach (i.e. which treatment can be best chosen if a man with a clinically 
insignificant PC presents). The Surveillance Therapy Against Radical Treatment trial is 
aiming at answering such a question. It is a large randomized controlled trial in which 
standard treatment with surgery or radiation will be compared against AS [28]. The trial 
is currently recruiting participants.
Quality of life aspects with AS
As the clinical features of AS studies look hopeful, the quality of life aspect should 
definitely be taken into account. Due to screening, low-risk cancers are diagnosed that 
would not have been detected during the man’s lifetime in the absence of screening. 
Men who underwent screening are confronted with having cancer. By offering AS they 
could feel like no treatment is offered at all and they have to face the fact that they 
are living with cancer. This thought, but also the fear of disease progression, can cause 
psychological problems.
Results from the PRIAS trial
Van den Bergh et al. [29-31] assessed the impact of AS on the quality of life of men 
participating in PRIAS. Van den Bergh firstly looked at the level of knowledge of PC 
and the perception of AS in men on AS [29]. It could be that patients perceive AS as a 
complex or contradictory treatment strategy, especially if these men are lower educated. 
Perception of the disease is an important aspect of treatment satisfaction. If men have 
a wrong perception of AS, treatment will most probably not be satisfactory. Hundred 
and fifty men who were recently diagnosed with PC received a questionnaire containing 
a 15-item measure on general knowledge of PC, an open-ended question on the most 
important advantages and disadvantages of AS and questions on the specific percep-
tion of AS. It was hypothesized that younger and higher-educated men showed higher 
knowledge scores. Van den Bergh et al. [29] reported that the patients included in the 
cohort had an adequate knowledge of PC and realistic expectations of AS. No true 
misconceptions on AS were identified.
Van den Bergh et al. [30] initiated a study regarding the levels of anxiety and distress 
among men on AS who were living with ‘untreated’ cancer. These possible feelings of 
anxiety and distress were quantified in a questionnaire using the decisional conflict scale 
(DCS), a measure for generic anxiety (STAI-6), depression (CES-D), PC-specific anxiety 
(MAX-PC), physical health (SF-12 PCS), personality (EPQ) and shared decision making. 
Hundred and fifty men received a questionnaire, of which 129 men responded by send-
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ing the questionnaire back (response rate of 86%). The majority of men included in 
this protocol-based program for AS showed favorable anxiety and distress scores in 
comparison with reference values and to groups of patients with PC who underwent 
other types of treatment [30]. It turned out that some aspects, such as a poor physical 
health, high PSA levels and a high neuroticism score, were associated with one or more 
of the CES-D, STAI-6, DCS and MAX-PC scores. A neurotic personality is therefore as-
sociated with unfavorable scores. After 9 months, the 129 men who filled in the first 
questionnaire received a second questionnaire. The aim was to investigate whether the 
levels of anxiety and distress among patients on AS changed over time. The response 
rate regarding the second questionnaire amounted to 90%. Men with low-risk PC who 
started and remained on AS during 9 months, remain to have favorable levels of anxiety 
and distress. Only 2/129 men (2.6%) discontinued AS because of non-medical reasons.
Other results
Whereas Van den Bergh et al. [30,31] reported very favorable levels of anxiety and 
distress among men under AS, Wallace [32] reported that men undergoing watchful 
waiting (i.e. initial surveillance followed by active treatment if and when tumour pro-
gression produces symptoms [32]) were uncertain. This uncertainty results in or from 
their perception of danger and therefore influences  men’s quality of life. Latini et al. 
[33] reported that treatment decisions were influenced by cancer anxiety and that more 
psychological support should be provided to men. Patel et al. [34] found, in an evalu-
ation of men undergoing AS, that 8% of men with no evidence of cancer progression 
were given active treatment because they had significant anxiety about the possibility 
of progression and about living with cancer. These results point towards the need of 
appropriate teaching and management interventions to alleviate anxiety.
Van den Berg et al. [29] reported that men on AS had adequate knowledge of PC. Avery 
et al. [35] reported that while most men found PSA testing and biopsy acceptable, their 
perception of risk were not always accurate. It should be stressed to men that the lack of 
relationship between the risk of PC and urinary symptoms is essential; urinary symptoms 
are more likely to indicate benign rather than malignant prostate disease. Next to that 
a two-stage information process may also be necessary to overcome barriers at both 
PSA testing and prostate biopsy. The provision of more tailored information on the one 
hand improves PC knowledge, while on the other hand it helps to facilitate informed 
decision making.
Furthermore, few studies regarding quality of life in men undergoing AS have been 
performed. Even fewer studies have measured utilities for AS health states. Utilities 
derived from Dale et al. [36] were used by Hayes et al. [16] in a modeling study. They 
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concluded that under a wide range of assumptions AS is a reasonable approach for a 
65-year-old man with low-risk PC. Hayes et al. [16] performed a decision analysis to as-
sess the quality-adjusted life expectancy of AS compared with initial definitive treatment 
with radical prostatectomy, intensity-modulated radiation therapy or brachytherapy. The 
authors reported that AS was the most effective strategy, with intensity-modulated ra-
diation therapy for progression. The most effective strategy was defined as the strategy 
that was associated with the highest quality-adjusted life expectancy. AS provided 6 
additional months of quality-adjusted life expectancy as compared to brachytherapy, i.e. 
the most effective initial treatment. However, it should be taken into account that the 
model is based on individual patient utilities and that the decision analysis only modeled 
outcomes for 65-year-old men.
Shared decision making
In the light of the above and taking into account that PSA is still the most important 
pillar for diagnosing PC, it is important to enhance informed and shared decision mak-
ing [37-39]. According to Marteau, an informed choice can be described as ‘a choice 
that is based on relevant knowledge, consistent with the decision maker’s value and 
behaviorally implemented’ [40]. Marteau [40] describes that at the beginning of the 
twenty-first century screening was largely viewed as a public health activity which was 
aimed at reducing disease prevalence. To achieve this, the emphasis has been upon 
high rates of uptake, and not upon an informed choice. Throughout the years, a shift in 
emphasis towards informed choice has occurred [40]. Several considerations reflect this 
shift. First, it reflects an increasing recognition of the fact that it is unethical for individu-
als not to be informed of the consequences of medical interventions. Men undergoing 
a PSA test should be made aware of the consequences that the PSA test could have 
on their lives. It is not just the pros and cons of the PSA test that should be weighted. 
Second, it reflects a belief that an informed choice is associated with better patient 
outcomes, as compared to an uninformed choice. Finally, the concern that failure to 
appreciate the consequences of screening may result in litigation has also resulted in 
the emphasis towards an informed choice. As PC screening is available to more men 
nowadays, it is important to raise awareness around an informed choice. Earlier it was 
already described that the PSA test is currently the most commonly used screening tool 
for PC [41]. However, the PSA test has both strengths and weaknesses. Men deciding 
to undergo PSA testing should be aware of both, which enables them to make a choice 
that is consistent with their individual values. It is also important for men to be informed 
about further medical consequences. If a PSA of ≥3 ng/ml is measured, in most cases 
a prostate biopsy will be recommended [5]. Nijs et al. [42] reported that the idea of 
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undergoing a prostate biopsy already caused anticipated pain and discomfort. Zisman 
et al. [43] found that undergoing a prostate biopsy can have an impact on the patient’s 
well-being due to causing pain and anxiety. Macefield et al. [44] reported that although 
most men coped well with undergoing a biopsy, a minority experienced elevated distress 
at the time of biopsy and after receiving a negative result. The authors stress that men 
should be informed of the risk of distress that is related to diagnostic uncertainty before 
consenting to PSA testing and possibly undergoing a biopsy.
While uncertainties persist around screening for PC using a PSA test, combining informed 
decision making with shared decision making  seems a logical step. If patients are able 
to make an informed choice, it is certain that their choice balances their personal values. 
By also recommending shared decision making, the professional and the patient will 
share information, jointly participate in the decision making and agree in a course of 
action that incorporates the patient’s personal preferences [45].
In general, decision aids help men make an informed decision about a number of 
preventive measures and treatments [8]. Throughout the years, several aids have been 
developed specifically to address PSA testing [8,46-52]; all showing a positive effect on 
informed decision making. O’Connor et al. [51] lists several elements which should be 
enhanced in a good decision aid: (i) improve knowledge of the problem, options and 
outcomes; (ii) create realistic expectations of outcomes; (iii) clarify personal values for 
outcomes; (iv) promote congruence between values and choice; (v) reduce decisional 
conflict; (vi) promote implementation of choices; and (vii) improve satisfaction with 
decision making.
In an evaluation study of decision points provided with the paper version of a risk indica-
tor the value of informed decision making has been assessed [41]. Two questionnaires 
were sent to a random sample of 2000 men, age 55-65 years. An informed choice in 
this study was defined as ‘relevant knowledge about the PSA test, a positive attitude 
towards a PSA test, and undergoing a PSA test’. A man also makes an informed choice 
if he has relevant knowledge about the PSA test, has negative attitude towards the 
test and does not undergo it. Other combinations reflected an uninformed choice. 
Van Vugt et al. [41] reported that significantly more men met the requirements of an 
informed choice after receiving information on PC and after receiving an individualized 
risk estimate made possible with a PC risk calculator: 81/535 men (15%) at the first 
versus 174/522 (33%) at the second assessment (p<0.001).
Volk et al. [53] reported that decision aids, focused on PC screening, showed a long-
term effect on screening behavior and also promoted informed decision making.
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As shared decision making is being engaged in several major guidelines (American Uro-
logical Association, American Cancer Society and the US Preventive Services Task Force) 
[45], the question rises whether shared decision making is applied effectively in practice. 
Several studies confirm that shared decision making is applied in practice [45,53-55]; 
however, it appears that discrepancies exist between the preferred role and the actual 
role of patients in the decision-making process [56]. Men are becoming more active 
in the decision-making process, as the study by Davison and Degner [57,58] (32% of 
men wanting their physician to make the final decision, versus 58% of men in a similar 
conducted study 5 years earlier) shows. However, in general it is still the doctor who sets 
the agenda and who decides how much information is presented to the patient [56]. 
Whether effective shared decision making is reached, is affected by the willingness of 
the urologist to involve the patient in the decision-making process.
Conclusions
Throughout the years, the knowledge on PSA and the PSA test has increased. However, 
that has not led to an unambiguous trust in the PSA test. The sensitivity and specificity 
of the PSA test are not optimal. Since no other prostate-specific biomarker is currently 
available, the PSA test will stay the most important diagnostic tool in both clinical and 
screening settings. Several screening studies, all using the PSA test as a diagnostic tool, 
have provided evidence regarding the efficacy of screening. Screening can lead to a 
disease-specific mortality reduction; however, it is currently also associated with overdi-
agnosis and overtreatment. AS seems a realistic strategy in avoiding overtreatment. AS 
is the subject of several ongoing studies, of which the results look promising.
It is important to enhance shared and informed decision making, because on the one 
hand the pros and cons of PSA testing should be clear to men who wish to be screened. 
On the other hand, informed and shared decision making can play a role when choosing 
a treatment strategy, especially when there are more options.
Suggestions for the future
Since Steginga et al. [59] reported that an informed choice about PSA testing was the 
exception rather than the rule, and since the advantages for patients have been docu-
mented by now, more urologists should enhance informed and shared decision making 
in clinical practice. Many men are tested without a preceding discussion or even because 
PSA is included in routine lists of laboratory tests. In the United States current guidelines 
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recommend that PC screening should be discussed with patients and that a PSA test 
should be provided to those men who decide to be tested [60-62]. However, if a man 
is not aware of the pros and cons of the test, as well as the consequences the result of 
the test can have, the doctor deciding for them does not seem justifiable, since decision 
making should balance personal values. A doctor can help in making such a decision; 
however, he should not make the decision himself unless asked.
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Abstract 
Purpose of review. To give insight into recent literature (during the past 12-18 months) 
reporting on oncologic outcomes of men on active surveillance.
Recent findings. From recent published trials comparing radical prostatectomy vs. 
watchful waiting we learn that radical treatment only benefits a small proportion of 
men and that a substantial part of men is overtreated. Therefore, active surveillance 
should aim at postponing treatment for most, but still generate the same disease-
specific mortality as radical prostatectomy by treating only those who benefit. In this 
review some recent published data on prostate cancer-specific mortality under active 
surveillance as well as intermediate outcomes are described.
Summary. Prostate cancer-specific mortality under active surveillance is very low, 
however, longer follow-up is warranted. When deferred radical treatment and immedi-
ate radical treatment are compared, results seem to be quite similar, suggesting that 
postponing treatment does not affect the outcomes of men under active surveillance. 
Furthermore, in the majority of men active treatment could be avoided completely, 
without compromising oncologic outcome.
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Introduction
Since the introduction of prostate-specific antigen (PSA) in the mid-1980s, a lot has 
changed in the world of prostate cancer. As a result of the embracement of PSA as a 
biomarker for the early detection of prostate cancer, a sharp increase in the incidence 
of prostate cancer was seen. Later on in time, after the prevalent cases were diagnosed 
and treated and the median volume of prostate cancer in newly diagnosed patients 
began to fall, a dramatic increase in the number of patients with low-risk disease, that 
is a prostate cancer never leading to symptoms or death irrespective of patients’ comor-
bidities or expected life span, was seen [1]. Here lies one of the key challenges in the 
management of prostate cancer; low-risk disease is very common [1-2]. Autopsy studies 
have shown that for men of age 60 years, cancerous cells can be found in 30-40% of 
the prostates [3], rising to 60-70% by the age of 80 years [4], although the eventual risk 
of death from prostate cancer is only about 3% [3]. Meanwhile randomized prostate 
cancer studies were initiated and have shown a positive effect of screening, with a 
reduction of the disease-specific mortality in the screening arm as compared with the 
control arm [5-6]. However, the related overdiagnosis and subsequent overtreatment 
evolving from PSA based prostate cancer screening have made that population-based 
screening is not (yet) a worldwide accepted strategy.
Up to now there are no biological or clinical parameters available that distinguish low 
risk from potentially aggressive prostate cancer. With the introduction of active surveil-
lance as management strategy for low-risk prostate cancer, it is attempted to balance 
the risks of the disease vs. the risks of treatment. Active surveillance aims to avoid 
overtreatment by initially withholding radical therapy. The tumor is closely monitored 
with the possibility to switch to active therapy with curative intent when progression oc-
curs [7]. Several active surveillance programs have been initiated worldwide, all with the 
aim to establish active surveillance as a proven treatment option and to determine the 
optimal selection and surveillance criteria for men on active surveillance. The purpose 
of this review is to give insight into oncologic outcomes of prostate cancers managed 
with active surveillance.
Differences in mortality between radical prostatectomy vs. 
watchful waiting
In 2011 and 2012 the results of the randomized Scandinavian Prostate Cancer Group 
Study Number 4 (SPCG-4 trial) and the Prostate Cancer Intervention versus Observation 
Trial (PIVOT trial) were published [8*-9*]. Bill-Axelson et al. [9*] reported that radical 
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prostatectomy was associated with a reduction in prostate cancer death of 38% as 
compared to watchful waiting (i.e. receiving no immediate treatment apart from 
transurethral resection in case of local progression [10]), after a median follow-up of 
12.8 years. In the radical prostatectomy group 55 of 347 men (16%) died because of 
prostate cancer. In the watchful waiting group 81 of 348 men (23%) died because of 
prostate cancer. In contrast, Wilt et al. [11] reported on the PIVOT trial that among men 
with localized prostate cancer, radical prostatectomy did not significantly reduce pros-
tate cancer mortality as compared to observation (i.e. watchful waiting with delayed 
palliative intervention upon disease progression) through at least 12 years of follow-up 
[8*]. Radical treatment was beneficial only for subgroups of men with more aggressive 
tumor features.
If looked at low-risk patients, Bill-Axelson et al. [9*] reported a non-significant differ-
ence in prostate cancer death of 14% and 8% in the watchful waiting and radical 
prostatectomy group, respectively (low-risk defined as PSA < 10 ng/ml and Gleason 
score < 7 or WHO grade 1). Most men were, however, diagnosed in the pre-PSA era. 
Wilt et al. [8*] reported lower rates of prostate cancer death for men with low-risk 
prostate cancer according to the D’Amico criteria (PSA < 10 ng/ml, Gleason score < 7 
and clinical stage < T2b) of 3% and 4% for the observation and radical prostatectomy 
groups, respectively.
Both studies seem to contradict in what they conclude, that is surgery being beneficial 
over watchful waiting in the SPCG-4 trial and radical prostatectomy not significantly 
reducing prostate cancer mortality as compared with observation in the PIVOT trial. 
What we can conclude from these studies is that radical treatment only benefits a small 
proportion of men with less favorable tumor characteristics and that a substantial part 
is overtreated. Therefore, active surveillance should aim at postponing treatment for 
most, but still generate the same disease-specific mortality as radical prostatectomy, by 
treating those who would benefit.
Prostate cancer mortality and active surveillance
Present studies on the value of active surveillance have reported low disease-specific 
mortality rates. In the Göteborg prostate cancer screening trial [12**] about half of all 
screen-detected prostate cancers were managed with active surveillance; a proportion 
that seemed to be stable throughout the entire study. The cohort of active surveillance 
patients consisted of 439 men with a median age at diagnosis of 65.4 years and a 
median follow-up of 6.0 years from diagnosis. Godtman et al. [12**] classified their 
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active surveillance patients according to the Epstein criteria as very-low-risk, low-risk, 
intermediate-risk and high-risk. Of all 439 men, 63% (277) continued on active surveil-
lance throughout the entire study period. Of the 162 men who switched to deferred 
active treatment at some point during the study period; 106 were treated with radical 
prostatectomy, 32 with radiotherapy and 24 with hormonal therapy. During follow-
up 60 men died; 59 from other causes than prostate cancer. One individual in the 
intermediate-risk group died after having received hormonal therapy 8.6 years after 
active surveillance. He developed distant metastases and died of prostate cancer 12.7 
years after diagnosis [12**].
Klotz [1] reported on a Canadian study initiated in 1995. This prospective, single arm 
cohort study was initiated to assess the feasibility of an active surveillance protocol 
with selective delayed intervention. This cohort consists of 450 patients with a median 
age of 70.3 years and a median follow-up of 6.8 years. Among the 450 patients 97 
died (21.6%). The 5-year and 10-year disease-specific survival was 99.7% and 97.2%, 
respectively. Five men died of prostate cancer, all of which had been reclassified as 
higher risk and were offered radical treatment.
Bul et al. [13**] reported on the outcomes of the Prostate cancer Research International: 
Active Surveillance (PRIAS) study. In this worldwide active surveillance cohort, 2494 men 
were followed prospectively with a median follow-up of 1.6 years. In 1480 men one 
or more biopsies were performed; 415 (28%) showed reclassification. Overall, 1885 
patients continued on active surveillance and 527 patients (21%) underwent active 
therapy. Of these 527 men, 387 (73%) underwent active therapy because of protocol-
based reasons, 47 men (9%) switched because of anxiety and 93 men (18%) of other 
reasons. The disease-specific survival rate was 100%, and during follow-up 18 men died 
of causes other than prostate cancer.
Tosoian et al. [14**] reported on the outcomes of the Johns Hopkins active surveillance 
study. In total 769 men were followed for a median of 2.7 years. Deferred active treat-
ment was given to 255 men (33.2%), of which 192 men had a follow-up after treat-
ment of more than one year. During follow-up no prostate cancer death or metastases 
were found.
If we compare the outcomes of these studies, the results in terms of disease-specific 
mortality are promising. However, longer follow-up is needed to be able to evaluate the 
potential of active surveillance as an acknowledged management strategy.
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From the article by Xia et al. [15] we learn that, even though empiric data have a too 
short follow-up, modeling data on prostate cancer mortality show promising results. 
The authors used a model to project prostate cancer mortality among contemporary 
low-risk cases on active surveillance, followed by radical prostatectomy if the disease 
progresses, and compared these projections with prostate cancer mortality had the 
cases received immediate radical prostatectomy [15]. The model projected that 2.78% 
of men on active surveillance and 1.64% of men with immediate radical prostatectomy 
would die of their disease in 20 years. On average, the model projected that men on 
active surveillance would remain free of treatment for an additional 6.4 years relative 
to men treated immediately. This modeling experiment shows that the performance of 
active surveillance is comparable to radical prostatectomy in terms of disease-specific 
mortality.
Intermediate outcomes
As active surveillance studies have a relatively short follow-up to compare disease-specific 
mortality, it may be worthwhile to evaluate the intermediate outcomes. Intermediate 
outcomes can be defined as, among others, PSA progression, local progression and 
metastases. To make a comparison between active surveillance and radical treatment 
we have looked at outcomes of radical treatment after an initial active surveillance strat-
egy as compared with immediate radical treatment. By evaluating these outcomes we 
can determine how many men on active surveillance had worse outcomes and should 
perhaps have been treated earlier.
Bul et al. [16**] presented data from the PRIAS study. Of the 189 radical prostatectomy 
cases, pathology results were available for 167. Pathology results showed 134 organ-
confined cases and 32 cases (19%) with extracapsular extension. Gleason scores 6 or 
less, 3+4, 4+3 and 8 were found in 79, 64, 21 and 3 cases, respectively. Unfavorable 
radical prostatectomy results (pT3-4 and/or Gleason score ≥4+3) were found in 49 
patients (29%), of whom 33 (70%) had a biopsy-related reason for deferred radical 
prostatectomy.
Tosoian et al. [14**] and Dall’Era et al. [17] reported on the biochemical recurrence 
rate after active treatment. Of the 192 men who were treated actively and had a 
follow-up of more than 1 year in the Johns Hopkins study, 9.4% showed biochemical 
recurrence after a median follow-up of 2.8 years for men who underwent radiotherapy 
and 2.0 years for men who underwent radical prostatectomy [14**]. Dall’Era et al. 
[17] compared outcomes of immediate treatment (within 6 months of diagnosis) vs. 
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an initial active surveillance strategy followed by active treatment. In total, 233 men 
with low-risk prostate cancer (defined as PSA < 10 ng/ml, Gleason sum ≤ 6, absence 
of Gleason grade 4 or 5, cancer involvement of ≤ 33% of biopsy cores and ≤ 50% of 
any single core, clinical stage T1/T2) were on active surveillance. A total of 65 men 
(28%) underwent deferred treatment, 33 of which received radical prostatectomy after 
a median time on active surveillance of 18 months. At radical prostatectomy, 30% of 
patients were upgraded to at least a Gleason score 7 and 21% of men on active surveil-
lance followed by radical prostatectomy showed upstaging to pT3A. These rates did not 
differ significantly from the 278 men who received immediate radical prostatectomy. 
Biochemical disease-free survival for men with more than 4 years of follow-up after 
radical prostatectomy was 98% and 100% for immediate surgery and surgery after 
active surveillance, respectively [17].
Godtman et al. [12**] defined failures after active surveillance as prostate cancer death, 
metastatic disease (which were both reported above) as well as PSA recurrence after 
curative treatment and hormonal treatment. Fourteen of 167 men (8%) had a PSA re-
currence after radical prostatectomy, radiotherapy or radical prostatectomy with salvage 
radiation [12**].
Ischia et al. [2] reported on the Australian experience. Men who chose active surveillance 
for their low-risk prostate cancer and were managed by one surgeon in Melbourne, 
Australia, were included in the study. This cohort consisted  of 154 men with a median 
age of 63.0 years and a mean PSA of 6.5 ng/ml. The median time of active surveillance 
was 1.9 years (0.1-16.1). Active surveillance was ceased in 29 patients (19%) after a 
mean of 2.4 years (0.2-7.9). Of these 29 men, 26 were upstaged, one chose curative 
treatment despite stable disease, and two died of disease not related to prostate cancer. 
Of the 17 men who received radical prostatectomy, four had T3 disease (31%). Ischia 
et al. [2] concluded that no biochemical recurrences or prostate cancer deaths were 
seen in men treated for prostate cancer during the short follow-up period. In table 1 all 
information is summarized.
These intermediate outcomes of active surveillance are harder to interpret, with less 
unequivocal end-points used in different studies. Overall, results after deferred radical 
treatment seem to indicate a proportion of men with less favorable outcomes (8-31%). 
It could be argued that these men should have been treated earlier. However, if com-
pared to immediate radical treatment, results seem to be quite similar, suggesting that 
postponing treatment does not affect the outcome of these men within the available 
follow-up. Active surveillance did, however, delay the side-effects of treatment and 
positively affects the patients’ quality of life [18-19]. Furthermore, the majority of men 
Lionne Venderbos BW CP4.indd   69 08-10-15   11:18
70
are still on active surveillance without the protocol indicating to switch to deferred 
active treatment. This suggests that the tumors in these men show very indolent growth 
patterns. Future active surveillance studies may compare immediate outcomes with 
outcomes of men receiving immediate radical treatment to demonstrate the safety of 
active surveillance.
Conclusion
Overall, it can be concluded that prostate cancer mortality under active surveillance is 
very low, which supports the suggestion of active surveillance being a safe management 
strategy for low-risk prostate cancer. However, longer follow-up is warranted as present 
studies on the value of active surveillance have rather short follow-up to assess mortal-
ity outcomes, considering the slow natural course of prostate cancer. With respect to 
intermediate outcomes of active surveillance, it is more difficult to draw conclusions, as 
less unequivocal end-points are used in ongoing active surveillance studies. After having 
reviewed the results published during the last 12-18 months, it seems that choosing an 
initial active surveillance strategy, if applicable looking at prostate cancer characteristics, 
does not affect the outcomes of these men compared with those men who choose 
immediate active treatment. Choosing active surveillance then has the advantage of 
delaying side-effects of treatment and preserving health-related quality of life.
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Abstract
Purpose. To study whether probabilistic selection by the use of a nomogram could 
improve patient selection for active surveillance (AS) compared to the various sets of 
rule-based AS inclusion criteria currently used.
Methods. We studied Dutch and Swedish patients participating in the European 
Randomized study of Screening for Prostate Cancer (ERSPC). We explored which men 
who were initially diagnosed with cT1-2, Gleason 6 (Gleason pattern ≤3+3) had histo-
pathological indolent PCa at RP [defined as pT2, Gleason pattern ≤3 and tumor volume 
(TV) ≤0.5 or TV ≤1.3 ml, and TV no part of criteria (NoTV)]. Rule-based selection was ac-
cording to the Prostate cancer Research International: Active Surveillance (PRIAS), Klotz 
and Johns Hopkins criteria. An existing nomogram to define probability-based selection 
for AS was refitted for the TV1.3 and NoTV indolent PCa definitions.
Results. 619 of 864 men undergoing RP had cT1-2, Gleason 6 disease at diagnosis and 
were analyzed. Median follow-up was 8.9 years. 229 (37%), 356 (58%), and 410 (66%) 
fulfilled the TV0.5, TV1.3, and NoTV indolent PCa criteria at RP. Discriminating between 
indolent and significant disease according to area under the curve (AUC) was: TV0.5: 
0.658 (PRIAS), 0.523 (Klotz), 0.642 (Hopkins), 0.685 (nomogram). TV1.3: 0.630 (PRIAS), 
0.550 (Klotz), 0.615 (Hopkins), 0.646 (nomogram). NoTV: 0.603 (PRIAS), 0.530 (Klotz), 
0.589 (Hopkins), 0.608 (nomogram).
Conclusions. The performance of a nomogram, the Johns Hopkins, and PRIAS rule-
based criteria are comparable. Because the nomogram allows individual trade-offs, it 
could be a good alternative to rigid rule-based criteria.
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Introduction
Early detection of prostate cancer (PCa) has led to increased prevalence of finding indo-
lent tumors, i.e. tumors that are unlikely to become symptomatic during life. The ability 
to predict indolent PCa is needed to avoid overtreatment [1]. Active surveillance (AS) 
has emerged as a feasible strategy to decrease the overtreatment of low-risk PCa. With 
AS, men with low-risk PCa are strictly monitored over time, and if risk reclassification 
or disease progression occurs, they can opt for curative therapy. Hence, the aim of AS 
is to safely delay or completely avoid side effects of active therapy [2]. There are 16 
unique world-wide AS cohorts which all have their highly variable own protocols [3]. 
So far, published results on AS study cohorts worldwide show encouraging results on 
biochemical recurrence (BCR) rates and disease-specific mortality [4]. Long-term effects 
are yet unknown. Research on how to improve the existing AS protocols is, however, 
needed as misclassification at diagnosis, and subsequent reclassification after one-year 
repeat biopsy is not uncommon [5]. For example, 28% of men within the Prostate 
cancer Research International: Active Surveillance (PRIAS) study were reclassified after 
one or more repeat biopsies [6].
Currently, all existing AS cohorts apply relatively simple combinations of inclusion criteria 
for patient selection (“rule-based selection”). More refined risk stratification through 
a nomogram may be preferable, especially in the light of individualized medicine and 
shared decision-making (“probability-based selection”) [7]. We aimed to assess the 
performance of inclusion criteria as used in several prospective AS protocols in iden-
tifying indolent cancer at radical prostatectomy (RP) and follow-up outcomes of men 
who received immediate RP but were also suitable for AS. For comparison, we used a 
previously developed and externally validated nomogram that predicts indolent disease 
[8,9]. We hypothesize that the use of probabilistic selection by the use of a nomogram 
that incorporates multiple patient characteristics may be better for selection.
Materials and methods
Patients
Men included in this study were participants in the screening arm of the European 
Randomized study of Screening for Prostate Cancer (ERSPC). Data cohorts of the Swed-
ish and Dutch sections of ERSPC were combined. All men were diagnosed with screen-
detected PCa and underwent RP as primary treatment. Details on both Dutch and 
Swedish screening protocols were previously studied [10,11].
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Methods
Men with T3-4, Gleason ≥7 PCa at diagnostic biopsy or an unknown tumor volume 
were excluded from this analysis, as well as men with positive lymph nodes or distant 
metastases at the time of diagnosis or at the time of surgery. A multiple imputation 
model was used to fill in missing data. We used the first imputation of a multiple impu-
tation procedure with the impute function in SPSS software (IBM Corp. Released 2012. 
IBM SPSS Statistics for Windows, version 21.0 Armonk, NY: IBM Corp). A total of 936 
confounder values were missing, comprising 13.5% of all values. Filling in these values 
through imputation allowed us to include the 382 (44%) patients with any missing 
value in the analysis. All tumour characteristics were used for the multiple imputation.
We first assessed the frequency of indolent PCa at RP according to the classic definition 
of pT2, tumor volume <0.5 ml (TV0.5), and pathological Gleason pattern ≤3 [12]. Men 
not fulfilling these criteria for indolent PCa (TV >0.5 ml and/or pathological Gleason 
pattern >3) were categorized as having significant PCa.
Second, we selected men from our study cohort with low-risk PCa at diagnosis defined 
according to the PRIAS (T1c-T2, PSA ≤10 ng/ml, PSA density <0.20 ng/ml/cc, Gleason 
≤3+3, ≤2 positive cores), Klotz (T1b-T2b, PSA ≤10 ng/ml, Gleason ≤6), and John Hopkins 
criteria (T1c, PSA density <0.15 ng/ml/cc, Gleason ≤6, ≤2 positive cores, ≤50% single 
core involvement). The frequencies of indolent PCa at RP in these groups were studied.
Third, we explored the use of a nomogram to estimate risk for indolent PCa at RP [13]. 
We assessed the effect of applying various eligibility criteria for the nomogram (T1c-T2a, 
PSA ≤20 ng/ml, Gleason ≤3+3, ≤50% positive cores, 20 mm PCa, 40 mm benign tissue 
in all cores) and of different thresholds in the predicted chance of harbouring indolent 
PCa (referred to as Pind) on the number of men remaining suitable for AS at diagnosis.
The classic definition of a pathologic indolent PCa (pT2, TV0.5 and Gleason pattern ≤3) 
might be too restrictive and not reflecting biology well [14]. Therefore, we repeated 
steps one to three with two updated and more recent definitions of indolent PCa: (1) 
pT2, tumor volume <1.3 ml (TV1.3) and Gleason pattern ≤3+3 [14-16]; (2) pT2, Gleason 
pattern ≤3+3 and tumor volume no part of definition (NoTV) [15]. For step three, the 
nomogram was refitted twice using the original data [13], to account for the adjusted 
definitions of an indolent PCa.
Having the availability of follow-up data, we were able to calculate BCR after RP. The 
criteria proposed by Freedland et al. [17] were used to define BCR, i.e. one PSA value 
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after RP >0.2 ng/ml. The different sets of rule-based selection criteria and Pind cut-off 
points were compared using the Kaplan-Meier method and log-rank test.
We finally applied decision curve analysis (DCA) [18] to evaluate the potential clinical 
usefulness of rule-based selection and probability-based selection models. We estimated 
a net benefit (NB) for the four models by summing the benefits (true-positive indolent 
PCa) and subtracting the harms (false-positive indolent PCa). The harms were weighted 
by a factor related to the relative harm of being unjustly included on AS versus being 
directly curatively treated while suitable for AS. This weighting was derived from the 
threshold probability at which a patient would opt for AS. This threshold varies between 
men and urologists. Clinical practice currently uses a threshold probability of 50-70% 
[19]. The interpretation of a decision curve is rather straightforward; the model with the 
highest NB at a particular threshold should be chosen over alternative models.
P-values (two-sided) <0.05 were considered statistically significant. For statistical analy-
sis, we used the Statistical Package for the Social Sciences (SPSS) version 21 (IBM Corp. 
Released 2012. IBM SPSS Statistics for Windows, version 21.0 Armonk, NY: IBM Corp) 
and R version 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Our study cohort consisted of 864 men of whom 619 had cT1-2, Gleason 6 disease 
at diagnosis and were therefore eligible for analyses. Median follow-up time after 
diagnosis was 8.9 years. Table 1 presents the study cohort characteristics at diagnosis 
and outcomes after RP. With TV0.5 cut-off, a total of 229 (37%) tumors at RP could 
be defined as indolent versus 390 (63%) as significant. When applying the TV1.3 and 
NoTV indolent PCa definitions, the number of indolent PCa increases to 356 (58%) 
and 410 (66%), respectively. Pind could be calculated for 455 (74%) men meeting the 
nomogram inclusion criteria.
Table 2 presents the sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) for all three indolent PCa definitions (TV0.5, TV1.3, NoTV) at RP 
of the rule-based selection and nomogram-based selection approaches. The table also 
contains the effect of applying different thresholds of the nomogram calculated risk of 
harboring indolent PCa, i.e. Pind.
The area under the curve (AUC) for the TV0.5 indolent definition was 0.658 for PRIAS, 
0.523 for Klotz, 0.642 for Johns Hopkins, and 0.685 for the nomogram. For the TV1.3 
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Table 1: Study cohort characteristics at diagnosis and outcomes after radical prostatectomy (n=619)
At diagnosis
ERSPC study centre:
The Netherlands (n, %)
Sweden (n, %)
336
283
54
46
Follow-up (years) (median, 25-75p) 8.9 5.9-10.9
Age (years) (median, 25-75p) 62.9 60.1-66.2
Clinical disease stage (n, %):
T1c
T2a
T2b
T2c
395
157
37
30
64
25
6
5
PSA (ng/ml) (median, 25-75p) 4.5 3.5-6.4
Prostate volume (cc) (median, 25-75p) 35.1 28.3-45.1
PSA-density (ng/ml/cc) (median, 25-75p) 0.13 0.09-0.18
Total number of cores (median, 25-75p) 6 6-6
Number of positive cores (median, 25-75p) 2 1-3
Total benign tissue (mm) (median, 25-75p) 67.6 56.0-78.5
Total PCa tissue (mm) (median, 25-75p) 4.0 2.1-8.1
Percentage cancer per positive core (median, 25-75p) 30.5 14.7-64.3
Gleason sum:
≤ 6 619 100
Prediction indolent cancer (median, 25-75p) (N=455 suitable for nomogram) 60% 40-78%
At radical prostatectomy
Tumour volume (n, %)
≤ 0.5 cc
> 0.5 cc
≤ 1.3 cc
> 1.3 cc
284
335
497
122
46
54
80
20
Gleason sum (n, %)
≤ 6 (no pattern 4)
≥ 7
468
140
76
24
Indolent cancer (tumour volume ≤0.5 cc, T2, Gleason ≤ 3+3 disease)
Yes (n, %)
No (n, %)
229
390
37
63
Indolent cancer (tumour volume ≤1.3 cc, T2, Gleason ≤ 3+3 disease)
Yes (n, %)
No (n, %)
356
263
58
42
Indolent cancer (T2, Gleason ≤ 3+3 disease, no tumour volume cut-off)
Yes (n, %)
No (n, %)
410
209
66
34
* 25-75p = 25-75 percentile
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indolent definition, the AUC for PRIAS was 0.630, for Klotz 0.550, for Johns Hopkins 
0.615, and for the refitted nomogram 0.646. For the NoTV indolent definition, the AUC 
for PRIAS was 0.603, for Klotz 0.530, for Johns Hopkins 0.589, and for the refitted 
nomogram 0.608.
Table 2 furthermore presents the number of men who experienced BCR after RP ac-
cording to the three definitions of indolent disease in the different sets of rule-based 
criteria and the nomogram suitable cohort. A log-rank test showed that the number 
of men experiencing BCR do not differ statistically between the groups. However, the 
distribution of BCR over the indolent and significant group changes, with a rising per-
centage of BCR in the indolent group (TV0.5 = 3.4%, TV1.3 = 4.9%, NoTV = 6.3%). We 
found that in ROC analysis (appendix fig. 1), the nomogram (TV0.5) had a slightly better 
sensitivity-to-specificity ratio than the PRIAS rules. The AUC for the nomogram (TV0.5) 
was 0.610, for PRIAS 0.584, for Klotz 0.524, for Johns Hopkins 0.615, for the refitted 
TV1.3 nomogram 0.595, and for the refitted NoTV nomogram 0.570.
In terms of clinical usefulness, we found that in DCA analysis (appendix Fig. 2a-c), no 
large differences in NB were seen for threshold probabilities 50-70%, which are clini-
cally most relevant.
Discussion
In our cohort of Dutch and Swedish screen-detected PCa patients who all underwent 
initial RP, 37% fulfilled the TV0.5 indolent PCa criteria at RP increasing to 58% for 
the TV1.3 indolent PCa criteria and 66% for the NoTV indolent PCa definition. More 
stringent rule-based AS inclusion criteria as well as stricter nomogram probability 
thresholds decrease the rate of misclassified tumors in a rather similar fashion, but both 
at the cost of a substantial number of patients no longer considered suitable for AS. The 
nomogram based on TV0.5 had slightly better sensitivity and specificity with respect to 
BCR outcome than the PRIAS and Klotz criteria. If we juxtapose the TV0.5 nomogram 
to the Johns Hopkins criteria, the latter performed better but at the cost of including 
less patients and thereby curatively treating patients that might also would have been 
suitable for AS.
On the basis of a Kaplan-Meier analysis (curves not shown), we cannot conclude that 
the use of the TV0.5 nomogram is preferred over the use of rule-based selection or 
vice versa. However, for BCR the TV0.5 nomogram outperformed the PRIAS and Klotz 
criteria. The TV0.5 nomogram, however, performed slightly worse than the Johns Hop-
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kins criteria. If we chose a slightly lower Pind and therewith allowing more men to be 
included on AS, sensitivity and specificity of the TV0.5 are still acceptable. This flexibility 
in application is a property of using a nomogram for selection rather than a strict set of 
rules and desirable in the light of individualized medicine and shared decision-making.
Because the classic definition of a pathologically indolent PCa may be too restrictive 
[14], we also used two more updated definitions of an indolent PCa. When juxtaposing 
the models, the TV0.5 nomogram (AUC 0.685) was slightly better in discriminating 
indolent from significant PCa than the PRIAS (AUC 0.658), Johns Hopkins (AUC 0.642), 
and Klotz (AUC 0.523) criteria. This trend of the nomogram predicting slightly better is 
also seen for the refitted TV1.3 and NoTV nomograms.
Perfect patient selection for AS using either rule-based selection criteria or by apply-
ing a nomogram seems difficult at present. The AUCs illustrate that both approaches 
are currently suboptimal in differentiating indolent from non-indolent disease at RP 
in a group of men with already low-risk features at diagnosis. This is confirmed by 
the study of Wang et al. [20] whom in a group of 273 AS patients who underwent 
multiple biopsies and/or delayed RP found that nomograms designed to predict indolent 
tumors only have a modest ability to predict biopsy progression and any progression 
on either biopsy or surgery in men choosing an AS management strategy. Wang et al. 
furthermore concluded that in a subgroup of 58 men, none of the various nomograms 
were able to predict surgical progression at RP [20]. Since AS is incorporated into many 
guidelines (AUA, NCCN, EAU, etc.) as a viable management strategy for men with either 
very low-risk or low-risk PCa, it is expected that more men will elect AS as their primary 
therapy. The optimization of both rule-based selection and probability-based selection 
is therefore warranted.
Over the past few years, magnetic resonance imaging (MRI) is emerging as a tool which 
may be able to more accurately determine the risk of significant disease and progres-
sion of disease over time by improving sampling through target biopsies [21]. MRI may 
therefore also help better select AS candidates [22]. Several studies have shown the 
additional value of MRI in an AS protocol [21-23]. Stamatakis et al. [22] combined 
MRI-based factors into a nomogram which generates a probability for confirmed AS 
candidacy. They found that three MRI-based factors, i.e. number of lesions, lesion 
suspicion, and lesion density, were associated with confirmatory biopsy outcome and 
reclassification. A created nomogram which uses these factors has promising predictive 
accuracy, according to Stamatakis et al. [22]. It could be that adding such factors to the 
currently existing rule-based selection criteria or the nomogram could improve sensitiv-
ity and specificity and therewith AS patient selection.
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A first limitation of our study lies in the fact that men in our cohort were diagnosed 
with sextant biopsies. Sextant biopsy does not reflect current clinical practice anymore; 
nowadays, current practice relies on 8-18 core biopsies. Studies that applied more 
extended biopsy schemes argue that with a sextant biopsy protocol, 10-30% of cancers 
are missed [24]. Several studies reported that when 8-12 cores were taken, the PCa 
detection rate in a clinical setting might increase [24,25]. We validated the previously 
developed nomogram in multiple other populations in which more extended biopsy 
schemes were used. Results of these validation studies showed that the nomogram 
predicted indolent PCa with good discrimination, indicating that it can be broadly ap-
plied in contemporary urological practice [26,27]. In addition, we extracted correction 
factors for the adjustment of the nomogram with which contemporary extended biopsy 
schemes can be addressed [28]. Another limitation is that follow-up time of our study 
cohort is too short to assess mortality outcomes and relate these to baseline selec-
tion criteria. The lack of mortality outcomes was also the reason to choose BCR as 
an endpoint instead. Many men with BCR, however, will never develop metastasized 
disease or die from PCa [29]. Thirdly, patients underwent RP in different centers in either 
Sweden of the Netherlands. They were operated by different surgeons using different 
techniques for RP, which might influence outcomes. Finally, 247 cases included in this 
analysis were also used in the validation and construction of the nomogram. This may 
lead to an overestimated performance of the nomogram and Pind. The strength of 
this study lies in the fact that all men were diagnosed with PCa within ERSPC (Sweden 
and the Netherlands), resulting in standardized pathological examination of biopsy 
specimens and structured data follow-up [30].
In conclusion, in our cohort of Dutch and Swedish screen-detected PCa patients who 
all underwent initial RP, 37% had TV0.5 indolent PCa at RP increasing to 58% for the 
TV1.3 indolent PCa criteria and 66% for the NoTV indolent PCa definition. Performance 
of an ERSPC-based TV0.5 nomogram and rule-based selection by the Johns Hopkins 
and PRIAS criteria is comparable. Because the nomogram allows individual trade-offs, it 
could be a good alternative to applying rigid rule-based criteria. Furthermore, a nomo-
gram anticipates on the continuous improvement of risk assessment by newly emerging 
risk criteria, including imaging modalities.
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Appendix figure 1: Receiver Operating Characteristics (ROC) curve for men that experienced BCR after 
RP within PRIAS, Klotz, Johns Hopkins and the nomogram.
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Appendix figure 2a-c: Decision Curve Analysis (DCA) showing the ability of the PRIAS, Klotz, Johns 
Hopkins and nomogram to discriminate between indolent and significant disease.
A. indolent PCa at RP with TV0.5
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B. indolent PCa at RP with TV1.3
C. indolent PCa at RP with noTV
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Abstract
Objective. Patients with potentially indolent prostate cancer (PCa) can be managed 
with active surveillance (AS). Our objective was to analyze how anxiety and distress 
develop in men with untreated PCa and whether highly anxious men quit AS.
Methods. One hundred and fifty Dutch patients who opted for AS in the Prostate 
cancer Research International: Active Surveillance study were invited to participate in 
an additional prospective, longitudinal quality of life (QoL) study within 6 months after 
diagnosis. Participants completed questionnaires with validated measures on anxiety 
and distress at inclusion (t=0), 9 (t=9) and 18 (t=18) months after diagnosis. We as-
sessed changes in scores on depression (Center for Epidemiologic Studies Depression 
(CES-D) scale), generic anxiety (State-Trait Anxiety Inventory (STAI-6)), PCa-specific 
anxiety (Memorial Anxiety Scale for Prostate Cancer (MAX-PC)) and decisional conflict 
(Decisional Conflict Scale (DCS)) about patients’ treatment choice between t=0, t=9 and 
t=18 using repeated measures analysis.
Results. Response rates for patients still on AS at t=0, t=9 and t=18 assessments were 
86%, 90% and 96%, respectively. Nine patients (7%, 9/129) between t=0 and t=9 and 
33 of 108 patients (31%) between t=9 and t=18 stopped AS, mostly (86%) because 
of protocol-based reasons. CES-D, total MAX-PC and DCS score did not change sig-
nificantly (p>0.05) when comparing t=18 with t=9 and t=0 scores, but generic anxiety 
(STAI-6; p=0.033) and fear of disease progression (sub-score of the MAX-PC; p=0.007) 
decreased significantly. These differences, however, were clinically modest (0.089 SD 
and 0.281 SD). Overall, six of 129 men (5%) discontinued AS because of anxiety and 
distress.
Conclusions. When men with low-risk PCa are managed with AS, fear of disease 
progression and general anxiety decreased, and only few may discontinue AS because 
of anxiety and distress. This suggests that negative QoL effects are limited in men with 
favorable clinical characteristics who opted for AS. (Registered trial number, NTR1718)
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Introduction
Screening and more intensive diagnostic work-ups lead to an increase in the detection of 
small, localized, well-differentiated prostate cancers (PCa). Therefore, the ratio between 
men dying with and from PCa is increasing. In many developed countries, detection and 
treatment are tightly linked; most patients with PCa receive radical treatment despite 
the favorable natural history of many tumors [1-3]. Treatment of small, localized, well-
differentiated PCa tumors should ideally be selective, reflecting each patient’s individual 
characteristics [4]. Active surveillance (AS), in that context, is considered a realistic initial 
alternative for curative therapy.
AS aims at selecting low-risk PCa with a likely favorable prognosis and strictly monitor-
ing these tumors over time. If risk reclassification or disease progression occurs, men can 
opt for curative therapy. The aim of AS is to safely delay or even completely avoid side 
effects of active therapy [5].
From the moment low-risk PCa is diagnosed, anxiety, distress, beliefs and expectations 
may play a role in a patient’s treatment decision-making [5], affecting the patient’s 
quality of life (QoL). The choice between an AS management strategy or active therapy 
potentially affects various QoL aspects. Although active therapy may provide patients 
with a feeling of certainty and being in control of their disease, the trade-off might 
be the worsening of sexual, urinary and bowel functions. Choosing AS spares these 
functions because active therapy is delayed or, potentially, completely avoided, but 
comes at the trade-off of continued uncertainty, anxiousness and distress. For patients 
who choose AS, there is always the possibility of missing ‘the window of curability’ or 
waiting too long before starting active therapy, which might lead to worse outcomes 
when compared with those with immediate treatment. It is hypothesized that such pos-
sibilities might have an unfavorable effect on sexual, urinary and bowel function as well 
as on anxiety and distress levels [6,7]. It is therefore recommended that these potential 
negative effects are thoroughly considered before choosing AS.
QoL among men on AS has been studied before [2,8-10]. Results showed that short-
term anxiety and distress levels were favorably low for men on AS compared with QoL 
of men choosing active therapy. Up to now, few studies reported longer-term QoL. With 
this longitudinal study, we report on the 18-month QoL of a cohort of men who agreed 
to participate in a well-defined, globally accepted AS protocol, the Prostate cancer 
Research International: Active Surveillance (PRIAS) study, and who accepted to follow 
the PRIAS protocol for an 18-month period. Of specific interest is how levels of anxiety 
and distress develop during follow-up. We hypothesize that anxiety and distress levels 
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remain favorable for men who continue AS for an 18-month period and that anxious 
men will discontinue AS early on.
Materials and methods
Patients included in this prospective QoL study were participants in the protocol-based, 
multicenter, prospective, observational PRIAS study [2,8,11]. PRIAS inclusion criteria 
are as follows: PCa diagnosis with a prostate-specific antigen (PSA) of ≤10.0 ng/ml; a 
PSA-density (PSA/prostate volume) of <0.2 ng/ml/ml; ≤T2; one or two positive prostate 
needle-biopsy cores, with a Gleason score of ≤3+3 = 6. The follow-up protocol included 
PSA measurements every 3 months for the first 2 years and every 6 months thereafter. 
Digital rectal examination was scheduled every 6 months for the first 2 years and once 
a year thereafter. Repeat biopsies were scheduled after 1, 4 and 7 years, and in the case 
of a PSA-doubling time between 3 and 10 years, yearly repeat biopsies were advised. 
Risk reclassification at repeat biopsy triggered a recommendation for active therapy and 
was defined as ≥3 positive biopsy cores and/or Gleason score of >6. A PSA-doubling 
time, which can only be reliably calculated after a minimum of one baseline and four 
follow-up measurements, of less than 3 years was also used as a trigger to initiate 
active therapy [11]. Men in our study thus have had several PSA measurements and 
underwent a repeat biopsy at 1 year post-diagnosis, that is, in between the t9 and t18 
measurement. Participation in PRIAS requires informed consent.
The inclusion period May 2007-May 2008 determined the sample size [12]. All Dutch 
PRIAS participants who were diagnosed with PCa (at most 6 months earlier) in that 
year were invited to be included in an additional QoL study (n=150). Besides the above-
mentioned PRIAS inclusion criteria, no additional inclusion or exclusion criteria were 
applied. Through regular mail, those who consented received a first QoL-questionnaire 
at their home address (t=0). If they had not returned their questionnaire within 1 month, 
they were reminded once by telephone. All patients who returned the first question-
naire received a second questionnaire 9 months after diagnosis (t=9). Patients who 
returned the second questionnaire received a third and final questionnaire 18 months 
after diagnosis (t=18).
The PRIAS study and its QoL study were approved by the Institutional Review Board of 
the Erasmus University Medical Center (MEC number 2004-339) and by the Institutional 
Review Boards of peripheral hospitals, taking local regulations into account. (Registered 
trial number, NTR1718).
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Measures included in the questionnaire
With the use of validated questionnaires, we evaluated levels of anxiety and distress of 
men on AS for low-risk PCa. We defined distress as ‘occurring when an individual can-
not adapt to stress’ [13]. Distress was measured through the Decisional Conflict Scale 
(DCS), Center for Epidemiologic Studies Depression (CES-D) scale and the self-estimated 
risk of progression scale.
We assessed potential decisional conflict regarding the choice for AS, using the DCS. 
The scale consists of 16 items with five response options each (score range per item is 
0-4). Scale scores range from 0 (no decisional conflict) to 100 (extremely high decisional 
conflict). DCS scores ≤25 tend to be associated with implementing decisions, while 
scores ≥37.5 are associated with decision delay or feeling unsure about implementation 
of a decision [2,14,15]. Subscales of the DCS were not analyzed in this study.
Symptoms of depression were assessed with the CES-D. The scale consists of 20 items 
with four response options each (score range per item is 0-3). The total score ranges 
from 0 to 60; the higher the score, the more symptomatology of depression is present. 
An individual is considered to be at high risk of clinical depression with a score of ≥16 
[2,16,17].
Furthermore, we assessed the self-estimated risk of disease progression with a self-
designed, non-validated, two question measure (Question 1: ‘Take in mind an average 
man with PCa who has also chosen an AS management strategy. What is his chance of 
progression of his PCa within the coming year?’ – ‘very unlikely, unlikely, average, likely, 
very likely’; Question 2: ‘Now imagine your personal situation. Do you estimate your 
chance of deterioration of your PCa in the coming year to become larger or smaller as 
compared to an average male on AS for PCa?’ – ‘The chance of deterioration for me 
is “very unlikely-”, “unlikely-“, “average-“, “likely-“, “very likely” as compared to an 
average male’). The answering categories of both items are scored 1-5 (very unlikely = 
1, very likely = 5). The total score of the self-estimated risk of progression scale ranges 
from -4 to 4 and is calculated by subtracting a man’s own self-estimated risk of the 
self-estimated average risk that this man reported. This measure is based on earlier 
research by Essink-Bot et al. [18].
Anxiety was measured through the State-Trait Anxiety Inventory (STAI-6) and the Me-
morial Anxiety Scale for Prostate Cancer (MAX-PC).
Generic anxiety was assessed with the abridged STAI-6. This scale consists of six items 
with four response options each (score range per item is 1-4). The total score ranges 
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from 20 to 80, with 80 indicating maximum generic anxiety. A STAI-6 score of ≥44 
defines an individual as highly anxious [2,19,20].
The MAX-PC was used to assess PCa specific anxiety. This scale consists of 18 items 
with four response options each (score range per item is 0-3). The total score ranges 
from 0 to 54, with 54 indicating maximum PCa specific anxiety. In earlier studies, a 
MAX-PC score of 27 has been applied to identify individuals with clinically significant 
PCa-specific anxiety [21]. The MAX-PC consists of three subscales that measure general 
anxiety related to PCa and treatment, anxiety related to PSA levels in particular and 
fear of recurrence (fear of disease progression) [2,21,22]. The MAX-PC subscale ‘fear of 
recurrence’ was not originally designed to measure fear of disease progression; it was 
designed to measure fear of recurrence after one was treated for PCa and the cancer 
was removed. With AS, it is not recurrence that men may be scared of, it is the progres-
sion of their cancer that they are worried about. Items of the subscale were structured 
in such a way that we consider them also applicable to fear of disease progression.
General physical health of participants was assessed at t=0 and t=18 with the short-
form health-survey (SF-12). The total scale consists of 12 items with two to six response 
options each, with which two summary scores can be calculated: the mental component 
summary (MCS) and the physical component summary (PCS). All 12 items are necessary 
to calculate both the MCS and PCS. In calculating the MCS and PCS, the distributions 
of weights for each item differ. Because of the conceptual overlap of the MCS with 
the CES-D, STAI-6 and MAX-PC, in this study the MCS items were not included in 
the analyses. The total score of the PCS subscale can range from 0 to 100, with 100 
indicating best overall health [23].
Validated Dutch translations of the DCS, CES-D, STAI-6, SF-12 and MAX-PC were used 
[24-28]. These measures had been validated in populations that are comparable to ours, 
that is, other cohorts of cancer patients, except for the CES-D, that had been validated 
in a cohort of older men from the general population. All measures were scored apply-
ing the official scoring system and regulations for missing values [14,19,21,23,29]. The 
Cronbach’s alpha of the self-estimated risk of progression scale was 0.84, indicating 
that the two items in this scale measure the same construct. While validation was not 
the aim of our study, we will nevertheless look at some psychometric properties of the 
used validated Dutch measures.
Previously, we presented baseline QoL outcomes and outcomes after 9 months of 
follow-up [2,8]. In the current article, the differences between scores on DCS, MAX-PC, 
STAI-6 and CES-D between t=0, t=9 and t=18 were analysed using repeated measures 
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analysis to assess changes over time. Differences in SF-12 (PCS) scores between t=18 
and t=0 were analysed with paired samples t-test after log-transformation due to non-
normal distribution. The clinical relevance of differences, that is, the smallest change 
in scores experienced as meaningful by patients, was determined using the minimal 
important difference, operationalized as half a standard deviation of the first measure-
ment [30]. Differences ≥0.5 SD were considered as relevant. Men with STAI-6 scores >44 
Table 1: Medical, demographic, and other characteristics at the moment of diagnosis of the total study 
population (N=129) [2]
Total number of patients 129
Medical
PSA* at diagnosis (median/25-75p**) 5.7 4.6-7.0 ng/ml
Last known PSA* before 2nd questionnaire (median/25-75p**) 5.6 3.8-7.0 ng/ml
Clinical stage at diagnosis
Non palpable
Localized
91
38
71%
29%
Number of positive biopsies at diagnosis
1
2
79
50
61%
39%
Demographics
Age at diagnosis (median/25-75p**) 64.6 60.2-70.4 Years
Education
Low (primary, secondary)
High (college, university)
Missing
86
42
1
67%
33%
Employed
Yes
No
Missing
76
50
3
60%
40%
Hospital
University/specialized
Other
68
61
53%
47%
Civil status
Married/living together
Other
119
10
92%
8%
Other
Major life event before diagnosis other than PC***
Yes
No
15
114
12%
88%
Sexually active
Yes
No
93
35
73%
27%
*PSA prostate specific antigen
**25-75p 25th – 75th percentile
***PC prostate cancer
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at baseline were considered as highly anxious [2,20]. We explored whether these men 
became less anxious during follow-up or whether these highly anxious men discontin-
ued AS. Analyses were performed with SPSS, version 20 (IBM, Armonk, NY, USA) and 
SAS, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
The average age of participants at baseline was 64.6 years, and their average PSA level 
was 5.7 ng/ml (table 1).
The t=0, t=9 and t=18 questionnaires were completed by 86% (129/150), 90% 
(108/120) and 96% (72/75) of participants still on AS (figure 1). The questionnaires 
were completed at a median of 2.4 months (25-75p: 1.3-3.9), 9.2 months (25-75p:9.0-
9.6) and 18.2 months (25-75p:17.6-18.6) after diagnosis. We compared the Cronbach’s 
alphas we found for our measures to the Cronbach’s alphas of Dutch validation studies: 
DCS 0.93 vs. 0.75-0.82 [24]; MAX-PC 0.77 vs. 0.77 [28]; STAI-6 0.77 vs. 0.83 [26]; CES-
D 0.60 vs. 0.80-0.90 [25]; SF-12 0.72 vs. 0.81-0.91 [27]. Questionnaires contained low 
numbers of missing values, and respondents added no remarks about the questions.
Between the t=0 and t=18 questionnaire, 42 men switched to active therapy; six upon 
their own request (5%, 6/129) because of anxiety and distress and 36 (28%, 36/129) 
because of reclassification or progression of their PCa. Treatment for these 42 men 
consisted of radical prostatectomy in 17 patients (40%), brachytherapy in 15 (36%), 
external beam radiation therapy in six (14%), High-Intensity Focused Ultrasound in one 
(2%), and an unknown treatment modality in three (7%).
 
Figure 1: Patient cohort selection. 
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Figure 2: Mean questionnaire scores at t=0, t=9, and t=18 (in accordance with table 2). 
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Table 2 presents the mean, median and interquartile range of questionnaire scores at 
t=0, t=9 and t=18. Figure 2 shows a graphical overview of the mean questionnaire 
scores at t=0, t=9 and t=18. We noted non-significant decreases in the mean scores 
between t=0, t=9 and t=18 for the DCS (p=0.336), CES-D (p=0.655), total MAX-PC 
(p=0.331) and self-estimated risk of progression (p=0.457) scores. For the SF-12 (PCS), 
a non-significant (p=0.428) decrease was seen between t=0 and t=18. Generic anxiety 
(STAI-6) (p=0.033) and fear of disease progression (subscale of the MAX-PC) (p=0.007), 
however, decreased significantly when comparing t=0, t=9 and t=18. These differences, 
however, were clinically modest: 0.089 SD and 0.281 SD, respectively.
Twenty-six men presented with STAI-6 scores >44 at baseline. Eight of these 26 men 
(31%) became less anxious and remained on AS. Six (23%) men were highly anxious 
at t=0, t=9 and t=18 but remained on AS. Three men (12%) were highly anxious at 
baseline, their scores decreased to ≤44 at t=9 and at t=18 they quit AS because of 
tumor progression. Seven men (27%) were highly anxious at baseline and stopped AS 
because of reclassification of their PCa at t=9. Two men (8%) were highly anxious and 
therefore stopped AS; these latter two belong to the group of six men who stopped AS 
upon their own request.
Discussion
In men with low-risk PCa who were managed with AS for an 18-month period, average 
levels of anxiety and distress remained favorably low. Our findings suggested further-
more that generic anxiety and fear of disease progression tended to decrease in men 
remaining eligible for AS. Only six of 129 men (5%) discontinued AS because of anxiety 
or distress. Eight of 26 men who were highly anxious at baseline became less anxious 
while remaining on AS.
This study provides additional information on the effect of AS on longitudinal QoL 
scores. Anxiety and/or distress were uncommon reasons to stop AS and switch to active 
therapy. A significant trend towards lower scores of fear of disease progression was ob-
served, which may be explained by the idea of stable disease providing confidence and 
tranquility of mind during follow-up [31] or by an upfront selection of those patients 
who expect that they can mentally deal with the potential progression of their disease. 
Our outcomes are supported by the results of a study among Finnish PRIAS participants 
that showed no deterioration of QoL after 1 [32] and 3 years [33] of follow-up. Instead, 
in this cohort of men, statistically significant QoL increases were seen, although clinically 
insignificant.
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Not all men with low-risk PCa may be candidates for AS. It was found that men with 
more neurotic personalities tend to have a higher chance of anxiety or psychological 
distress, which may lead to not choosing AS at all or stopping AS early [2,34]. It has 
been hypothesized that such men could benefit from psychological support in making 
a treatment decision. Bellardita et al. found in multivariate logistic regression models 
that factors predicting poor QoL during AS were having no partner, impaired mental 
health, recent diagnosis, influence of clinicians and lower number of core samples 
taken at diagnostic biopsy [7]. They concluded that the assessment of such predictors at 
entrance in AS could be useful in identifying more vulnerable patients to prevent poor 
QoL by promoting educational support from physicians and emotional/social support. 
Such predictors can also help in designing and implementing educational psycho-social 
interventions to support patients and in promoting well-being and positive adjustment 
to cancer [7]. In the Finnish AS cohort, men newly diagnosed with PCa were thoroughly 
informed about their treatment options by a urologist as well as by a specialized PCa 
nurse [32,33]. Only patients who seemed to accept the idea of living with a possible clini-
cally insignificant PCa for which no immediate treatment was needed were offered AS 
as a primary management option. The support that was provided in making a treatment 
decision led to none of the patients discontinuing AS because of anxiety in this cohort 
[32]. In our cohort, men were informed about all possible treatment options by their 
treating urologist. Potential additional methods of counselling were not standardized 
and decided upon by the individual centers. Applying predictors of poor QoL upfront 
inclusion on AS to prevent poor QoL by promoting educational support by physicians, 
as suggested by Bellardita et al. [7], or offering counselling, as suggested by Vasarainen 
et al. [32], to the two men who presented with STAI scores >44 could potentially have 
led to the continuation of AS.
The strengths of the present study are the prospective design and the availability of clini-
cal parameters for all participants. The outcomes of our study provide support for AS as 
a management strategy for low-risk PCa. Furthermore, we consider the use of validated 
measures in our cohort as a strength. The measures show similar Cronbach’s alphas 
compared with Dutch validation studies, except for the CES-D, which is potentially due 
to differences in the populations in which the Dutch translation of the measure was vali-
dated. The low number of missing values on the questionnaires indicates that patients 
considered the questions acceptable and that the questions were well understood.
Limitations of our study are the unavailability of a baseline measurement of anxiety 
and distress, the rather limited sample size, and that we cannot compare 18 months 
follow-up data of men on AS to QoL data of men who initially chose an AS strategy but 
later opted for curative therapy.
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The fact that we were unable to obtain a baseline measurement of anxiety and distress 
levels before men made a treatment decision may have led to an underrepresentation in 
our cohort of men who expected to experience feelings of anxiety and distress about liv-
ing with untreated PCa. It is therefore unknown how many men preferred active therapy 
over AS to avoid potential feelings of anxiety and distress of living with untreated PCa.
As men switching to active therapy during follow-up were not included in this study, we 
recommend focusing future research on QoL of men who switched from AS to active 
therapy. We found that of the six men who stopped AS because of anxiety and distress, 
two had reported high anxiety scores. It would be interesting to know how their QoL 
evolved after their decision to opt for curative therapy and the initiation of treatment. 
Also, four men discontinued AS because of distress, but this was not reflected in their 
anxiety scores.
Conclusion
When men with low-risk PCa are managed with AS, fear of disease progression and 
general anxiety decrease, and only few may discontinue AS because of anxiety and 
distress. This suggests that negative QoL effects are limited in men with favorable clini-
cal characteristics who opted for AS. The sample size was small, however, and further 
research is needed to confirm our results.
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Abstract
Prostate cancer (PCa) treatment by active surveillance (AS) has emerged over the last 10 
years. In the literature, AS is predominantly described from the point of view of patients 
and their potential benefit when they opt for AS. Throughout the years, several clinical 
studies were initiated and have reported their results, showing the feasibility of an AS 
program [1-4]. However, longer follow-up is needed to ensure the recognition of AS as 
an evidence-based treatment strategy. While much attention is paid to the validity and 
safety of AS, as well as the consequences for patients, also in terms of quality of life 
and psychological features, urologists’ opinion about AS have been described less often. 
Therefore, this chapter will focus on urologists’ acceptance of AS and their opinions 
about it within the USA and the Netherlands.
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Background
In general, the concept of screening refers to identifying a disease at a stage in its natural 
history during which treatment can be applied to prevent death or suffering [5]. Potential 
benefits of screening should be an increased, however not excessive rate of early-stage 
detected cancers, a decrease in the occurrence of metastatic cancer and a reduction in 
disease-specific mortality. Screening for PCa is challenging as the natural history of the 
disease differs markedly between slow-growing indolent tumors and highly aggressive 
and potentially fatal forms [5]. Early detection of PCa was initiated around 1994, after 
the American Food and Drug Association approved prostate-specific antigen (PSA) as a 
screening test for PCa [6]. In that same period, several major screening studies, i.e. the 
European Randomized study of Screening for Prostate Cancer (ERSPC) [7], the Göteborg 
randomized population-based PCa screening trial [8], and the Prostate, Lung, Colorectal 
and Ovarian Cancer Screening Trial (PLCO) [9], were started to assess whether PSA 
testing can reduce disease-specific mortality. In 2009 and 2010, the major screening 
studies provided evidence regarding the beneficiality of PSA screening for PCa-specific 
mortality. While the ERSPC and the Göteborg screening trial both reported a decrease 
in disease-specific mortality after a follow-up of 11 and 14 years, respectively, the PLCO 
trial did not show such an effect. On the contrary, according to the PLCO trial, screening 
for PCa does not lead to a decrease in disease-specific mortality. As the results are con-
troversial, the efficacy of PCa screening using PSA remains debatable. What the studies 
have in common is that a large number of indolent cancers will be diagnosed when 
population-based screening would be applied. Although population-based programs 
have not been introduced, large numbers of men have had a PSA test at least once in 
their life.
Due to the introduction of PSA-based screening for PCa, increasing numbers of patients 
with low-risk tumors are being detected (low risk being defined as clinical stage T1c, 
biopsy Gleason score ≤6, the presence of disease in ≤3 biopsy cores, ≤50% PCa involve-
ment in any of these cores, PSA density <0.15 ng/ml/g [10]). Data from the US Surveil-
lance, Epidemiology and End Results (SEER) program confirm that between 1975-2005, 
the number of PCa cases increased substantially [11]. Later on, incidence declined again, 
though this did not retain to the level that was seen before the introduction of the PSA 
test. Currently, in the USA, nearly 200,000 PCa cases are diagnosed annually [12,13] 
versus nearly 9,900 PCa cases in the Netherlands [14].
The described increase in PCa incidence is not accompanied by an increase in disease-
specific death rates. Apparently, the increased incidence does not reflect a true increase 
of the disease, and an explanation has to be found elsewhere. According to Challacombe 
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et al., the trend can be explained by the large stage shift from diagnosing palpable and 
locally advanced disease to diagnosing impalpable and localized disease [15]. Most of 
these screen-detected, low-risk tumors have favorable characteristics with high percent-
ages of long-term survival [16-18]. Probably most of these malignancies would never 
have caused any symptoms if they had remained undiagnosed, because they resemble 
autopsy tumors [19,20]. Due to screening, these cancers are detected which leads to 
overdetection and therefore overdiagnosis [21], often resulting in overtreatment. Men 
diagnosed with these low-risk cancers are subjected to unnecessary costly and invasive 
treatment with the risk of the occurrence of side effects [22] and should therefore be 
protected against such overtreatment.
Active surveillance
Replacing initial active treatment by closely monitoring the disease and indicating cura-
tive treatment if risk reclassification occurs may contribute to achieve this aim. By avoid-
ing or delaying active treatment - and its possible side effects - quality of life might also 
be preserved longer [22]. AS has been the subject of ongoing studies since the 1990s. 
Klotz et al. [2], Carter et al. [3], Kakehi et al. [4], van den Bergh et al. [1], Carroll at al. 
[23], Soloway et al. [24], Parker [25], Khatami et al. [26] and Stattin et al. [27] have all 
initiated studies regarding the value of AS. Klotz et al. [2] reported a median follow-up 
of 6.8 years in 2010; the other studies reported a shorter median follow-up [1-4, 23-27]. 
Up to now, reported results look promising; all studies show that a program of careful 
selection and monitoring of men who are likely to harbor clinically insignificant cancers 
is a rational alternative to active treatment. However, data still need to mature further 
for AS to be regarded evidence-based.
Comparison of the Official National Guidelines
Even though reported study results have not yet reached evidence-based status, guide-
lines in both the Netherlands and the USA already recommend AS as a treatment strat-
egy for certain groups of men. In table 1, national guidelines from both countries are 
compared. Differences are seen with respect to last update, definition of AS, theoretical 
basis, groups to whom AS is recommended as well as the definition of low-risk PCa. 
The Dutch guideline was last updated in 2007, as compared to 2009, 2010 and 2011 
for the American guidelines. Large differences are seen regarding the data on which the 
guidelines are based. The Dutch guideline is based on only two publications, whereas 
the American guidelines base their recommendations on 22, 7 and 7 publications, 
respectively. The guidelines of the NCCN and the American Cancer Society are based 
on more recent literature. A definition of AS is provided in three of the four guidelines. 
Where the Dutch guideline does not describe AS, the American guidelines do. The 
guidelines of both the NCCN and the American Cancer Society incorporate the defini-
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tion of AS as ‘intervening with curative intent if the cancer progresses’. The decision to 
recommend AS or not is based on tumor characteristics, but also on life expectancy. 
The briefest description of the target population is presented by the American Cancer 
Society guideline; AS is offered to men who have a cancer with a Gleason score ≤ 6. The 
American Cancer Society guideline does not provide a description of a low-risk tumor. 
The Dutch guideline and the NCCN guideline use the same definition of a low-risk 
PCa, whereas the definition on the AUA guideline differs slightly (T1-T2a in the NCCN 
guideline, versus T1c-T2a in the AUA guideline). The NCCN guideline is the only one to 
distinguish a very low-risk PCa from a low-risk PCa. Overall, the authors feel that the 
NCCN guideline provides the most informative recommendation. The Dutch guideline 
requires updating, a definition on AS and a broader theoretical base.
Rate of men treated with AS
In the USA, currently approximately 200,000 new cases of PCa are diagnosed annu-
ally as compared to nearly 9,900 in the Netherlands. According to Snyder et al. [55] 
approximately 90% of the PCas are clinically localized at diagnosis. This is confirmed 
by Jemal et al. [56] who report that approximately 92% of the prostate cancers are 
diagnosed at either an early or regional stage. After having received the diagnosis of 
early or regional stage prostate cancer, the 5-year relative survival rate of these cancers 
approaches 100% [56]. Many of these men are eligible for AS; however, it is estimated 
that in the USA, currently only approximately 10% of all PCa eligible for AS is treated 
with AS [57]. Data from the SEER database show that the percentage of patients treated 
with AS has decreased in the last years [58].
Within the Netherlands, hospitals and insurers use a ‘DBC pricing system’. A DBC is 
a code which describes a provided treatment, including the associated costs. It en-
compasses all activities and medical surgeries that a patient undergoes in hospital for 
the treatment of a certain disease during a certain time period. Currently, no DBC is 
available for AS, which makes it difficult to estimate how many men newly diagnosed 
with PCa are put on an AS regimen. Based on reports of Dutch urologists about the 
number of newly diagnosed patients with PCa they see every year and the number of 
patients opting for AS as a treatment strategy, we estimate that approximately 17.7% 
of the newly diagnosed PCa patients choose AS as their initial treatment strategy.
Viewpoint of the Dutch and American urologists
On the one hand, there is a rising demand for an evidence-based approach regard-
ing AS; on the other hand, not all urologists have a positive attitude towards such a 
program of closely monitoring the disease and interfering when progression occurs. 
The way in which urologists describe PCa to newly diagnosed patients influences their 
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perceptions of the seriousness of their condition and sets the tone for the ensuing 
treatment consultations [57]. Other studies confirm that patients with PCa rely heavily 
on recommendations by urologists in their choice of treatment [69-61]. It is important 
that urologists are aware of this. The fact that not all urologists have a positive attitude 
towards AS is shown in a study by Gorin et al. [61]; of all respondents that were eligible 
for AS, 36% were actually offered AS by the urologist who had first diagnosed their 
PCa. Gorin et al. concluded that a significant proportion of the study population, i.e. 
64%, were denied access to this option solely by their urologists’ attitude about AS [61].
Observed opinion about AS of the urologists in the USA and the 
Netherlands
To analyze the opinion of the urologist on AS, a questionnaire was developed by the 
authors including questions on how many newly diagnosed patients with PCa the urolo-
gist sees every year, whether the urologist brings up AS as a treatment option, whether 
patients ever bring up AS as a treatment option, whether AS is offered to patients with 
a low-risk PCa, etc. (see table 2). Within the Netherlands, 328 urologists, all senior 
members of the Dutch Urology Society (NVU), were addressed of whom 180 responded 
(response rate 55%). Of the respondents 87% (156/180) were working in a peripheral 
hospital and 13% (24/180) in an academic hospital. All urologists report to bring up 
AS as a treatment option, especially for low-risk PCa (low-risk being defined as T1-T2a, 
Gleason score < 7, PSA ≤ 10 ng/ml). For intermediate PCa, 55 urologists (31%) bring up 
AS as a treatment strategy as opposed to 69% who do not offer AS. Urologists were 
also asked  whether patients ever bring up AS during a consultation; 103 urologists 
(57.2%) confirmed this, while 77 urologists (42.8%) reported that their patients did not 
bring up AS. 128 urologists (71.1%) offer watchful waiting as an alternative for AS to 
patients eligible for AS. Overall, the Dutch urologists reported to have a positive attitude 
towards AS.
Table 2: Questions included in the urologists questionnaire
- How many newly diagnosed patients with PC do you see each year?
- Do you bring up AS as a treatment option?
- Do patients ever bring up AS as a treatment option?
-  Do you offer AS to patients with low-risk PC? Low risk PC is defined as T1-T2a, Gleason score < 7,  
PSA < 10 ng/ml.
- Do you offer AS to patients with intermediate PC? Intermediate PC is defined as a T3 tumor.
- Do you offer watchful waiting (WW) as an alternative to AS?
- Are you familiar with the (Dutch) ‘Guideline prostate carcinoma: diagnostics and treatment’.
- Opinion on the AS section in the Dutch guideline.
-  Which factors influence your recommendation for AS; patient request, the guideline, own experiences, 
financial incentives, ongoing AS studies, or other factors. Please list in your order of importance.
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Throughout the years, in the USA, awareness for PCa screening was raised by media 
stories and awareness campaigns sponsored by hospitals and by the US Postal Service 
who wanted to raise awareness for PCa by selling stamps (the PCa stamp was released 
in 1999) [62,63]. As a result, men visited the physician with the request for a PSA test. If 
the PSA test was negative, a patient would be grateful, but also when a suspicious PSA 
result was followed by a negative biopsy result. And a patient would also be grateful 
in the case of an early-detected PCa. For a professional, i.e. a physician or a urologist, 
the situation could be interpreted as a ‘no-lose’ situation. According to Ransohoff et al., 
time has to be spent in persuading a patient that screening for PCa is not necessary. At 
the same time, the health professionals risk an allegation of malpractice if screening is 
not performed and a cancer is found later, even when several discussions between the 
professional and the patient preceded the final decision not to screen [63]. Ransohoff et 
al. described that medical malpractice operates in a one-directional way; lawsuits only 
occur when a cancer is detected too late and not when a diagnosis is made too early so 
that an applied therapy is not beneficial. Because of the risk of malpractice allegation 
and the gratefulness of patients for being diagnosed early, a system without negative 
feedback regarding PCa screening has developed throughout the years [63].
AS can reduce the overtreatment that results from the overdiagnosis by screening for 
PCa. When on AS, the patient is closely monitored, and if risk reclassification occurs, 
curative treatment is started. In the in-between visiting periods, the chance of reclas-
sification is at stake. Here again, the risk of malpractice allegation is present as reclas-
sification of the tumor can arise too late in the sense that curative therapy is no longer 
possible; however, this is an exception rather than the rule. Klotz et al. performed a 
PSA test every 3 months in the first 2 years and then every 6 months in patients with 
a stable PSA [2]. They reported a 10-year cancer-specific survival rate of 97.2%. The 
cancer-related mortalities occurred in men who had been reclassified as higher risk and 
who had been offered radical treatment [2]. Krakowsky et al. report that some patients 
with favorable-risk disease at diagnosis harbor more aggressive disease and may be at 
risk for PCa mortality in spite of close monitoring [64].
To protect patients against inexpert and inaccurate performances of healthcare profes-
sionals and to maintain quality standards of care, cases of medical malpractice within the 
Netherlands can be reported at regional medical disciplinary tribunals [65]. In 2010, the 
regional medical disciplinary tribunals settled 11 urologic complaints (on approximately 
600 professionals) which amount to 1.83 complaints per 100 professionals for that year 
[66]. In the USA, Stimson et al. report on 1,516 unsolicited patient complaints filed 
against 268 urologists from January 1, 2004 through December 31, 2007 [67], which 
amounts to 141 complaints per 100 professionals per year. Such patient complaints can 
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result in malpractice claims. In the USA, Perrotti et al. report on urological malpractice 
claims that were filed with the Medical Liability Mutual Insurance Co. (MLMIC) of New 
York State that were consecutively closed between 1985 and 2004 with indemnity 
payment. MLMIC insured approximately 400 of the 1,100 urologists practicing in New 
York State. A claim was considered urological malpractice when the insured practitioner 
was a urologist. In most cases, the claim was directly related to the practice of urology, 
but it also included alleged negligent acts related to additional clinical data. A total 
of 469 urology malpractice claims were closed with indemnity payment [68], which 
averages to 6 claims per 100 professionals per year. For the Netherlands it is not clear 
how many complaints ended in indemnity payment. However, when comparing the 
1.83 per 100 professionals rate with the 141 per 100 professionals, it is not likely that 
the rate of complaints ending in indemnity payment in the Netherlands will rise above 
the American rates.
In the USA, the option of expectant management is offered to a small percentage of 
patients, approximately 10% of healthy 65-year-old men who have a Gleason score > 4 
or a PSA > 4.0 ng/ml [69,70]. Choosing AS is a complex decision a man has to make as 
he has to deal with the thought of living with untreated cancer. In it lies the concept of 
regret. According to Ransohoff et al., regret, just like medical malpractice, operates in 
a one-directional way; if cancer progresses during AS, a patient may regret not having 
acted sooner. On the contrary, regret may not occur when active therapy was chosen, 
because the patient knows that every possible measure to cure his cancer was taken 
[63]. Also here, radical therapy may lead to a no-lose situation for the professional; if 
radical therapy does not lead to cure, then still everything possible was done to cure the 
patient’s cancer. If a patient remains asymptomatic without recurrence, he will ascribe 
his survival to both detection and therapy. Although many urologists in the USA refrain 
from offering AS to men with low-risk PCa and are cautious to recommend it, several 
urologists acknowledge that by opting for AS the management of early-diagnosed PCa 
can be individualized [3,11,25] and morbidity as a result of treating low-risk PCa can be 
avoided or delayed.
Table 3: Frequency of discussing active surveillance (AS) in various circumstances (n=180 Dutch urolo-
gists)
Question Yes N (%) No N (%)
Do you bring up AS as a treatment strategy for low risk PC 180 (100) -
Do you bring up AS as a treatment strategy for intermediate risk PC 55 (30.6) 125 (69.4)
Do patients ever bring up AS during a consultation 103 (57.2) 77 (42.8)
Do you offer watchful waiting as an alternative for AS 128 (71.1) 52 (28.9)
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The Guidelines
Guidelines in the USA differ slightly in their definition of AS and recommendations 
about its target groups. However, the guidelines do provide a framework which is used 
in several American AS studies [2,3,24].
In the Netherlands, almost all urologists (96.7%) reported that they are familiar with the 
Dutch guideline. Most urologists agree with the current 2007 guideline on AS; however, 
some have the opinion that, instead of the current preference for curative treatment, 
AS could also be offered to men under the age of 75 years. Also, they would like to 
see a more specific description of AS in the guideline, as AS is now easily confused 
with watchful waiting, while the aim of the treatments differs. AS can be described as 
withholding initial radical treatment and instead closely monitoring the disease with the 
purpose of switching to invasive local therapy with a curative intent if risk reclassification 
occurs [1]. Watchful waiting is predominantly offered to older men who are physically 
unfit and have a limited life expectancy. It also consists of withholding initial treatment 
and monitoring the patient; however, when symptomatic progression occurs, often pal-
liative therapy is offered to the patient instead of radical treatment. The aim of watchful 
waiting is to alleviate disease symptoms without attempting to cure the disease [25,71].
Factors that influence the opinion of urologists regarding AS
The opinion of urologists about AS influences patient treatment decisions. It is therefore 
worthwhile to take a closer look at the observed differences between the USA and the 
Netherlands and to identify factors that influence the choice of a urologist to recom-
mend AS or not.
US urologists have been reported to be predominantly led by clinical characteristics of 
the patient such as PSA, PSA kinetics, PSA doubling time, digital rectal examination, 
transrectal ultrasound, results of repeat biopsies and patient comorbidity [25,72] in 
deciding whether or not to recommend AS. According to Klotz, who summarized the 
results of quality of life studies on AS [54,73-75], surveillance may be stressful for some 
men, but anxiety about PSA recurrence is common among both treated and untreated 
patients [11]. Klotz feels that such anxiety can be avoided by educating patients to 
appreciate the indolent natural history of most good-risk PCa [11].
We asked Dutch urologists which factors influenced their decision to offer AS most; the 
request of the patient, the guideline, own experiences, financial incentives and/or the 
current lack of mature follow-up data on AS. Urologists could list additional influential 
factors if desired. Dutch urologists reported to be predominantly led by the wish of 
the patient (55%, n=99 urologists); financial incentives played the least influential role 
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(<1%, n=1 urologist). More than half of the respondents reported that they also take 
into account patients’ physical and psychological characteristics, as well as clinical char-
acteristics when deciding which treatment would suit the patient best.
Financial incentives
Undoubtedly, there are different financial incentives that may play a role in the various 
medical care systems. Costs of treatments and their reimbursement are of continuous 
interest to health professionals. Also, when advising AS, urologists have to regard these 
aspects. The Dutch urologists - except one - reported that financial incentives did not 
play a dominant role, which does not have to mean that financial incentives never play 
a role at all. Also, within the USA, the potential role of financial incentives influenc-
ing medical malpractice is acknowledged by Barry et al. [76]. They report that when 
patients face medical decisions with multiple options, there are many stakeholders 
with different (financial) interests in promoting a particular choice, e.g. pharmaceutical 
agents, manufacturers of screening tests and medical devices, insurance companies and 
doctors [76]. According to Ransohoff, screening and therapy occur in an environment 
where financial incentives occur at several levels, which may give the impression that 
healthcare institutions and industry support screening for PCa [63]. We conclude that 
AS is possibly not offered to patients because of unfavorable clinical characteristics, the 
urologist not being convinced of AS as a treatment strategy or because more money can 
be earned by opting for other treatment options. Nguyen et al. described the latter and 
recognized that newer, more expensive technologies for treating prostate cancer have 
rapidly been adopted throughout the last years, without them being cost-effective [77]. 
Newer and more expensive alternative treatments will also be introduced in the future 
as technology keeps on striving forward. Interest from patients and providers in these 
new technologies as well as the belief by advocates that they could improve outcomes is 
sometimes sufficient to introduce these new technologies into clinical practice [77]. AS is 
said to be a novel strategy in treating PCa [25]; however, it does not enhance enormous 
earnings for healthcare providers and cannot be compared to, e.g. robotic surgery in 
which technology as such plays a crucial role. Perhaps we can say that although AS is a 
novel strategy, it is not a technology and as such the speed of its introduction is limited.
Discussion
Differences between the Netherlands and the USA regarding AS were described with 
respect to the guidelines, the rate of men treated with AS, the observed opinion towards 
AS and factors influencing the decision of the urologist in recommending AS including 
the possibility of financial incentives and the risk of malpractice allegations. The analysis 
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was performed on questionnaire data of Dutch urologists and on the available literature. 
We conclude that environmental circumstances are not likely to obstruct the adoption 
of AS as a treatment strategy; however, the circumstances do not encourage adoption 
either. It will depend to a large extent on the urologist and his working environment, 
whether or not AS is adopted as a treatment strategy.
The authors of this chapter feel that the Dutch guideline on AS should be updated and 
should take into account the available longer follow-up data on AS as well as including 
more literature on which to base the arguments for or against AS. With respect to the 
American guidelines, the authors feel that, in particular, the American Cancer Society 
guideline should be more explicit about to whom AS should be recommended as well 
as what should be considered  a low-risk PCa.
The rate of men treated with AS is approximately twice as high in the Netherlands as 
in the USA. The difference can possibly be explained by the more reserved attitude of 
American urologists towards AS, as they encounter a higher risk of malpractice allega-
tion. In both countries, however, the percentage of men treated with AS is considerably 
small. More mature follow-up data are necessary before AS can/will be recognized as 
an evidence-based treatment option. It should be taken into account, however, that the 
risk of malpractice allegation is not likely to change in the USA.
It is rather difficult to compare the opinions of the urologists from both countries. While 
results of the survey in the Netherlands show a very positive attitude towards AS so 
far, it cannot be judged whether the non-respondents share the same opinion as the 
respondents. Cultural differences between Dutch and American urologists may lead to 
different opinions. Also, within the USA, a segregation is seen between urologists who 
have a positive opinion about AS and the ones who do not. It is not likely that in the 
future all urologists will be positive towards AS.
In the light of possible malpractice allegation, it is likely that American urologists are 
predominantly led by clinical characteristics in recommending AS. Clinical characteristics 
are objective and therefore not subject of debate. When a patient opts for AS after 
having discussed it at length with a urologist, this discussion and weighing of pros and 
cons is of small use, with respect to malpractice allegation, when the cancer progresses 
unexpectedly and the patient dies as a result [63]. Such a situation does probably not 
reflect everyday reality; still, urologists may run into a claim which may translate into 
reluctance in recommending AS.
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Conclusion
Differences between the Netherlands and the USA in recommending AS can possibly be 
explained by the judicial status of malpractice procedures. Within the Netherlands, such 
continuous risk of malpractice allegation is present, however, to a much lesser extent 
when compared to the USA. Next to that the possible lack of financial incentives for AS 
should be incorporated into the overall perspective on AS. Arguments like follow-up 
data of AS not being mature enough, professionals facing the risk of a malpractice 
allegation if not ‘everything is done’, new technologies being available for treating PCa 
patients with less side effects and patients feeling relieved when cured from PCa all 
influence the choice of a urologist to offer AS.
Epilogue
Longer follow-up data are awaited from ongoing AS studies. The availability of such 
data will, most probably, result in a slight increase in men put on AS. However, the 
discussed elements of malpractice allegation in combination with new technologies 
and the possible financial incentives resulting from immediate curative treatment will 
probably restrain an increase in the number of patients opting for AS as their preferred 
treatment option. The authors expect that the rate of men on AS in the Netherlands will 
increase gradually over the coming years as AS is seen as a realistic strategy in reducing 
overtreatment.
For the future, a more accurate differentiation between aggressive and potentially 
indolent PCa is important. Prediction models can support the provision of tailored risk 
predictions to the urologist and the patient. Van Vugt et al. provided insight into the 
implementation of the ERSPC risk calculator in five Dutch hospitals. Urologists in a 
clinical setting appeared to be prepared to use the prediction model and its treatment 
recommendations to support treatment decision-making in men with localized PCa [78].
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Abstract
Active surveillance (AS) for prostate cancer (PCa) has become a viable management 
strategy for men with low-risk PCa. With AS being offered more often and more pa-
tients being included in AS studies, the aim of this paper is to describe AS from a legal 
perspective. What might be pitfalls in the management strategy that urologists should 
be aware of? In order to construct an answer to our research question, a patient from 
the Prostate cancer Research International: Active Surveillance (PRIAS) study will be used 
as an example. In the methods section, first some information on the PRIAS study is 
given. Then a PRIAS case will be described after which the Dutch legal framework will 
be set-out. Finally, the Dutch legal framework will be applied to the PRIAS case to 
find what would happen if that particular patient would file a complaint. On the basis 
of the analysis we can conclude that urologists that offer AS should be aware of the 
information they provide to the patient when entering AS but also during follow-up. 
It is furthermore important that urologists act in line with their medical professional 
standards. Therefore it is advised that urologists follow the progress that is made within 
the field of AS carefully, as the field is moving rapidly.
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Background
One of the first publications describing prostate specific antigen (PSA) as a potential 
biomarker for prostate cancer (PCa) was published in the 1960’s [1]. In 1986 the PSA-
test was approved by the American Food and Drug Association (FDA) as a test to aid in 
the management of patients diagnosed with PCa, and in 1994 the FDA approved the 
PSA-test as a diagnostic tool [2]. Since then, much progress has been made in the field 
of PCa detection.
With increasing evidence that PSA could be used for the early detection of PCa [3], it 
was in the beginning of the 90’s that researchers from Belgium and the Netherlands 
made plans to conduct a randomized study of screening for PCa [4,5]. Pilot studies were 
initiated of which the most important conclusion was that a randomized controlled trial 
of screening for PCa in Europe seemed feasible. However, it was necessary to seek inter-
national cooperation to meet the large sample size [6]. Finally, the European Random-
ized study of Screening for Prostate Cancer (ERSPC) was initiated in 1994. Around the 
same time in the US the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening 
trial was initiated [7].
After the introduction of the PSA-test and the initiation of screening trials, the incidence 
of PCa in Western countries increased remarkably. Data from the American Cancer 
Society as well as from the European Cancer Observatory confirm this [8,9]. Over time 
incidence declined; however, the incidence rates did not retain to the level that was 
seen before the introduction of the PSA-test as a diagnostic tool in the beginning of the 
1990’s. If this observation would reflect a true PCa increase, it should be accompanied 
by an increase in disease-specific mortality. This is, however, not the case, not even 
today [8]. The contrary seems to be true; PCa-specific mortality declined between 1975-
2010 [8,10]. Now that the increase in incidence and mortality do not collide, another 
explanation for this phenomenon has to be found.
Screening for PCa has resulted in a marked stage shift; fewer men present with meta-
static disease, while more men present with earlier and lower stage, lower grade and 
lower PSA at diagnosis [11,12]. Although screening has shown to be effective when 
done in a systematic way as compared to a situation with hardly no screening [13,14], it 
also causes overdiagnosis in the range of 27-56% [15,16]. Overdiagnosis occurs when a 
tumor is detected that, if left unattended, would not have become clinically apparent or 
caused death [11,15]. If such overdiagnosed tumors are actively treated, one speaks of 
overtreatment. Overdiagnosis and overtreatment are associated with harms from treat-
ment, like incontinence and impotence, but also with a psychological burden. To date, a 
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lot of PCa research therefore focuses on how to reduce overdiagnosis. The discovery of 
a biomarker that would be able to distinct aggressive from indolent PCa (a PCa that is 
unlikely to become symptomatic during life, also known as a low-risk or minimal cancer) 
would solve a large part of the overdiagnosis dilemma; however, no such biomarker is 
currently available.
Because most PCa’s found nowadays are low-risk PCa’s which have favorable character-
istics and a beneficial long-term survival, active treatment is not immediately necessary 
[17]. It is thought that the replacement of initial active treatment with active surveillance 
(AS) in patients with low-risk PCa is a realistic option [17]. The aim of AS is to avoid 
overtreatment. With AS the tumor is closely monitored with the purpose of switching 
to active treatment if progression occurs. Over the past decade several AS studies have 
been initiated worldwide, which so far show encouraging results [18].
That AS becomes a more viable option is also recognized by many national and interna-
tional urological associations. Guidelines of the European Association of Urology (EAU), 
the American Association of Urology (AUA), the Societé International d’Urology (SIU), 
the German Urological Association (DGU) and the Dutch Urological Association (NVU) 
all have been updated in recent years, including AS as a management strategy for very 
low-risk or low-risk PCa [19-21].
Now that AS is more often offered to men with low-risk PCa and more patients are 
included in AS studies, the aim of this paper is to describe AS from a legal perspective. 
With AS the chance always exists that the ‘window of curability’ is missed and that 
switching to active treatment comes too late with worse outcomes on radical prosta-
tectomy or radiotherapy as a consequence. What would happen if a patient who was 
in such a situation, would file a complaint? How will such a complaint be dealt with 
within the Dutch legal system? What might be pitfalls in the management strategy that 
urologists should be aware of?
Methods
Worldwide, several AS studies have been initiated. In this paper a patient from the 
Prostate cancer Research International: Active Surveillance (PRIAS) study will be used 
as an example. First some information is given on the PRIAS study. Then a PRIAS case, 
patient X, will be described after which the Dutch legal framework will be set-out. 
Finally, we will apply the Dutch legal framework to our PRIAS case to find out what 
would happen if that particular patient would file a complaint.
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PRIAS
PRIAS is a protocol-based, multicenter, observational study which started in 2006. It 
was initiated by investigators of the Rotterdam section of the ERSPC and the Depart-
ment of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands. It 
was designed to validate a protocol designed on currently available knowledge and if 
necessary adapt the management of low-risk PCa with AS. The PRIAS study is entirely 
web-based [17]. Currently, PRIAS holds more than 4,300 patients.
PRIAS inclusion criteria are: PCa diagnosis with a PSA of ≤ 10.0 ng/ml; a PSA-density 
(PSA/prostate volume) of < 0.2 ng/ml/ml; T-stage ≤ T2; one or two positive prostate 
needle-biopsy cores, with a Gleason score of ≤ 3+3 = 6. The follow-up protocol includes 
PSA measurements every three months for the first two years and every six months 
thereafter. Digital rectal examination (DRE) is scheduled every six months for the first 
two years and once a year thereafter. Repeat biopsies are scheduled after 1, 4 and 
7 years, and in case of a PSA-doubling time between 3 and 10 years, yearly repeat 
biopsies are advised. Risk reclassification at repeat biopsy triggers a recommendation 
for active therapy and is defined as ≥ 3 positive biopsy cores and/or Gleason score > 6. 
A PSA-doubling time (PSADT), which can only be reliably calculated after a minimum 
of one baseline and four follow-up measurements, of less than three years is also used 
as a trigger to initiate active therapy [22]. Men entering into PRIAS all sign an informed 
consent.
Study protocol versus guidelines
As said, many national and international guidelines have captured AS in their guidelines 
[19-21].
Although AS is recognized as a reliable management strategy, the inclusion criteria are 
not straightforward yet. Differences in the AS inclusion criteria are seen in different 
parts of the world and captured in the various guidelines. Furthermore, the guidelines 
on AS are not yet clear-cut and still leave room for interpretation and improvement. 
Currently, for instance, the feasibility of including multi parametric imaging (MRI) into 
the AS protocol is being researched. It is hypothesized that with the use of MRI the 
percentages of undergrading of systematic prostate biopsy and upstaging of the tumor 
may decline [23].
In 2013 the Movember – GAP3 project was initiated to integrate the various existing AS 
protocols into one straightforward, unambiguous protocol. The project started in 2014 
and the results are expected within two years from now (www.movember.com).
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AS in Dutch daily clinical practice
Earlier research shows that when offering AS to patients 84% of Dutch urologists follow 
the PRIAS protocol. Most urologists (97%) are also familiar with the NVU guideline 
on PCa [24]. In comparison; the PRIAS inclusion criteria are: PSA of ≤10.0 ng/ml; a 
PSA-density of < 0.2 ng/ml/ml; T-stage ≤ T2; one or two positive prostate needle-biopsy 
cores, with a Gleason score of ≤ 3+3 = 6. The NVU guideline AS inclusion criteria are: 
T1c-2a, Gleason score < 7, PSA < 10 ng/ml and one or two positive needle-biopsy cores.
Case description
PRIAS patient X, aged 63, is diagnosed with T2a, Gleason 6 PCa in 2 out of 12 cores in 
2010. He is suitable for AS according to the PRIAS protocol and thus decides to undergo 
AS as an initial treatment option for his PCa. After 1 year he receives a repeat biopsy 
(according to protocol) which shows Gleason 6 PCa in 3 out of 12 cores. With more 
than 2 cores positive for PCa the protocol advised to switch to definitive treatment. In 
addition his PSA is rising (PSADT < 3 years) which would also be a trigger for active 
treatment. The patient and physician decide to ignore this advice and to continue with 
AS (most likely because the Gleason score is still 6, accepting the known undergrading 
rates of systematic prostate biopsies). One year thereafter, so two years after diagnosis, 
he receives another biopsy. This biopsy shows a Gleason 9 PCa in 2 out of the 12 cores. 
Patient discontinues AS and undergoes radical prostatectomy (RP).
One year post-surgery patient X experienced permanent erectile dysfunction, urinary 
incontinence and biochemical recurrence (defined as two subsequent PSA values of > 
0.2 ng/ml after RP). The last PSA of patient X amounted to 21.6 ng/ml.
Dutch legal framework
In the Netherlands, the patient-doctor contract is regulated by the Medical Treatment 
Contract (Wet Geneeskundige Behandelingsovereenkomst, [WGBO]). The WGBO, 
which is part of the Dutch Civil Code, runs from article 7:446 to 7:468 Civil Code and 
contains the patient’s core rights. According to art. 7:468 Civil Code the provisions of 
the WGBO are binding. Core values of the WGBO are the right of self-determination 
and human dignity [25].
Art. 7:446 Civil Code describes the patient-doctor contract that is realized once medical 
actions are performed. In the Netherlands such a patient-doctor contract is not explicitly 
signed, but is assumed to exist when medical actions are performed for the first time. 
Clauses 2 and 3 of art. 7:446 Civil Code define what medical actions are, i.e. all patient 
related actions that intend to cure the patient, to prevent sickness, to judge a person’s 
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health condition or providing obstetrical assistance. Nursing and caring, in certain situ-
ations, can be defined as medical actions as well.
The patient-doctor contract holds rights and obligations for both the patient and the 
doctor. Doctors should provide their patients with information, they have to obtain 
consent from their patients before starting treatment, they have to act according to 
their professional standards, they have to file all patient information and give patients 
the right to inspect their files, they hold the oath of secrecy and only under very special 
circumstances can one-sidedly terminate the patient-doctor contract.
While the goal of the WGBO is patient protection, patients not only have rights. They 
also have obligations. On the basis of art. 7:452 Civil Code patients should provide all 
information that doctors need in their decision making process as well as cooperate and 
collaborate in effectuating the doctor-patient contract.
Art. 7:448 Civil Code mainly concerns the right of information that patients have. A 
doctor is obliged to provide information about the intended medical actions, treatment 
and the patient’s current health status that is clear, relevant and adjusted to patients’ 
educational level. It would be recommended if patients receive written information on 
these matters as well. Art. 7:448 Civil Code mentions the following aspects on which 
information should be provided: what the intended medical actions/treatment holds, 
risks, goal, nature and alternatives of the intended medical actions/treatment. Finally, the 
doctor informs the patient what all this means for their future health and the patient’s 
perspectives. The right of information is intended to enable patients to make a well-
informed decision on whether or not to provide consent on the proposed treatment. 
In providing the information, the doctor should be guided by what the patient should 
reasonably know regarding the nature and purpose of the treatment, the anticipated 
risks and effects, the possible alternatives and its prospects. Failing the fulfillment of this 
obligation raises the possibility that a patient cannot use, or only partly use, his right 
of self-determination which increases the risk of the patient making a choice he would 
not have made had he been well-informed. In case the discussed risks occur, the patient 
has to pose and proof that he, had he been well-informed, as a reasonably competent 
patient and/or due to personal circumstances would have made another choice [26-28].
Art. 7:450 Civil Code indicates that in line with the patient-doctor contract a patient’s 
consent is needed before any medical actions are started. To overcome discussions on 
whether consent was provided by the patient, an option would be to have patients 
sign an informed consent (art. 7:451 Civil Code). Patients should only sign such an 
informed consent if they feel adequately informed and can take a well-considered 
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decision to consent. If this is not the case it would result in a violation of their right of 
self-determination.
Art. 7:453 Civil Code requests doctors to act according to their professional medical 
standards. Based on these professional medical standards, a doctor is required to work 
according to knowledge and competences deemed familiar in their area of expertise. 
Professional medical standards are based on knowledge and competences a doctor 
should learn during their specialist-training, knowledge gained from literature, attend-
ing medical conferences, sub-speciality consensus meetings, refresher courses, in-service 
trainings, protocols, guidelines and own experiences.
The WGBO holds the obligation that doctors should make an effort in treating their 
patients instead of contracting a result. Doctors are legally responsible if they have 
trespassed their obligation to make an effort, if they have not done their upmost best, 
i.e. a violation of art. 7:453 Civil Code. This is the case when a doctor has not acted in 
line with the professional medical standards of their specialty.
Furthermore, doctors are legally responsible if a patient foregoing medical treatment 
is not sufficiently informed about treatment, treatment related effects and possible 
alternatives. The patient has made a decision on the basis of poor information. A doctor 
is legally responsible for the adverse effects of that treatment in case the patient would 
have chosen another alternative had he received all relevant information.
On the basis of art. 7:463 Civil Code it is impossible for doctors to contractually limit or 
exclude their shortfalls.
A special feature of the patient-doctor contract lies in its central liability. Because patient-
doctor contracts are often effectuated in hospitals where various healthcare workers are 
involved in the care process of a patient, it may be difficult for the patient to hold one of 
them responsible in case a fault is made. Art. 7:462 Civil Code determines that in such 
situations it would suffice if the patient holds the hospital responsible.
Art. 7:462 Civil Code therefore also protects patients. The article provides an additional 
point of contact for patients to turn to. This may be necessary in case a doctor cannot 
provide sufficient resources.
What happens when patient X from our case description holds its doctor legally respon-
sible?
Lionne Venderbos BW CP4.indd   154 08-10-15   11:18
155
Chapter 9 | Active surveillance: a legal perspective
For a patient it is not easy to prove that due to the actions of his doctor damage oc-
curred for which the doctor is liable. In principle it is up to the patient to prove this and 
he therefore should make use of the opinion of an independent medical expert. This 
expert will write a report in which he passes his judgment on the course of illness and/or 
about the effect of medical treatment on the course of the illness. The patient can take 
this report to court and try to convince the judge - who is not medically trained - the 
doctor is liable for the damages occurred. The medical expert thus plays an important 
role; the facts and the expert’s opinion are in general decisive, unless valid and compel-
ling reasons regarding the expert’s report exist.
In court, parties can request a judge to appoint an independent expert. The judge will, 
in consultation with the parties, appoint an expert and formulate the questions the 
expert must provide his judgment on. Another possibility is that the parties themselves 
appoint an independent expert. When parties reach agreement on who is to fulfil the 
role of expert as well as the key question that he should answer, then, in practice, the 
report of the by parties appointed expert is valued the same as the report of the expert 
appointed by a judge.
For this article we have asked two urologists specialized in urologic oncology (one with 
over 30 years of experience and one who recently completed his residency) and both 
working in an academic setting to act as ‘experts’ and to provide an expert opinion on 
patients’ X case. The authors have set-up a questionnaire (table 1) which was sent to the 
experts together with the patient file.
After men are diagnosed with PCa a treatment strategy has to be chosen. Which treat-
ment options are offered, depends on the physical conditions of the patient and his 
tumor characteristics. In case of low-risk PCa and a good physical condition of the 
patient the experts would offer either AS, RP, radiotherapy (RT) or brachytherapy (BT). 
The urologists’ preference will influence the order in which the options are discussed.
Table 1: A selection of questions included in the questionnaire sent to the experts
•  How would you handle the conversation in which a patient has to choose his treatment?
•  Which risks, complications and alternatives did a reasonable and reasonably competent urologist in 
2010 should have discussed with patient X? Please refer to relevant literature, protocol and guidelines 
as much as possible.
•  How often, in your experience, did patients choose AS after having provided all relevant information?
•  Do you consider that the conduct of the urologist of patient X during the AS strategy between 2010-
2012 at any time did not meet the standard of care that could be expected from a reasonable and 
reasonably competent professional? Please take into account the then prevailing medical standards.
•  In case of a negligent act, please discuss the consequences for patient X?
•  May the damage also have occurred when the urologist would have acted carefully? If so, please 
express through percentages.
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Risks and complications of AS that, according to the experts, needed to be discussed 
were the risk of PCa progression and the subsequent possibility of being ‘too late’, 
meaning that a second treatment will no longer be curative. Furthermore, the risks of 
repeated biopsies should be discussed as well as the AS follow-up scheme. The patient 
information brochure of the Dutch Cancer Society (KWF) says that every three to six 
months the urologist will perform a DRE and a PSA-test. If the course of disease stays 
stable over a period of two years, the frequency of the follow-up visits decreases to 
once a year. If the PSA increases, a yearly echo of the prostate as well as yearly prostate 
biopsies will be taken. In case of signs of tumor progression, switching to curative treat-
ment is advised.
The experts feel that for RP it is important to discuss the perioperative risks of the 
operation as well as the potential long term consequences. Perioperative risks of this 
abdominal/urological surgery are the possibility of haemorrhage, urine leakage, lymfo-
cele, infections and thrombosis. Long term consequences that should be discussed are 
potential incontinence and impotence.
When discussing RT as a treatment option, it is important to discuss that besides the 
possibility of becoming incontinent or impotent, also radiation cystitis and proctitis can 
occur. This means that patients can experience radiation damage, which may cause 
urinary problems or fecal urgency. Side effects of BT are comparable to that of RT, 
although less intense.
The experts have experienced that once good information is provided, many patients 
(75-90%) comply with the initially advised AS protocol.
With respect to patient X, both experts feel that he was correctly included in the PRIAS 
protocol as he fulfilled the inclusion criteria of the study. According to the protocol 
patient X undergoes a repeat biopsy after 1 year. The outcomes of that biopsy showed 
a Gleason 6 PCa in three out of twelve cores taken. Protocol wise this was a reason to 
switch to curative treatment. Also his rising PSA which led to a PSADT < 3 years was a 
trigger to start curative treatment. It is at this moment in time that an important decision 
was made. The urologist and patient X decided to ignore this advice and to continue 
with AS. In the case of patient X it is unclear, due to the anonymity of PRIAS patients, 
which information was provided to the patient and how the decision was eventually 
made. One of the experts stated that when overlooking the case he feels that the urolo-
gist of patient X, taking into account the age of patient X, should have discouraged the 
decision to stay on AS. It is important to emphasize that it is the protocol’s advice to 
switch to curative treatment and that continuation of AS comes with the risk of disease 
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progression which might lead to metastases. If, despite the before mentioned informa-
tion, the patient decides to continue AS, the urologist should emphasize that that is the 
patient’s  decision. If the urologist has not discussed these matters, the expert feels that 
one might speak of a negligent act for which the urologist can be blamed. However, 
if the urologist provided the right information and the patient decided to continue AS 
anyway, the doctor lived up to his professional standards.
Due to the decision to continue AS the tumor had the chance to grow. Two years 
after patient X’s PCa diagnosis he underwent a second biopsy (this second biopsy is in 
line with the PRIAS protocol). This time a Gleason 9 PCa is found in two out of twelve 
biopsies. Patient X underwent an RP. One year post-surgery he suffers from permanent 
erectile dysfunction, urinary incontinence and biochemical recurrence. His last PSA 
amounts to 21.6 ng/ml. The question that should be answered is not whether these 
outcomes would have been the same had patient X been treated a year earlier, although 
this does seem to be the obvious question from a medical point of view, but whether 
the decision to continue AS after the first repeat biopsy was justified. More specifically: 
does the decision to continue with AS after the first repeat biopsy meet the standards 
of art. 7:453 Civil Code?
The experts stated that regarding the question whether the urologist has acted as could 
be expected from a reasonable and reasonably competent doctor (art. 7:453 Civil Code) 
when continuing AS, it is likely that he has. Low-risk PCa is a complex disease and it is 
currently not possible to distinguish which low-risk cancers will become more aggressive 
and which will stay indolent and therefore not cause any symptoms or death of its car-
rier. The AS protocol has been designed to delay or avert curative treatment in men with 
true indolent PCa. It has been shown, however, that with the PRIAS AS protocol perhaps 
still too many men are advised to switch from AS to curative treatment, indicating that 
the protocol might still be too strict. Bul et al. [29], for example, showed that of the 
446 PRIAS AS men that underwent deferred treatment after their initial biopsy, 189 
underwent RP. For 167 men (88.4%) pathology results were available. 118 cases (71%) 
had favorable RP results (pT2 and Gleason ≤ 3+4), while 49 patients (29%) experienced 
unfavorable results (pT3-4 and/or Gleason ≥ 4+3). Of the 118 cases with favorable 
results, 88 (75%) had been given a protocol-based advice to switch. Assuming that 
the urologist of patient X is aware of the ongoing debate surrounding low-risk PCa 
and AS, the experts state that deviating from the protocol in itself is tolerable. The case 
described enters what the expert state as ‘the grey zone’ for which it is not entirely clear 
what is the best way to handle.
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Discussion
In this article we have looked at AS for PCa from a juridical point of view. As AS is a 
viable management strategy that is incorporated into many national and international 
guidelines, the authors were interested in potential pitfalls - from a juridical point of 
view - for urologists.
With the help of two urologists, appointed as ‘experts’ - as would be done in prac-
tice - we found that there are two very important aspects that need to be taken into 
consideration when offering AS: (1) providing that type of information to the patient 
on which he can base his informed consent and (2) urologists acting according to their 
professional standards.
According to art. 7:448 Civil Code patients have a right of information, meaning that a 
doctor is obliged to provide information that concerns medical actions, treatment and 
patients’ current health status. This information should be clear to the patient, relevant 
and adjusted to his educational level. When offering AS it is important that urologists 
provide information on the risk of PCa progression and the subsequent possibility of 
being too late and thereby missing the window of curability. The follow-up scheme 
should be explained, as well as the potential risks of repeated biopsies. Furthermore, 
it is important that the risks and benefits of the other treatment options are explained 
well so that the patient can make a well-informed decision on whether or not to provide 
consent on the proposed treatment.
We have seen that information plays an important role throughout the entire AS period. 
There are various points in time during which the decision to continue or discontinue AS 
has to be taken. It is important, and in line with art. 7:448 and art. 7:450 Civil Code, to 
constantly inform the patient well so that he can take the decision or agree on the deci-
sion to continue/discontinue AS. We would like to advise that the discussions between 
the doctor and the patient are surveyed into his medical record. Men entering the PRIAS 
study sign and informed consent. We would like to suggest that men who are offered 
AS outside study environment sign informed consent as well.
Furthermore, we found that in line with art. 7:453 Civil Code urologists should act in 
line with their medical professional standards. Patient X was assumed well-informed 
and therefore the question was whether continuation of AS was in line with art. 7:453 
Civil Code. Due to the complex situation with respect to low-risk PCa, the experts stated 
that deviating from the protocol was tolerable. As the urologist of patient X engaged 
in including patients into the PRIAS study, it is likely that he is aware of the discussions 
Lionne Venderbos BW CP4.indd   158 08-10-15   11:18
159
Chapter 9 | Active surveillance: a legal perspective
surrounding low-risk PCa and AS in particular. The national and international guidelines 
also leave room for interpretation with respect to offering and the (dis)continuation of 
AS. It is, however, of upmost importance that the progress within this area of expertise 
is followed carefully.
Conclusion
From a juridical point of view, urologists that offer AS to their patients should be aware 
of the information that they provide to patients, both when entering AS as well as 
during follow-up. Furthermore it is important that urologists act in line with their medi-
cal professional standards. To be able to do so, it is advised that urologists follow the 
progress that is made within this field carefully, as the field is moving rapidly.
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In the introduction of this thesis, several research questions were formulated. First, the 
main answers to each of these research questions will be summarized as key findings 
after which they will be discussed in more detail, both for population-based screening 
and for active surveillance. This chapter will conclude with recommendations for clinical 
practice and for future research initiatives.
10.1 Key findings
Part I – Screening for prostate cancer
Research question 1: How do tumor characteristics and treatment patterns change in 
the course of a screening trial for prostate cancer?
As described in chapter 2, the tumor characteristics of prostate cancers diagnosed in the 
screening arm of ERSPC showed a favorable shift over time. This development coincided 
with a change of treatment, namely an increasing choice for expectant management 
as initial treatment for indolent disease. Over time, the tumor characteristics of prostate 
cancers detected in the control arm became more comparable to those of prostate can-
cers in the initial screening round, pointing towards an increasing rate of opportunistic 
testing in men randomized to the control arm.
Research question 2: How to advice patients who consult their general practitioner or 
urologist with a screening request?
Men should be informed on the pros and cons of screening before having a PSA test, 
for which informed and shared decision making is the paradigm (chapter 3). Decision 
aids can help men weigh the pros and cons, making it possible for them to choose 
according to their own preferences and personal values. Shared decision making will 
give both professionals and men the option to express their thoughts on screening, 
to jointly participate in the decision making process and agree on a course of action 
that incorporates patients’ preferences and is acceptable from a medical point of view. 
In case a PSA test is done, multivariable risk prediction models can help in deciding 
whether further diagnostic tests are needed.
Part II – Active surveillance for low-risk prostate cancer
Research question 3: As active surveillance cohorts mature, how do the related clinical 
outcomes develop?
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So far, reported prostate cancer mortality under men on active surveillance is very low, 
which supports the suggestion that active surveillance is a safe management strategy 
for low-risk prostate cancer (chapter 4). Longer follow-up, is however, needed as pres-
ent studies mostly have an average follow-up of less than 10 years. When considering 
intermediate outcomes such as PSA progression, local progression and metastases, it 
is difficult to draw conclusions, because less unequivocal definitions are used in the 
ongoing studies. It seems, however, that choosing an initial active surveillance strategy 
does not affect the clinical outcomes of men when compared to those who choose 
immediate active treatment. Active surveillance then has the advantage of delaying 
side-effects of treatment and preserving health related quality of life (chapters 6 and 7).
Research question 4: In the light of personalized medicine, what is the best way to select 
patients for active surveillance?
In chapter 5 we assessed whether patient selection can be improved by using risk strati-
fication through a nomogram instead of the currently used rule-based inclusion criteria. 
The results showed that more stringent rule-based active surveillance inclusion criteria 
as well as stricter nomogram probability thresholds decrease the rate of misclassified 
tumors in a rather similar fashion, but both at the cost of a substantial number of 
patients no longer considered suitable for active surveillance. We concluded that the 
performance of a nomogram and rule-based criteria are similar. A nomogram could be 
a good alternative to the rule-based criteria as it explicitly allows for making individual 
trade-offs, taking into account, amongst others, the risk-averseness of urologists and 
patients.
Research question 5: How does quality of life develop in men who follow an active 
surveillance management strategy for a longer period of time? How does their quality 
of life compare to that of men who underwent direct curative therapy?
In chapter 6 we analyzed how anxiety and distress developed in men who were man-
aged with active surveillance for an 18-month period and whether highly anxious men 
adhered to that protocol. We found that the average levels of anxiety and distress 
remained favorably low. Generic anxiety and the fear of disease progression tended 
to decrease in men who remained eligible for active surveillance. Six out of the 129 
respondents (5%) discontinued active surveillance because of anxiety and distress. 
Among the 26 men who were highly anxious at baseline, eight became less anxious 
while remaining on active surveillance. Our results suggest that negative quality of life 
effects are limited in men with favorable clinical characteristics who chose active surveil-
lance. Patient reported outcomes of longer follow-up (chapter 7) reveal that in terms of 
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general health men who underwent active surveillance have better physical and mental 
health than those on radical prostatectomy and radiotherapy and a reference group 
of men without cancer. All groups show low generic anxiety rates. Compared to the 
18 month follow-up data, prostate cancer anxiety and the fear of disease progression 
(both subscales of the MAX-PC) decreased further for men on active surveillance. Men 
on active surveillance and the men without cancer reported very similar urination scores. 
Statistically significant differences are mainly seen between the radical prostatectomy 
and radiotherapy groups with respect to urinary function and urinary incontinence, 
with the radiotherapy group reporting better function. Regarding sexuality, the active 
surveillance group reported the best outcomes, while the radical prostatectomy group 
reported the worst. Overall, we can conclude that from a quality of life perspective, in 
the long run active surveillance is a good alternative to immediate active therapy.
Research question 6: With the increasing clinical acceptance of active surveillance 
as a feasible alternative to immediate active therapy, how do urologists value active 
surveillance and what should they be aware of in such a fast moving area of expertise? 
(Chapters 8 and 9)
Through questionnaire research we were able to get an insight into urologists’ accep-
tance of active surveillance and their opinions about the newly emerged management 
strategy (chapter 8). All urologists reported to bring up active surveillance as a treatment 
option for low-risk prostate cancer and a third of the urologists did so for intermediate 
risk prostate cancer.  Factors that influenced their decision to offer active surveillance 
mainly were the requests of patients, guidelines, own experiences, patients’ physical 
and psychological well-being and their clinical characteristics. More than half of the 
patients that were seen by urologists tended to bring up active surveillance. Two-thirds 
of the urologists, furthermore, reported to offer watchful waiting as an alternative for 
active surveillance to patients eligible for active surveillance. Overall, we concluded that 
Dutch urologists tend to have a positive attitude towards active surveillance.
Because active surveillance has become a viable management strategy and is being 
offered more and more often, the aim of the study in chapter 9 was to describe active 
surveillance from a legal perspective. What might be pitfalls in the active surveillance 
management strategy that urologists should be aware of? From our analysis we can 
conclude that urologists who offer active surveillance to their patients should be aware 
of the information they provide on potential progression of the prostate cancer, the 
active surveillance follow-up scheme used and the potential risks of repeated biopsy, 
both before starting the management strategy as well as during follow-up, and that 
the information discussed and resulting discussions are surveyed shortly into patients’ 
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medical records. Urologists should furthermore act in line with their medical professional 
standards. Urologists need to keep themselves updated on the evolving guidelines and 
the scientific literature published on active surveillance by, for instance, attending medi-
cal conferences, in-server training and participation in journal clubs.
10.2 Screening for prostate cancer
Having a median of 9 years of follow-up, the ERSPC reported for the first time a 20% 
mortality reduction in favor of the screening arm in an intention-to-screen analysis [1]. 
Such an analysis provides an estimate of the effectiveness of screening on a population 
level and is influenced by two types of noncompliance: (i) nonattendance in men who 
are randomized to the intervention arm, and (ii) contamination, i.e. the use of PSA 
testing in men randomized to the control arm [2]. In chapter 2 we looked for changes 
in tumor characteristics and treatment that could potentially indicate the occurrence 
of opportunistic testing in the screening and control arm of the ERSPC. It is important 
to assess such an effect as it can influence the primary endpoint of the trial due to the 
potential diminished differences between the screening and control arm, as was seen in 
the PLCO study [3]. In this thesis, data from the ERSPC study up until the end of 2006 
were used. Study results showed that tumor characteristics became more favorable 
over time in both the screening and control arm of ERSPC, which was mainly reflected 
in increasing proportions of T1c tumors (29% in 1994-1998 vs. 50% in 2003-2006 for 
the control arm and 48% in the initial screening round vs. 75% at the third screen-
ing round). The stage and grade shift that was observed coincided with a change of 
treatment, namely an increasing occurrence of expectant management as the initial 
treatment strategy for organ-confined disease (15% in 1994-1998 vs. 23% in 2003-
2006 for the control arm and 17% vs. 36% for the initial and third screening round, 
respectively). The observed tumor characteristics in the 2003-2006 control arm period 
were comparable to tumor characteristics in the first round of the screening arm. These 
findings point towards an increasing rate of opportunistic testing in men randomized 
to the control arm [4]. In our study we did not determine the order of magnitude 
of opportunistic PSA testing in the control arm (i.e. contamination). Roobol and col-
leagues assessed the rate of contamination in the control arm of ERSPC Rotterdam and 
extrapolated these data to the entire ERSPC study cohort [2]. They were thus able to 
estimate the efficacy of organized PSA testing in men actually screened, concluding that 
PSA screening reduces the risk of prostate cancer death by up to 31% in men who are 
actually screened [2]. Bokhorst et al. determined the prostate cancer mortality reduction 
from screening after adjustment for nonattendance and contamination a few years later 
in ERSPC Rotterdam. They concluded that prostate cancer screening as carried out in 
Lionne Venderbos BW CP4.indd   168 08-10-15   11:18
169
Chapter 10 | General discussion
ERSPC Rotterdam, could reduce the risk of dying from prostate cancer up to 51% for 
an individual man choosing to be screened repeatedly compared to a man who was not 
screened [5]. If, as a result of this increased individual risk reduction, more men choose 
to be screened, this will increase the rate of overdiagnosis and overtreatment.
How to advice a patient?
The advantages of screening should be weighed against its disadvantages. Because at 
this moment the harms of screening outweigh the benefits, population-based screen-
ing programs have not been introduced. Screening in its current form is not the way 
forward, nor is the recommendation by the U.S. Preventive Services Task Force not to 
screen at all [6-8]. In chapter 3 we highlighted the importance of informed and shared 
decision making. Informed decision making refers to a choice that is based on relevant 
knowledge and is consistent with the decision maker’s value and is behaviorally imple-
mented [9]. Men who are at the point of having their PSA measured should be aware 
of the consequences such a decision might have on their lives. This was well reflected 
in a qualitative study by Chapple et al. where most of the patients underwent a PSA 
test with minimal information given to them upfront [10]. Afterwards, some men felt 
relieved that they were treated for their prostate cancer and that it had been found at 
an early stage. Other men were more doubtful and sometimes regretted that a PSA 
test was done. They were thinking about what their lives would have looked like, had 
they not taken the test and not suffered the side-effects of treatment which affected 
their quality of life [10]. These men are cancer survivors and have to live with the con-
sequences of treatment the remaining years of their lives [11]. In the first years after 
treatment the feeling of relief will prevail, but later on doubts may arise on whether it 
has all been worth it. Clinicians, general practitioners but also patients themselves need 
to be aware of the issues that can affect quality of life, both immediately after diagnosis 
and treatment, as well as in the many years that follow [11].
In practice it has been seen that the number of PSA tests requested in the Netherlands 
and the United States has decreased since the publications of the ERSPC and PLCO 
in 2009, indicating a slightly decreasing rate of opportunistic screening [1, 12-14]. 
Updated guidelines of the American Urological Association (AUA) [15], the American 
Cancer Society [16], the American College of Preventive Medicine [17], the European 
Association of Urology (EAU) [18], and the Dutch Urology Society (NVU) [19] in the 
meanwhile have all agreed on the importance of a combination of informed and shared 
decision making in deciding whether or not to screen for prostate cancer. It is expected 
that this will further decrease the rate of opportunistic testing.
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10.2.1 Future research directions that can alter the balance between harms 
and benefits in individual and population-based screening
Risk prediction
PSA based screening for prostate cancer currently has substantial harms, such as over-
diagnosis, overtreatment, and living an increased number of years with the adverse 
effects of treatment, which has resulted in the discouragement of population-based 
screening programs [20]. On an individual level early detection for prostate cancer can 
benefit some men specifically and therefore testing for prostate cancer should be made 
more selective. To find out who is likely to benefit and who is not, the use of individual-
ized multivariable risk prediction modelling is encouraged in the literature as well as in 
guidelines [18,19]. Various nomograms have been developed with the aim of reducing 
the number of unnecessary biopsies and to selectively identify those men at elevated 
risk for a potentially life threatening prostate cancer [21-26]. Further validation of these 
models is needed as well as their extension with new risk markers. Most of the risk 
prediction tools currently available are targeted at urologists. It will be worthwhile to 
investigate whether such tools can be used by the general practitioner as well. In the 
Netherlands, the general practitioner serves as the gatekeeper; patients with questions 
concerning their health will first visit their general practitioner before being referred to 
a urologist. The application of risk prediction tools by the general practitioner in the 
prostate cancer diagnostic process can potentially reduce the number of referrals to the 
urologist and decrease the number of false-positive PSA tests.
The role of multi-parametric imaging (MRI)
Currently the role of MRI in screening for prostate cancer is being studied. Quentin et 
al. assessed the value of MRI in a clinical trial, concluding that MRI-guided in-bore and 
systematic TRUS-guided biopsies achieved equally high detection rates in biopsy naïve 
men with an increased PSA. MRI-guided in-bore biopsies required significantly fewer 
cores compared to TRUS-guided biopsy and revealed a significantly higher percentage 
of cancer involvement per biopsy core [27]. Grenabo and colleagues presented results 
of their pilot study in which they offered men with a PSA ≥1.8 ng/ml a pre-biopsy 
MRI in the final screening round of the Göteborg Cancer Screening Trial [28]. They 
compared three strategies including 1) PSA ≥3 + systematic biopsy, 2) PSA ≥3 + MRI + 
targeted biopsy and 3) PSA ≥1.8 + MRI + targeted biopsy. They found that the accuracy 
of prostate cancer detection significantly improved for the PSA ≥ 1.8 + MRI + targeted 
biopsy option compared to a strategy of PSA ≥ 3 and systematic biopsy alone (AUC 
0.77, CI 0.6707-0.8621 vs. AUC 0.58, CI 0.48-0.69, p=0.035). The MRI missed 7 out 
of 28 prostate cancers of which 5 were Gleason 3+3 and 2 were Gleason 3+4. As a 
result of their findings, a randomized trial including 40,000 men will be initiated to 
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determine whether screening with PSA and MRI of the prostate cancer can improve the 
diagnostic accuracy of detection, potentially decreasing the amount of overdiagnosis 
and therewith attempting to balance the benefits and harms of screening [28].
In one of the first randomized controlled trials, Baco et al. compared the rate of de-
tection of clinically significant prostate cancer in men who underwent prostate biopsy 
guided by computer-assisted fusion of MRI and TRUS to the rate in men who underwent 
12-core random biopsy [29]. In this study 175 biopsy-naïve men with a suspicion of 
prostate cancer were randomized to the MRI (n=86) or the control group (n=89). The 
overall number of clinically significant prostate cancers found was similar between the 
two groups, indicating that the methods were comparable, rather than the MRI method 
being superior. More results from randomized controlled trials are needed with respect 
to the efficacy of MRI in the diagnostic process. In 2016 the results of an MRI-side study 
within ERSPC Rotterdam on the sensitivity and effectiveness of TRUS-guided systematic 
biopsy versus MRI-ultrasound fusion targeted biopsy in men previously screened are 
expected.
With respect to individualized medicine and the increasing use of nomograms in the 
detection, staging and follow-up of prostate cancer, MRI could play a role as well. 
Current nomograms such as the Prostate Cancer Risk Calculator (www.prostatecancer-
riskcalculator.com) or the Prostate Cancer Prevention Trial risk calculator could be 
extended by adding MRI parameters. Salami et al. compared the performance of the 
PCPT high-grade risk calculator against multi-parametric MRI in predicting men at risk of 
prostate cancer [30]. The area under the receiver operating characteristic curve (AUC) of 
the PCPT high-grade risk indicator was 0.676 while the AUC of multi-parametric MRI for 
high-grade prostate cancer was 0.769 and 0.812 for clinically significant prostate cancer, 
indicating that adding MRI characteristics to a nomogram which already includes PSA, 
age, life-expectancy, etc., could potentially further enhance the predictive probability.
Markers
The perfect marker for prostate cancer screening is yet to be found. Recently published 
markers, for instance, prostate cancer gene 3 (PCA3) and the urine marker TMPRSS2:ERG 
have been shown to be of limited clinical value as a first line diagnostic tool [31,32]. 
Other PSA-related derivatives and subforms, such as the Prostate Health Index (PHI) and 
the 4-kallikrein panel, have shown an improved diagnostic accuracy as compared to 
PSA alone, but only a marginal improvement when incorporated into multivariable risk 
assessment [33-38]. The search for the “holy grail” marker is like searching for a needle 
in a haystack. Although further development of this area of research is urgently needed, 
on the short-term risk prediction combined with MRI is thought to be most promising.
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10.3 Active surveillance for prostate cancer
As described above, screening coincides with overdiagnosis and subsequent overtreat-
ment. Active surveillance has emerged as a management strategy for the by nature slow 
growing indolent prostate cancer from which a man is not likely to die, with the goal 
of delaying or completely avoiding active therapy to avert the potential side-effects of 
treatment, preserving quality of life [39,40]. Men are monitored instead and can switch 
to active therapy in case of reclassification or signs of disease progressions.
Feasibility of active surveillance
Most prospective active surveillance cohorts have only short- or intermediate-term data 
available. In chapter 4 of this thesis we reviewed mortality results from various active 
surveillance cohorts; low disease-specific mortality rates have been reported. After a 
median follow-up of 6.8 years, the five and ten-year disease-specific survival reported by 
Klotz [41] amounted to 99.7% and 97.2% respectively. The PRIAS and Johns Hopkins 
studies both reported  a disease-specific survival rate of 100% after median follow-ups 
of 1.6 and 2.7 years respectively [42]. So far, these results seem promising. Longer 
follow-up is however needed because of the slow growing nature of this type of pros-
tate cancer.
In our literature review we have furthermore evaluated intermediate outcomes from ac-
tive surveillance cohorts, like PSA progression, local progression and metastases in men 
who initially opted for active surveillance and switched to either radical prostatectomy or 
radiotherapy. It is more difficult to interpret these outcomes, because studies report less 
unequivocal endpoints. Results after deferred radical treatment seem to indicate that 
proportion of men (8-31%) have less favorable outcomes. Whether these men should 
have been treated earlier is debatable. Compared to men who opted for immediate 
radical treatment we found results to be quite similar, suggesting that postponing treat-
ment with one to two years did not affect intermediate outcomes. By initially opting for 
active surveillance the side-effects of treatment were delayed which positively affected 
patients’ quality of life [43].
In the meanwhile, Klotz et al. [44], reported unique 15-year follow-up results from their 
prospective, single-arm cohort study carried out at an academic health sciences center 
in Canada; 2.8% (28/993) of patients developed metastatic disease and 1.5% (15/993) 
died of prostate cancer. Because this mortality rate is consistent with the expected mor-
tality in favorable-risk patients who are managed with initial definitive treatment, Klotz 
et al. conclude that active surveillance seems safe within a 15-year time frame [44]. Xia 
et al. used a model to assess prostate cancer mortality among contemporary low-risk 
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cases on active surveillance who switched to radical prostatectomy due to disease pro-
gression. These projections were then compared to the rate of prostate cancer mortality 
had the cases received immediate radical prostatectomy. According to the model, 2.8% 
of men on active surveillance and 1.6% of men with immediate radical prostatectomy 
would die of their disease in 20 years’ time. The model projected furthermore that on 
average men on active surveillance would remain free of treatment for an additional 
6.4 years relative to men who were treated immediately [45].  Both studies, for now, 
confirm the safety of active surveillance as a management strategy. Longer-term results 
are required from other cohorts to confirm these results.
Patient selection for active surveillance
While the disease-specific mortality under active surveillance is low, research on how to 
improve the existing active surveillance inclusion criteria is needed as misclassification at 
diagnosis or reclassification after one-year repeat biopsy is common [42,46].
At this moment all active surveillance studies apply rather rigid patient inclusion criteria. 
In the light of individualized medicine and shared decision making (chapter 2), tak-
ing into account patient preferences like whether or not they are risk-averse, it might 
be preferable to apply more refined risk stratification. In this thesis we have assessed 
whether the use of a nomogram in selecting patients for active surveillance is preferable 
over the currently used rule-based criteria (chapter 5). We found that the performance 
of the PRIAS, Johns Hopkins and ERSPC-nomogram were comparable. Because patient 
selection with all three options is currently sub-optimal, reflected in areas under the 
curve when discriminating between indolent and significant disease of 0.59-0.69, risk 
stratification needs to be improved. MRI can play a potential role in selecting men 
for active surveillance [47]. Stamatakis et al. found that the number of lesions, lesion 
suspicion and lesion density were associated with confirmatory biopsy outcome and 
reclassification [48]. A nomogram that incorporates these three factors showed to have 
promising predictive accuracy through which active surveillance patient selection can be 
improved [48].
Quality of life
With the emergence of active surveillance as a new management strategy, the col-
lection of quality of life data started as well. It was hypothesized that choosing active 
surveillance could lead to anxiety and distress due to living with ‘untreated’ prostate 
cancer. If so, better selection upfront, or targeted psychological interventions might be 
considered. Furthermore, it was unknown how men would appreciate the periodical 
control visits. In this thesis (chapters 6 and 7) quality of life outcomes of men who were 
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managed with active surveillance for a shorter period, up to 18 months of follow-up, 
and a longer period of follow-up (i.e. 5- to 10-years), are presented.
Men who followed an active surveillance strategy for an 18 month period on average re-
ported favorably low levels of anxiety and distress (chapter 6). These results were in line 
with patient reported outcomes measured in the first six months of follow-up [49,50]. 
The fear of disease progression and general anxiety decreased, but that decrease was 
not clinically significant. Only a small percentage of men in our cohort stopped active 
surveillance for anxiety reasons. We furthermore analyzed whether highly anxious men 
quit active surveillance. Of the 26 men who were highly anxious at baseline (STAI-6 score 
> 44), eight became less anxious during the course of the active surveillance program, 
suggesting that the control visits and the stability of the disease provided tranquility of 
mind. Six (23%) men reported high anxiety scores during the entire 18 month follow-up 
period but remained on active surveillance. Three men (12%) were highly anxious at 
baseline, their scores decreased to ≤44 after 9 months of follow-up and after 18 months 
of follow-up they quit AS because of tumor progression. Seven men (27%) were highly 
anxious at baseline and stopped AS because of reclassification of their prostate cancer 
at 9 months of follow-up. Two men (8%) were highly anxious and therefore stopped 
active surveillance. Our results are in line with, for instance, the results of a study among 
Finnish PRIAS participants, who reported no deterioration of their quality of life after 1 
and 3 years of follow-up [51,52] or a study amongst Australian men which suggested 
that no clinically significant anxiety was present amongst their cohort [53]. Published 
data so far all address relatively short follow-up periods. Longer-term quality of life data 
are currently lacking. Because of the maturing of the PRIAS active surveillance cohort we 
had the opportunity of obtaining unique 5-year patient reported outcome data (chapter 
7). Furthermore, we were able to collect 5-year follow-up patient reported outcome data 
of men who underwent radical prostatectomy or radiotherapy, and compare our results 
to a reference group of men without prostate cancer. This is one of the rare publications 
in which such a direct comparison in terms of quality of life is made between the various 
treatment options for low risk prostate cancer. We found general health of men to be 
comparable between the four groups, with the active surveillance group reporting the 
best general health. With respect to urinary, bowel and sexual function, men on active 
surveillance report the best function as well. Our results seem to indicate that with 
longer follow-up active surveillance is not just a safe option from a clinical perspective, 
but also a good alternative from a quality of life perspective.
Because most patient reported outcome assessment instruments tend to capture the 
negatives of active surveillance, we developed questions that focused on the positives 
of active surveillance and included them at the 5-year measurement point (chapter 7). 
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These showed that the control visits provided tranquility of mind to most men (85%) 
and that they trusted the follow-up scheme (82%). 81% of men were glad that their 
cancer was diagnosed at an early stage and 77% said that they could cope with the 
thought of having prostate cancer. These results are somewhat biased, because men 
that truly cannot cope with active surveillance switch to deferred treatment in a much 
earlier stage, mostly within the first year [54]. It does, however, give a first overview of 
how men who opt for active surveillance perceive the periodical control visits.
Since qualitative research has shown that the use of generic quality of life instruments 
in a group of prostate cancer patients will not detect side-effects of treatment as they 
are domain specific [55,56], we combined in our research (chapters 6 and 7) generic and 
disease-specific measures, which is a strength of our study. A limitation is the lack of a 
baseline quality of life measurement.
Acceptance of active surveillance
From a clinical and quality of life perspective, evidence is pointing towards the widespread 
acceptance of active surveillance which is reflected in the fact that active surveillance is 
included in many urological guidelines (EAU, AUA, etc.). There is a group of urologists 
whose interest in active surveillance is reflected by their efforts to include patients in 
active surveillance studies or involvement in contributing to the literature. In chapter 8 
we were interested in assessing the opinion of a larger group of urologists, including 
urologists that are not directly involved in studies like PRIAS. We therefore invited all 
senior members of the Dutch Urology Society to fill out a self-designed questionnaire 
and share their practice patterns and opinions on active surveillance. Most urologists 
reported a positive attitude towards active surveillance and applied the PRIAS inclu-
sion and follow-up criteria (without including patients into the study). Urologists were 
predominantly led by the wish of the patient, the guideline, their own experiences, 
patients’ physical and psychological well-being and their clinical characteristics when 
recommending active surveillance. Gorin et al. and Azmi et al. assessed the knowledge, 
acceptance and practice of active surveillance in American-based and European-based 
urologists [57,58]. They found that of the participants that replied (response rates 
amounted to only 9% and 8%, respectively), the majority were knowledgeable and 
accepting of active surveillance. The practice pattern for active surveillance, however, is 
heterogeneous, with urologists not adhering to a protocol or involved in an active sur-
veillance study applying less rigorous criteria for both eligibility and monitoring of active 
surveillance [57,58]. While having urologists to participate in a survey on their attitude 
towards and experiences with active surveillance was challengeable, the increasing per-
centage of men choosing active surveillance instead of immediate active therapy may 
be seen as a proxy for the acceptance of active surveillance as a management strategy. 
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Up to a few years ago, only a small percentage of eligible men started an active surveil-
lance management strategy [59]. Over the years, although solid worldwide statistics 
are scarce, it seems like regionally the percentage of men with low-risk prostate cancer 
that chooses active surveillance is rising [60-62]. Smaller initiatives, like the Michigan 
Urological Surgery Improvement Collaborative (MUSIC) reported that approximately half 
of their patient cohort underwent initial active surveillance [61]. The growing number of 
PRIAS participants - from approximately 2,100 patients included in July 2011 to almost 
5,000 in May 2015 - is also an indicator that more men are nowadays included on active 
surveillance.
In chapter 9 of this thesis active surveillance was described from a legal perspective. 
Active surveillance is a realistic treatment strategy that is included in many guidelines. 
Still the chance exists that the ‘window of curability’ is missed. What should urologists 
be aware of, from a legal perspective, when offering active surveillance to patients? 
Urologists should be aware of the information they provide to patients, highlighting the 
importance of informed decision making (chapter 3), when entering active surveillance 
but also during follow-up. Deviating from, for instance, the PRIAS active surveillance 
protocol, is allowed as long as such a deviation can be substantiated and has been 
discussed and agreed upon by the patient (chapter 3).
10.3.1 Future perspectives – how is the field of active surveillance 
expected to move forward in the coming years?
Besides the PRIAS study, which includes over 5,000 participants in 17 countries, most 
other active surveillance studies are single-center, relatively small cohorts. It will be 
important to join databases to increase the number of patients, and therewith events. A 
first attempt is made with the Movember, GAP3 project in which at least 19 top institu-
tions and candidate centers from all over the world will join their data and expertise, 
comprising a database of over 10,000 active surveillance patients. It will be of upmost 
importance to continue the GAP3 collaboration after the retrospective part of the study 
has ended and turn the then unique database into a prospective study, comprising the 
world largest active surveillance database. In 5-10 years that will give us the opportunity 
to report with much more certainty on the disease-specific mortality rate, number of 
metastases and other important end-points amongst active surveillance patients. This 
will influence the guidelines on active surveillance, by echoing a worldwide consensus 
statement on inclusion and follow-up criteria for active surveillance.
Patient selection and follow-up for active surveillance should, furthermore, be improved 
by means of risk stratification methods and the incorporation of MRI into the diagnostic 
pathway. The currently used nomogram in chapter 5 for the prediction of indolent dis-
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ease is based on data from the ERSPC and should be updated. Currently it still includes 
Gleason 2+3 as a parameter, which does not reflect clinical practice any longer. It also 
includes length of cancerous tissue and length of benign tissue as parameters, which 
are not always clinically available. Alternatives have to be sought and the addition of 
MRI parameters should be considered. Inclusion of such parameters might reduce the 
need for invasive prostate biopsies that are not without risk, making the protocol more 
patient-friendly, while not losing performance.
With respect to measuring quality of life of men on active surveillance, a core set of 
measures is needed. At the moment it is not clear which quality of life measure can 
best be used to measure a certain domain, e.g. anxiety, urinary incontinence, erectile 
dysfunction, depression, regret, which has led to splintered quality of life reporting, 
making it difficult to compare published patient reported outcomes. A guideline which 
supports clinicians in deciding what tool to use for measuring a specific physical or 
psychological domain should be developed and will be helpful to the professional as 
well as for the patient. The professional is provided with a clear overview of tools that 
can help him pinpoint the area of unmet needs, while the patient is no longer burdened 
with filling out numerous questions that might be less relevant for him, saving them 
both time and improving quality of care.
Furthermore, quality of life research should focus on the inclusion of the pre-treatment 
decision moment. In this thesis it was shown that men who follow an active surveil-
lance strategy for a longer period of time have good quality of life and do not seem to 
experience problems due to living with ‘untreated cancer’. It is relevant to assess the 
motives of men that were diagnosed with low-risk prostate cancer and did not choose 
active surveillance. Would it be possible, for instance, to offer them active surveillance 
combined with a psychosocial intervention that helps them to cope with living with 
untreated cancer, while delaying or potentially avoiding treatment and its side-effects?
In recent years, patients’ self-management of disease has gained very much attention. 
From the ProtecT trial we have learned that many men after having received their cancer 
diagnosis, have engaged in doing something themselves to be in control of their disease 
[63,64]. This ranges from changes in diet, increasing the amount of physical activity or 
to stop smoking. It will be worthwhile to assess whether men on active surveillance 
for prostate cancer in the PRIAS study are interested in self-management or perhaps 
already have adopted lifestyle changes and see how this affects their quality of life and 
perception of care.
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Current research on prostate cancer focuses mainly on how screening for prostate 
cancer can be improved and how the associated overdiagnosis and overtreatment can 
be reduced. This quest will continue in the years to come. For active surveillance the 
research focus will mainly be how to improve patient selection and follow-up criteria, 
while not missing the disease’s window of curability. Modelling studies, retrospective 
and prospective data contribute to the literature acknowledging active surveillance 
for low-risk prostate cancer being a safe approach, as the mortality rates are in the 
same range as those of favorable-risk patients that were managed with initial curative 
therapy. It has furthermore been found that active surveillance could be feasible for pa-
tients with intermediate-risk prostate cancer, based on short- and medium-term results 
[44,45,65,66]. It is not likely that active surveillance will become obsolete in the coming 
years, as the rate of overdiagnosis will not diminish to zero and the strategy itself will go 
through a ‘response shift’, extending its area of research to intermediate-risk prostate 
cancer. Expanding active surveillance to a selected group of intermediate-risk prostate 
cancer patients will most likely result in delaying rather than avoiding treatment in these 
patients. Research should focus on how to balance the number of men who can safely 
delay immediate active therapy, without compromising on the number of aggressive 
tumors missed. Furthermore, we will have to investigate whether such a period of delay 
adds to patients’ quality of life as is seen for low-risk patients, or whether it diminishes 
it because of the higher likelihood of receiving treatment after all.
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Summary
Chapter 1 holds an introduction to prostate cancer, prostate cancer screening and active 
surveillance. The European Randomized study of Screening for Prostate Cancer (ERSPC) 
and the Göteborg Randomized Population-based prostate cancer screening trial have 
shown that screening for prostate cancer resulted in a relative reduction of the disease-
specific mortality by 21-44%. Once corrected for non-compliance and contamination, 
the effect increases further to 51-56%. Besides the positive effect of screening, it is 
also associated with overdiagnosis and subsequent overtreatment of low-risk prostate 
cancers that are likely never to cause any symptoms or lead to death. While methods are 
being researched to decrease the rate of overdiagnosis, active surveillance for prostate 
cancer has been introduced to lower the rate of overtreated prostate cancers. With 
active surveillance immediate curative treatment is delayed or completely avoided and 
replaced by a monitoring strategy. Herewith side-effects of treatment can be averted 
and quality of life preserved. If risk classification towards a higher risk or disease progres-
sion is suspected, a switch to curative treatment can be made.
The first part of this thesis focuses on screening for prostate cancer. In chapter 2 it was 
studied how tumor characteristics and treatment patterns for prostate cancer change 
during the course of a screening trial. In the initial screening round T1c tumors were 
found in 48% of the cases versus 75% in the third screening round. The percentage of 
Gleason 6 tumors remained around 70% throughout all three screening rounds. In the 
control arm of ERSPC increasing proportions of T1c were seen as well; 29% in the 1994-
1998 period versus 50% in the 2003-2006 period. The percentage of Gleason 6 tumors 
slightly decreased over time from 58% to 51%, Gleason grade 7 tumors increased over 
time from 21-32%, and a decreasing trend was seen for the Gleason 8-10 tumors (21% 
in the 1994-1998 period to 17% in the 2003-2006 period). The stage and grade shift 
that was observed coincided with a changing treatment pattern in both the screening 
and control arm. Active surveillance was more often the initial treatment strategy for 
organ-confined disease: 17% vs. 36% for the initial and third screening round; 15% 
in 1994-1998 vs. 23% in 2003-2006 for the control arm. Tumor characteristics in the 
2003-2006 control arm period were similar to the tumor characteristics observed in the 
first round of screening, pointing towards an increasing rate of opportunistic testing 
(screening) in men who were randomized to the control arm.
Because of the conflicting messages regarding screening for prostate cancer, i.e. the 
ERSPC and Göteborg trial showing an effect of screening versus the PLCO trial not 
showing an effect, and the fact that screening is associated with overdiagnosis and 
overtreatment, in chapter 3 we highlighted that men wishing to be screened for pros-
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tate cancer should be informed about the pros and cons of screening before having a 
PSA test. Using decision aids to inform men can help them weigh the pros and cons 
in such a way that their choice balances their own preferences and personal values. 
Through shared decision making both the professional and the man requesting a PSA 
test can express their thoughts on screening and agree on a course of action that bal-
ances the man’s preferences and is acceptable from a medical point of view.
The second part of this thesis focuses on active surveillance for low-risk prostate cancer. 
In chapter 4 we reviewed the literature and how outcomes of active surveillance cohorts 
developed over time. Up to this point in time, the PRIAS and Johns Hopkins active sur-
veillance cohorts, amongst others, reported a 100% disease-specific survival rate after 
a median follow-up of 1.6-2.7 years. Because active surveillance is still a relatively new 
management strategy, the follow-up of most studies is too short to effectively compare 
disease-specific mortality. We therefore evaluated some intermediate endpoints such as 
the percentage of PSA progression, local progression and metastases. We used cohorts 
of men who were radically treated after an initial active surveillance strategy (deferred 
treatment) and compared them to men who received immediate radical treatment to 
see whether men with deferred treatment had worse outcomes. We found that 8-31% 
of patients in the studies we reviewed seemed to have less favorable outcomes after 
deferred radical treatment. It could be hypothesized that these men would have had 
better outcomes if treated earlier. If compared to outcomes of men who were treated 
radically immediately, results seemed to be quite similar. This suggests that postponing 
treatment did not affect the outcomes of men who choose an initial active surveillance 
strategy within the follow-up time available.
In chapter 5 we analyzed whether patient selection for active surveillance could be im-
proved by using risk stratification through a nomogram instead of applying the current 
fixed active surveillance inclusion criteria. We assessed this in a group of men diagnosed 
with prostate cancer and treated with radical prostatectomy who would also have been 
eligible for active surveillance. The performance of the PRIAS, Klotz and Johns Hopkins 
fixed active surveillance inclusion criteria was compared to the performance of a nomo-
gram that predicts indolent disease. It was found that the performance of the nomo-
gram, the Johns Hopkins and the PRIAS active surveillance criteria was similar, indicating 
that the use of a nomogram is a good alternative to the fixed criteria, especially because 
the nomograms allows the urologist and the patient to make individual trade-offs.
Living with an untreated cancer can be regarded as counterintuitive and therefore cause 
anxiety and distress. The purpose of the study described in chapter 6 was to analyze 
how anxiety and distress developed in men who were managed with active surveillance 
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for an 18-month period of time and whether highly anxious men switched to curative 
treatment. We found that the average levels of anxiety and distress were favorably 
low for men that choose to stay on active surveillance. Fear of disease progression 
and generic anxiety furthermore tended to decrease for men that remained eligible for 
active surveillance. Of the 26 men who were highly anxious at baseline, eight (31%) 
became less anxious over time. Overall, 5% (6/129) of men discontinued active surveil-
lance and switched to curative treatment because of anxiety and distress. In chapter 
7 we evaluated quality of life of men who have been following an active surveillance 
strategy for more than four years (median follow-up 6.5 years) and compared the results 
to quality of life of men who underwent curative treatment (radical prostatectomy or 
radiotherapy) and a group of men without prostate cancer. Significant and clinically rel-
evant differences regarding physical functioning, urinary function, urinary incontinence 
and sexual function were found for men on active surveillance as compared to men who 
underwent radical prostatectomy. When comparing men on active surveillance to men 
who underwent radiotherapy we found significant and a clinically relevant difference 
in sexual functioning. Furthermore we found that the quality of life of men on active 
surveillance was very similar to that of men without prostate cancer.
With the increasing clinical acceptance of active surveillance as an alternative to im-
mediate radical treatment, in chapter 8 we aimed to assess how urologists value active 
surveillance. We invited all 328 senior members of the Dutch Urology Society (NVU) to 
complete a questionnaire including questions on how many newly diagnosed prostate 
cancer patients the urologist sees on a yearly basis, whether the urologist mentions 
active surveillance as one of the treatment options, whether patients ever bring up 
active surveillance as a treatment option, etc. 55% (180/328) of the invited urologists 
responded. All urologists reported that they discuss active surveillance as a treatment 
option for low-risk prostate cancer. A third of the urologists also did so for men with 
intermediate risk prostate cancer. The requests of patients, guidelines, own experiences, 
patients’ physical and psychological well-being and their clinical characteristics were fac-
tors that urologists were most influenced by in deciding whether or not to offer active 
surveillance. Urologists furthermore reported that approximately half of their patients 
tended to bring up active surveillance themselves. We concluded that overall, Dutch 
urologists have a positive attitude towards active surveillance.
Not actively treating a cancer can be a potential threat for both the patient and the physi-
cian. Therefore, in chapter 9 active surveillance was described from a legal perspective. 
What potential pitfalls should urologists be aware of when offering active surveillance? 
In this paper a PRIAS case was used to see what would have happened had that patient 
filed a complaint. Just like in practice, two ‘experts’ were appointed who provided their 
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opinions regarding the patients’ case. We found that there are two aspects that need 
to be taken into consideration when offering active surveillance: (1) providing the right 
type of information in a for the patient understandable manner on which he can base 
his informed consent and (2) urologists acting according to their professional standard. 
When offering active surveillance the experts pointed out that the following risks and 
complications of active surveillance should be discussed: the risk of prostate cancer 
progression and the subsequent possibility of being ‘too late’, the risks associated with 
repeat biopsies and the active surveillance follow-up scheme.
Finally, key findings of the studies described in chapters 2-9 were summarized and dis-
cussed in chapter 10. Regarding screening for prostate cancer, research will continue to 
focus on how to reduce the rate of overdiagnosis. In that context MRI and stratification 
will most likely play an important role. For active surveillance research will focus on, 
amongst others, patient selection; will it be possible to safely expand the inclusion cri-
teria so that a selected group of intermediate-risk prostate cancers will become eligible 
for active surveillance as well? It will have to be studied how that affects the number of 
aggressive cancers missed and whether these intermediate-risk patients will experience 
similar good quality of life as was seen for low-risk prostate cancer patients on active 
surveillance. It is furthermore to be hoped that the Movember GAP3 initiative in which 
19 top institutes and candidate centers from around the world have joined forces, will 
continue a prospective, unique database with over 10,000 patients, providing us with 
the opportunity to further add to the evidence on active surveillance as a safe manage-
ment strategy.
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Samenvatting
In het eerste hoofdstuk van dit proefschrift worden de onderwerpen prostaatkanker, 
prostaatkankerscreening en het actief afwachtend beleid (active surveillance) geïntro-
duceerd. De Europese gerandomiseerde studie naar de waarde van vroege opsporing 
van prostaatkanker (ERSPC) en de Göteborg prostaatkankerscreening studie toonden 
een relatieve risicoreductie aan van screenen op de ziekte-specifieke mortaliteit van 
21-44%. Indien er wordt gecorrigeerd voor non-compliance en contaminatie, dan zien 
we dat het effect van screening toeneemt en in de orde van grootte van 51-56% ligt. 
Naast positieve effecten van prostaatkankerscreening, zijn er ook nadelen, te weten: 
overdiagnose en overbehandeling van laag-risico prostaatkankers. Deze laag-risico 
prostaatkankers zullen naar alle waarschijnlijkheid nooit tot klachten leiden en man-
nen met een dergelijke vorm van prostaatkanker zullen daar ook niet aan overlijden. 
Momenteel wordt er hard gewerkt aan het vinden van een methode om het aantal 
overgediagnosticeerde laag-risico kankers terug te dringen. In de tussentijd is er een 
strategie ontwikkeld waarmee de overbehandeling van laag-risico kankers kan worden 
tegengegaan. Met active surveillance wordt actieve behandeling uitgesteld danwel 
vermeden. Mannen worden in plaats daarvan volgens een vast follow-up schema in 
de gaten gehouden. (Op vaste tijdstippen (follow-up schema) wordt beoordeeld of er 
sprake is van een stabiele situatie). Zodra zich tekenen van reclassificatie of progressie 
van de kanker voordoen, zal een overstap naar actieve therapie worden gemaakt.
In deel één van dit proefschrift hebben we bekeken hoe het patroon van tumorka-
rakteristieken en behandeling in een screening- en controlegroep zich gedurende een 
prostaatkankerscreening studie ontwikkelt (hoofdstuk 2). In de eerste screeningsronde 
werd 48% van de mannen gediagnosticeerd met een T1c prostaatkanker. In de derde 
screeningsronde liep dit percentage op tot 75%. Het aantal Gleason 6 tumoren lag 
in alle drie de screeningsronden rond de 70%. Vergelijken we deze percentages met 
de controlegroep, dan zien we dat ook in deze groep het aantal T1c tumoren toenam 
naarmate de tijd vorderde: 29% in de periode 1994-1998 versus 50% in de periode 
2003-2006. In tegenstelling tot de screening arm, nam in de controlegroep het percen-
tage Gleason 6 tumoren af van 58% naar 51%. Het percentage Gleason 7 tumoren 
nam toe van 21% naar 32%, terwijl het percentage Gleason 8-10 tumoren daalde 
van 21% in de periode 1994-1998 tot 17% in de periode 2003-2006. De verschuiving 
in stadering (stagering – stadium) en gradering van de tumoren viel samen met een 
verandering in behandelingspatroon in zowel de screening als de controle arm van 
ERSPC. Het percentage deelnemers met een laag-risico kanker dat een initieel active 
surveillance beleid volgde nam toe van 17% in de eerste screeningsronde tot 36% in 
de derde screeningsronde en voor de controlegroep van 15% in de periode 1994-1998 
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tot 23% in de periode 2003-2006. Controlegroep tumorkarakteristieken in de periode 
2003-2006 waren vergelijkbaar met de eerste screeningsronde tumorkarakteristieken. 
Dit wijst er op dat er een groter percentage controlegroep mannen is die zich opportu-
nistisch laat testen.
Terwijl de ERSPC en de Göteborg prostaatkankerscreening studies aantoonden dat 
screening leidt tot een vermindering van de ziekte-specifieke mortaliteit, toonde de 
Prostate, Lung, Colorectal and Ovarian cancer screening trial (PLCO studie) datzelfde ef-
fect niet. Met deze conflicterende uitkomst in het achterhoofd en het feit dat screening 
is geassocieerd met overdiagnose en overbehandeling, wordt in hoofdstuk 3 aan 
mannen die bij hun huisarts om een PSA-test vragen geadviseerd zich eerst goed te 
informeren over de voor- en nadelen van prostaatkankerscreening met behulp van PSA. 
De huisarts en de Prostaatwijzer® kunnen mannen helpen de voor- en nadelen van 
prostaatkankerscreening met behulp van PSA af te wegen. Gezamenlijke besluitvorming 
tussen de huisarts en de man met het PSA-test verzoek zal - naar alle waarschijnlijkheid 
- leiden tot een beslissing waarin zowel de arts als de man zich in kunnen vinden.
Het tweede deel van dit proefschrift richt zich op active surveillance voor laag-risico 
prostaatkanker. In een review van de literatuur is bekeken hoe uitkomsten van ver-
schillende active surveillance cohorten zich door de tijd ontwikkelden (hoofdstuk 4). 
Na een mediane follow-up van 1.6-2.7 jaar waren er in de PRIAS en Johns Hopkins 
active surveillance cohorten geen deelnemers overleden aan prostaatkanker. Omdat 
active surveillance nog een relatief nieuwe behandelstrategie is en de follow-up van de 
meeste studies te kort is, zijn er ook enkele intermediaire eindpunten bekeken, zoals de 
percentages PSA progressie, lokale progressie en metastasen.
In hoofdstuk 5 onderzochten we of de selectie van patiënten voor active surveillance 
kan worden verbeterd door gebruik te maken van risicostratificatie met behulp van een 
nomogram, in plaats van de huidige vastgestelde inclusiecriteria. De uitkomsten laten 
zien dat de PRIAS en Johns Hopkins inclusiecriteria in vergelijking met het nomogram 
vergelijkbare resultaten vertoonden. Het gebruik van een nomogram voor het includeren 
van patiënten met laag-risico prostaatkanker in active surveillance kan dan ook als een 
alternatief worden gezien voor het gebruik van de huidige vastgestelde inclusiecriteria.
Omdat mannen op active surveillance angst en stress kunnen ervaren vanwege het 
leven met een niet-behandelde kanker, bekeken we in hoofdstuk 6 hoe angst en stress 
zich ontwikkelden in mannen die 18 maanden een active surveillance beleid volgden. 
Daarnaast bekeken we of mannen met hoge angstscores kozen voor een switch naar 
curatieve behandeling. Uit onze resultaten blijkt dat mannen die 18 maanden een active 
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surveillance beleid volgden, lage angst en stress scores rapporteerden. Ten opzichte van 
een meting net na de start van het active surveillance beleid bleek, dat de angst voor 
progressie van de kanker en generieke angstscores significant waren gedaald na 18 
maanden follow-up. In ons cohort koos 5% (6/129) van de patiënten vanwege angst 
ervoor het active surveillance beleid te stoppen en over te stappen naar curatieve behan-
deling. In hoofdstuk 7 analyseerden we lange-termijn-kwaliteit-van-leven-uitkomsten 
voor mannen op active surveillance en vergeleken deze met de uitkomsten van mannen 
die curatieve therapie (chirurgische verwijdering van de prostaat of radiotherapie) on-
dergingen en met de uitkomsten van mannen die geen prostaatkanker hebben. Signifi-
cante en klinisch relevante verschillen zagen we op het gebied van fysieke gesteldheid, 
urinefunctie, urine-incontinentie en seksueel functioneren van mannen die een active 
surveillance beleid volgden ten opzichte van mannen bij wie de prostaat chirurgisch 
werd verwijderd. Vergelijken we active surveillance met radiotherapie dan zien we sig-
nificante en klinisch relevante verschillen in seksueel functioneren. In beide gevallen zijn 
de scores van mannen op active surveillance beter. Daarnaast bleek uit onze resultaten 
dat de kwaliteit van leven van mannen op active surveillance vergelijkbaar is met de 
kwaliteit van leven van mannen zonder prostaatkanker.
Omdat active surveillance vanuit klinisch perspectief meer en meer als een alternatief 
wordt gezien voor direct invasief ingrijpen, onderzochten we in hoofdstuk 8 hoe 
urologen tegenover active surveillance staan. Alle 328 urologen, aangesloten bij de 
Nederlandse Vereniging voor Urologie, ontvingen een vragenlijst met vragen als: ‘Brengt 
u active surveillance weleens ter sprake?’, ‘Brengen patiënten zelf active surveillance 
weleens ter sprake?’, Biedt u weleens active surveillance aan, aan patiënten met een 
laag-risico prostaatkanker?’, ‘Volgt u bij active surveillance patiënten een protocol?’. De 
responsie bedroeg 55% (180/328). Alle urologen gaven aan active surveillance als een 
behandeloptie voor laag-risico prostaatkanker te bespreken. Een derde van de urologen 
doet dit ook als mannen een intermediair-risico prostaatkanker hebben. Factoren waar-
door urologen zich het meest laten beïnvloeden in de keuze voor active surveillance 
blijken het verzoek van de patiënt, richtlijnen, eigen ervaringen, de fysieke en mentale 
gesteldheid van de patiënt en de patiënt zijn klinische karakteristieken. Urologen gaven 
aan dat ongeveer de helft van de patiënten die zij op het spreekuur zagen zelf active 
surveillance ter sprake brachten.
In hoofdstuk 9 werd active surveillance vanuit een juridisch perspectief beschreven. Op 
welke potentiële valkuilen moeten urologen bedacht zijn wanneer zij active surveillance 
als behandelstrategie aanbieden? Een PRIAS casus werd gebruikt om te illustreren wat 
er zou kunnen gebeuren als een active surveillance patiënt een klacht zou indienen. 
Net als in de praktijk, werden er twee experts aangesteld die het dossier van de patiënt 
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bekeken en hun oordeel gaven over de situatie. Op basis van de analyse concluderen wij 
dat er twee belangrijke punten zijn waarvan urologen zich bewust moeten zijn bij het 
aanbieden van active surveillance: (1) de patiënt moet goed en volledig geïnformeerd 
worden om de juiste keuze te kunnen maken ten aanzien van de behandeling. Bij het 
verstrekken van de informatie dient de uroloog zich te laten leiden door hetgeen de 
patiënt redelijkerwijs dient te weten ten aanzien van de aard en het doel van de behan-
deling, de te verwachten gevolgen en de risico’s daarvan, over eventuele alternatieven 
en vooruitzichten; (2) het is van belang dat de uroloog handelt volgens de professionele 
standaarden.
In hoofdstuk 10 worden de belangrijkste studieresultaten van de hoofdstukken 2-9 
bediscussieerd en in perspectief geplaatst. Onderzoek naar prostaatkankerscreening 
zal zich de komende jaren met name richten op het reduceren van overdiagnose. 
Hierbij spelen de toepassing van MRI en risicostratificatie naar grote waarschijnlijk-
heid een belangrijke rol. Ten aanzien van active surveillance zal onderzoek zich onder 
meer richten op patiëntenselectie; is het bijvoorbeeld mogelijk om een geselecteerde 
groep intermediair-risico prostaatkankers te includeren op active surveillance? Er zal 
moeten worden bekeken of de inclusie van dergelijke tumoren op active surveillance 
niet leidt tot het missen van potentieel agressieve kankers. Daarnaast is het interessant 
om te onderzoeken of de groep patiënten met een intermediair-risico prostaatkanker 
een vergelijkbaar goede kwaliteit van leven ervaart als werd gezien bij de mannen 
met laag-risico prostaatkanker op active surveillance. Verder is het wenselijk dat het 
Movember GAP3 initiatief, waarin 19 topinstituten hun krachten hebben gebundeld, 
wordt voortgezet als een prospectieve database-studie waarin de gegevens van meer 
dan 10.000 active surveillance patiënten zijn verzameld. Een dergelijke database biedt 
vele onderzoeksmogelijkheden evenals de mogelijkheid om over enkele jaren met veel 
meer zekerheid uitspraken te kunnen doen over veiligheid van active surveillance op de 
lange termijn.
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